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ABSTRACT 
This dissertation describes the isolation of secondary metabolites from natural origins 
through a series of chromatographic techniques and spectrometric characterization in the 
effort of drug discovery. The isolated compounds obtained were used as drug leads 
against tropical diseases, namely malaria and leishmaniasis. While first chapter offers an 
introduction on the use of a natural product by itself as an effective therapeutic and its 
role on inspiring the discovery of new drugs, the later chapters will concentrate on 
isolation and characterization of bioactive natural products from an Antarctic sponge and 
mangrove endophytic fungi during the dissertation work. 
The second chapter describes the attempt to develop a new method of solving the 
absolute configuration of tertiary alcohol using lanthanide chiral shift reagent and 13C 
NMR spectroscopy. The third chapter describes the isolation of five new steroids, 
norselic acids A-E, from Crella sp. collected in Antarctica. The structures of the norselic 
acids were established by NMR and MS techniques. The absolute stereochemistry of 
norselic acid A was elucidated by SXRD. The antimicrobial and anti-leishmania activities 
of norselic acid A have been studied. Norselic acid A displays antimicrobial activities 
against methicillin-resistant S. aureus (MRSA), S. aureus, E. faecium, and C. albicans. 
Norselic acids B-E exhibit mild antimicrobial activities. All norselic acids exhibit strong 
cytotoxicity against leishmania. 
The fourth and fifth chapters describe a Medicine for Malaria Venture (MMV) funded 
malaria bioassay-guided screening program. The chemical investigation of the crude 
 xv 
 
endophytic fungal extracts has led to the isolations of a series of known cytochalasins 
along with the discovery of a few new compounds, including a new simple carboxylic 
acid, and several known and novel compounds belonging to the dimeric xanthone family. 
Majority of the cytochalasins display mild cytotoxicity and outstanding inhibition to 
chloroquine-resistant reference strain Plasmodium falciparum (W2) with IC50 ranging 
from 25.8 nM to 2900nM. However, their cytostatic properties hinder them from being a 
good drug candidate. The dicerandrols display good activity with the lowest IC50=0.63 
µM against malaria with low cytotoxicity. The structures of the compounds isolated and 
the associated anti-malarial activities are reported herein. 
 1 
 
 
 
 
CHAPTER 1 
Drug Discovery and Natural Products 
1.1 Introduction of Natural Products  
Natural products are secondary metabolites produced by organisms, that are non-essential 
to life. These secondary metabolites are often produced from complex combinations of 
biosynthetic pathways for ecological purposes such as chemical defense against 
predation, mediation of spatial competition, prevention of fouling, facilitation of 
reproduction, protection against UV radiation and chemical signaling to ensure 
survival.1Plants, terrestrial and marine animals located on the lower branch of the 
phytogenetic tree, and microbes have contributed to the vast diversity of natural product 
sources. These organisms all contribute to producing chemically-diverse 
pharmacologically active secondary metabolites; they often construct structurally diverse 
secondary metabolites by using a limited pool of simple building blocks such as small 
amines or amino acids, acetylCoA, isopentenylpyrophosphate, and simple aldehydes 
from primary metabolic pathway.2,3Historically, natural products are structurally 
important substances as pharmaceuticals, nutritional supplements, cosmetics and 
agrochemicals.2,3This dissertation will concentrate on the application of natural products 
in the field of drug discovery on tropical diseases. 
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1.2 Natural Product and Therapeutic Development 
Humans learned to utilize natural products as therapeutics in the early history. Today, the 
majority of medicinal drugs have been generated from natural products and from 
compounds derived from natural products.1 Natural products are used as medicine to treat 
wide range of human diseases including infectious diseases, cancer, lipid disorder and 
immunomodulation for organ transplant.4 According to a review article written by the 
National Cancer Institute (NCI) scientists, 61% of the 877 small molecule new chemical 
entities introduced as drugs worldwide during 1981-2002 can be traced to or were 
inspired by natural products (6%), natural product derivatives (27%), synthetic 
compounds with natural product-derived pharmacophores (5%), and synthetic 
compounds designed on the basis of knowledge gained from a natural product 
(23%).5Factors such as drug resistance, emergence of new or mutated viruses, existing 
diseases which have no cure and expensive drug costs all fuel the constant need for the 
discovery of novel, affordable and effective drugs.6 
For a “hit” compound to be discovered at the bench to be applied safely at the bedside is 
an extremely time-consuming and complicated process. An active compound has to go 
through multiple stages including Absorption, Distribution, Metabolism, Excretion and 
Toxicology (ADME/Tox) safety tests, preclinical testing and four phases of clinical trials 
in order for the FDA to approve it as a drug.The average time for a drug lead to be 
discovered and go through the clinical trials and to develop into a clinical drug is 10-15 
years.7Sometimes, rules such as the Lipinski’s rule of five of drug likeness helps in 
ADME consideration early in the preclinical development and avoids costly late stage 
preclinical and clinical failures. It predicts that poor absorption and permeability is more 
 3 
 
likely when (1)there are more than 5 H-bond donors, (2)10-H bond acceptors, (3)the 
molecular weight is greater than 500 and (4)the calculated Log P is greater than 5, (5) 
Log p is a measure of lipophilicity.8However, the Lipinski’s fifth rule states that the first 
four rules do not apply to natural products or to any molecule that is recognized by an 
active transport system when considering “druggable chemical entities”.9 
1.3 Bioactive Natural Products 
1.3.1 Bioactive Marine Natural Products 
The marine environment is comprised of more than 70% of the Earth’s surface and is a 
rich source of both biological and chemical diversity. The Census of Marine Life Project 
estimated there are at least a million marine species and tens of millions of species of 
microbes in the ocean. In the year of 2007 alone, 961 new compounds isolated from 
marine sourceswere discovered and reported by a small number of academic scientists, 
limited efforts of large pharmaceutical company and a few small biotechnology 
companies.10Accessibility of marine organisms is one of the reasons the diversity of 
marine organisms remains under-explored, especially for deep sea water or cold water. A 
wide diversity of macroorganisms such as protozoans, jellyfish, anemones, flatworms, 
roundworms, bryozoans, clams, squid, copepods, annelids, sea stars, sea cucumbers, 
corals, sponges, and algae exist in the ocean. As for microorganisms, open ocean 
seawater contains as much as 106 bacterial and 103 fungal cells per milliliter and 108 
bacterial cells per gram of ocean sendiments.11 
There are currently three Food and Drug Administration (FDA) approved marine natural 
product drugs on the US market and one other approved by the European 
Agency.12Vidarabine (Ara-A) (1.1) received FDA approval in 1976 as a treatment of 
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acute keratoconjunctivitis, recurrent epithelial keratitis caused by herpes simplex virus 
type 1 and 2 if conventional medicine, topical idoxuridine (Herplex®) has been 
ineffective. Vidarabine is the synthetic purine nucleoside, and was originally isolated 
from the Caribbean sponge Tethya crypta. It exerts its activity by inhibiting viral DNA 
polymerase and DNA synthesiss of herpes, vaccinia and varicella zoster viruses.12 
Cytarabine (Ara-C) (1.2) is available as conventional form (Cytosar-U®) or as liposomal 
formulation (DepoCyt®) and has received FDA approval in 1969.Similar to vidarabine, 
cytarabine is the synthetic pyrimidine nucleosidespongothymidine originally and 
alsoisolated from isolated from the Caribbean sponge Tethya crypta.Cytarabine is used as 
a antimetabolic reagent for the treatment of acute lymphocytic leukemia, acute 
myelocytic leukemia and blast crisis phase of chronic myelogenous leukemia and 
meningeal leukemia. The liposomal formulation is administered intrathecally for 
lymphomatous meningitis. Cytarabine selectively inhibits DNA polymerase and DNA 
synthesis of target cells.12 
Ziconotide (Prialt®) (1.3) is the synthetic omega-conotoxin originally isolated from 
venom produced by marine cone snail Conus magus. It is a peptide containing 25 amino 
acids with disulfide rich scaffolds formed between cysteine residues, giving rigidity and 
stability to constrain the peptide’s conformation. Ziconotide was approved in 2004 for 
treatment of chronic pain resulting from spinal cord injury and is the only non-opioid 
intrathecal (IT) therapy approved for severe chronic pain. The mechanism of action of 
this drug is novel. The drug reversibly blocks N-type calcium channels located on 
primary nociceptive afferent nerves in the superficial layers of the dorsal horn of the 
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spinal cord. Since it is not an opioid form of treatment, Ziconotide does not produce 
tolerance.12 
The anticancer compound trabectedin (Yondelis®) (1.4) was approved by the European 
Agency for the Evaluation of Medicinal Products (EMEA), and is in Phase III studies in 
the US. Trabectedin is tetrahydroisoquinoline alkaloid isolated from a marine tunicate, 
Ecteinascidia turbinata, found in the Caribbean and Mediterranean Seas.Trabectedin is 
used for treating soft tissue sarcoma and for relapsed platinum-sensitive ovarian cancer. 
In addition to these four marine drugs, many other have entered the pre-clinical and 
clinical trials.12 
 
Despite the low number of current approved marine drug from the sea, there are 13 other 
marine natural products currently have already moved onin different phases of the 
clinical pipelinesuccessfully (Table 1.1), with the European Union approved trabectedin 
(ET-743), ceribulin mesylate and soblidotin being in Phase III clinical studies. 
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Table 1.1.The marine natural products that have entered the clinical pipeline(Adapted from reference 12). 
Clinical 
Status 
Compound Name Marine 
Organism 
Chemical class Company or 
Institution 
Disease area 
Phase III Eribulin Mesylate  
(E7389) 
Sponge Macrolide Eisai Inc Cancer 
 Soblidotin 
(TZT1027) 
Bacterium Peptide Aska 
Pharmaceuticals 
 
Cancer 
Phase II DMXBA (GTS-21) Worm Alkaloid Commentis Cognition 
Schizophrenia 
 Plinabulin (NPI-
2358) 
Fungus Diketopiperazine Nereus 
Pharmaceutical 
Cancer 
 Plitidepsin Tunicate Depsipeptide Pharmamar Cancer 
 Elisidepsin Mollusc Depsipeptide Pharmamar Cancer 
 PM 1004 Nudibranch Alkaloid Pharmamar Cancer 
 Tasidotin, 
Synthadotin (ILX-
651) 
Bacterium Peptide Genzyme 
Corporation 
Cancer 
 Pseudopterosins Soft coral Diterpene 
glycoside 
NA Wound 
healing 
 
Phase I Bryostatin 1 Bryozoa Polyketide National Cancer 
Institute 
Cancer 
 Hemiasterlin  
(E 7974) 
Sponge Tripeptide Eisai Inc Cancer 
 Marizomib 
(Salinosporamide 
A; NPI-0052) 
Bacterium Beta-lactone-
gamma lactam 
Nereus 
Pharmaceutical 
Cancer 
 
There are currently two marine natural products, eribulin mesylate (E7389) (1.5)and 
soblidotin (TZT1027) (1.6), which have progressed into the phase III clinical trial. 
Eribulin mesylatewas originally isolated from a marine sponges and inhibits microtubule 
dynamics through a unique mechanism distinct from those of taxanes and 
vincas.12Soblidotin is a synthetic derivative of the dolastatin backbone and is both a 
vascular disrupting and tubulin-inbhitory agent. Dolastatins were originally isolated from 
the Indian Ocean sea hare Dollabella auricularia and later the marine cyanobacterium 
Symploca sp. VP642 from Palau.13-15 
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1.3.2 Bioactive Coldwater Marine Natural Products 
The cold water habitat can be defined as water near constant 4°C throughout the year and 
it includes polar waters and temperate and tropical deep-seas such as the Canadian 
Maritimes, the Northern Sea of Japan and the Kuril Islands.16The cold water chemistry 
described in this dissertation will focus primarily on the Antarctic specimens. The 
Antarctic water is an ecosystem exposed to unique environmental characteristics resulting 
in communities structured both by biotic interaction such as predation and competition 
and abiotic factor such as seasonality and ice-scouring.1 The western Antarctic Peninsula 
(WAP) is close to the Antarctic circumpolar current (ACC), which transports nutrients 
and ocean heat from the circumpolar deep water. The rich nutrients from this current 
have sustained the autotrophs such as algae, diatoms and cryptomonads; and suspension-
feeding macroinvertebrates including sponges, soft corals, bryozoans, hydroids, and 
ascidians.17 The biodiversity of the microorganisms and marcorganisms located at the 
lower branches of the phytogenetic tree is largely unexplored and uncharacterized 
because they are often difficult to access. Since the Antarctica Peninsula separated from 
South America over 25 million years ago, the current benthic marine invertebrate 
community had opportunity to evolve the types or predatory and competitive relationship 
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independently from the temperate water of South America. ACC also isolated the 
continent from all other oceans, creating an isolated and unique ecosystem. 
Palmerolide A (1.7) was first isolated from Antarctic circumpolar colonial tunicate 
Synoicum adareanum by the Baker and coworkers.18 Palmerolide A exhibits selective 
activity against melanoma (UACC-62 LC50, 18nM) in the National Cancer Institute’s 
(NCI) 60 cell line panel. It is a promising anti-cancer drug candidate.Palmerolide A is a 
potent inhibitor of vacuolar-ATPase (VTPase). 
 
Variolin B (1.8) is a natural product isolated from the sponge Kirkpatrickia variolosa 
found in Antarctica. Variolin B is a cyclin-dependent kinase inhibitor. Variolin B is 
tricylcic planar with the pyrido-(3’,2’,4,5)-pyrrolo-(1,2,c)-pyrimidine ring system.19,20 
 
Rossinone A(1.9) and B (1.10) were first isolated from an Antarctic ascidian of the 
Aplidium genus collected by dredging in the Ross Sea, Antarctica. The Rossinones 
exhibit anti-inflammatory, antiviral and antiproliferative activities. The first total 
 9 
 
synthesis of Rossinone B was reported shortly in 2010 after the discovery of Rossinone A 
and B.21,22 
 
1.3.3 Bioactive Natural Products from Endophytic Fungi  
Endophyte (internal plant) describes the relationship between fungal tissue within the 
cells or tissues of a plant when there is no evidence of disease or pathology. The 
relationship between the host and endophytic fungi could be symbiotic. Endophytic fungi 
produce a wide diversity of organic compounds to eliminate other microorganisms 
competing in the same environment during their life span. The compounds produced by 
such kind of fungi can be carcinogenic, vasoactive and can be toxic to more than one type 
of effect.23 
Marine derived fungi that live within invertebrates or plants represent a new exciting 
source of bioactive compounds. Endophytic fungi represent a new source for drug 
discovery. The major advantage of endophytic fungi is a renewable and reproducible 
source. An analysis estimated that fungal endophytes alone are a hyperdiverse group of 
fungi with an estimated range of 30-150 species per host plant.24Endophytic fungi, like 
many other microorganisms, can produce many different bioactive compounds when 
cultivated under different conditions.10 
In 1962, the world’s billion dollar anticancer drug Taxol (Paclitaxel) (1.11) was first 
isolated as part of the National Cancer Institute’s(NCI) program in search of anticancer 
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compounds. It is a highly efficient, low toxicity, and broad-spectrum anti-cancer drug 
originally isolated from the bark of the Pacific yew tree, Taxus brevifolia. Natural 
abundance of taxol in the yew tree is very low (0.01%-0.05%). Currently, semi-synthesis 
starting from a related metabolite isolated from the needle of a common English yew is 
supplying the clinical demand. Stierle and co-workers reported the first groundbreaking 
production of paclitaxel and other taxanes an endophyte of Taxus brevidfolia, Taxomyces 
andreanae. Endophytic fungi offer a cheaper alternative to the expensive semi-synthesis 
of taxol to reduce the cost of drug therapy.25 
 
Podophyllotoxin (1.12) and its glycoside are both clinically important anti-cancer 
reagents. These compounds were first isolated from an endangered plant species, 
Podophyllum hexandrum. Recently, Podophyllotoxin were found to be produced by the 
endophyte of P. hexandrum. These fungi were slow-growth, but were able to yield a 
moderate amount of metabolite in broth cultures (0.5µg/L-189µg/L). The mechanism of 
action of podophylltoxin involves inhibition of tubulin polymerization and disruption of 
mitosis during metaphase of the cell cycle. More water-soluble and less gastric toxic 
synthetic derivatives, etoposide (1.13), teniposide (1.14) and etoposide phosphate (1.15), 
are the current three clinically used anti-cancer drugs.25 
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Camptothecin (1.16) isantitumor alkaloid produced by an unidentified endophytic fungal 
strain in the bark of Nothapodytes foetida growing in India.It was first isolated from the 
wood of the Chinese plant Camptotheca acuminata and later in several other plant 
species such as N. foetida.25Camptothecin is selectively and significantly cytotoxic to 
several human cell lines including A-549 (lung carcinoma), HEP-2 (liver carcinoma), and 
OVCAR-5 (ovarian carcinoma). It exhibits an unique mode of action, which traps the 
cleavable DNA-topoisomerase I complex and inhibits RNA synthesis by preventing the 
relaxation of DNA during replication and transcription. Because of poor water solubility 
of the originally natural products, more water-soluble synthetic derivatives, topotecan 
(1.17) and irinotecan (1.18), have been prepared for the clinical used.25 
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1.4Natural product as Inspiration of Drugs and Combinatorial chemistry 
Natural product often serves as an inspiration or a lead for medicinal chemists for 
synthesizing new drugs in addition to their direct use as a drug.26Many drugs are 
designed from the knowledge gained from a natural product or from the pharmacophore 
of a natural product. Structure-property relationship (SPR) and structure activity 
relationship (SAR) studies performed by organic synthesis aid in natural product drug 
lead optimization.27Combinatorial chemistry and parallel synthesis involves synthetic 
modification on drug lead containing certain template for synthetic scaffolds. 
Combinatorial biosynthesis involves the manipulation of genetic sequence and enzyme 
from a biosynthetic pathway of producing a natural product.28 The result of the genetic 
modification is a new suite of modified natural products. Relying on the previous 
knowledge gained from natural products, combinatory chemistry can generate a big 
library of new compounds rapidly for High Throughput Screening (HTS), a technique 
used by big pharmaceutical company to screen compounds against specific disease in a 
short amount of time.  
Natural product inspired diversity oriented synthesis generate a library of natural product-
like compounds by organic synthesis for HTS.29 The synthesis is often simple and can 
generate number of different compounds for studies rapidly (Scheme 1.1). 
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a)  
b)  
c)
 
Scheme 1.1.a) Bioactive quinlones.b) Strategy for synthesizing the compounds library inspired by the 
bioactive natural product, quinlones. c) Compounds library synthesized by simple combinatorial chemistry. 
(Scheme adapted from reference 29). 
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Rebeccaycin and staurosporine are two natural products with antitumor properties which 
belong to the family of indolocarbazole alkaloids. Combinatorial biosynthesis was 
achieved by genetic engineering work on gene cluster isolation and expression in an 
acetinomycete host, stereptomyces albus, to produce a suite of known and newly isolated 
indolocarbazole compounds (Scheme 1.2).30 
 
 
Scheme 1.2. A)Rebeccamycin and Staurosporine.B)The suite of known and newly isolated produced by 
combinatorial biosynthesis. (Scheme adapted from reference 30) 
 
1.5 Current Challenges and Solutions to Natural Product Drug Development 
Natural products or natural product-derived compounds contribute 25% to 50% of 
currently marketed drugs during the period of 1981 to 2006.26Although with such an 
impressive history, the development of new drugs from natural products relies on many 
factors. Pharmaceutical companies often rely on a few blockbuster drugs for their main 
source of their profit. Decline in number of new natural product drugs over the recent 
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years is due to many pharmaceutical companies having eliminated or at least downsized 
their natural product research because of the following reasons: (1) high chance of 
duplication of natural product library during HTS will result in no high profit making 
patent; (2)problem with reliable supply and access; (3) synthetic compounds for HTS are 
generally simple and easy to make molecules; (4)problems with bioassay including poor 
solubility of compounds and low concentration and small quantity of the compounds; (5) 
natural products are often structurally complex, making the modification of complex 
natural product with organic reaction challenging; (6)time consuming and labor intensive 
process to discover new natural product is not compatible with the rapid screening in 
large pharmaceutical companywhose primary goal is to bring new drugs to the market 
with a the lowest possible budget and in the shortest amount of time.31 
Despite all of the above challenges, it is important to note that since secondary 
metabolites are products produced through secondary biosynthetic pathway by 
evolutionary pressure, target-based natural product evolution is sculpted by evolution to 
bind to its target. The resulting metabolites interact with drug target enzymes or protein 
better than the synthetic counterpart.2For instance, natural polyketide has a “hit rate” of 
0.3% vs 0.001% hit rate for HTS of synthetic compound libraries from a 7000 known 
polyketide structures screen.32Furthermore, modes of actions of natural products are 
much broader than that of HTS-derived synthetic compounds. The pharmacophores of the 
natural products often include more hydrogen bond donors and are less linear than 
synthetic drugs. Many bioactive natural products are able to exert their activities in 
aqueous media.3 
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As mentioned in section 1.4, natural product has been a successful source and inspiration 
for the drug discovery.Advances in organic synthetic methodologies aids in the drug 
discovery process. Sometimes, natural products may not be perfect and may not be the 
most drug-like molecules. This is when combinatory chemistry comes in useful to 
optimize and enhance drug discovery effort from natural product but not to replace the 
discovery of natural product.6 
The development of a streamlined screening process for natural products in response to 
the competition from the synthetic compound library helps making better drugs 
faster.The latest cryoprobe and stronger magnetic field NMR technology offers increased 
NMR sensitivity for elucidatingnatural product structure at microgram level. Robotic 
combined technologies such as high-pressure liquid chromatography (HPLC) with 
nuclear magnetic resonance (NMR) helps providing faster and more reliable bioassay 
results during the HTS.33 
Advances in microbial genomics technology, such as rapid and inexpensive genome 
sequencing silent pathways,helps speeding up the drug discovery process.By looking at 
the genomic information, it is possible to predict the structures a microbe can produce, 
thus eliminating the chances of re-isolating known compounds.18Microorganisms are a 
renewable and reproducible source. In addition, improved natural product sourcing; 
combinatorial biosynthesis; and microbial genomics all helped expedite the process of 
drug discovery from natural products. 
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1.6 Summary and Research Objectives 
Natural products have proved to occupy an irreplaceable position in the field of drug 
discovery.  They haveeither been a source itself or an inspiration for synthetic chemists or 
bioengineers to discover new drug leads. Natural products has reached the new potential 
of all times coupling with new advances in HTS natural product isolation, 
characterization and synthesis, biosynthetic pathway engineering. Microbes proved to be 
a reliable and renewable source which can generate a great diversity of compounds. The 
great diversity of compounds will be tested against different drug targets. 
In this dissertation, bioactive compounds, novel and previously discovered, were isolated 
either through NMR-guided or bioassay guided methods. Their separation scheme, 
structural elucidation and bioactivity against several tropical diseases are 
reported.Tropical diseases including malaria, leishmaniasis, schistosomiasis, 
onchocerciasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and 
dengue are prevalent in tropical and sub-tropical countries but are rare in the developed 
countries. Current therapeutics exists for the tropical diseases relied on the first 
generation drugs with many of them being toxic. 
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Chapter 2 
The Application of Lanthanide Chiral Shift Reagent (LCSR) on Stereochemical 
Determination 
2.1 Introduction 
2.1.1 Methods of Stereochemistry Determination in Natural Products  
Stereochemical determination is often a very challenging task as part of the process of 
structural elucidation of anovel natural product. NMR spectroscopy is one of the most 
powerful techniques for the analysis of the relative configuration of organic compounds. 
Simple NMR nuclear overhauser effect (NOE) experiments can be performed to obtain 
conformational and stereochemical information for cyclic compounds with small (three to 
six membered) rings displaying a predictable conformational behavior.34 However, there 
are currently no definite strategy of stereochemical analysis for the flexible systems, such 
as structurally complex natural products. Sometimes stereochemistry can be solved by as 
simply extracting two or three bonds carbon-proton spin-coupling constants (2,3JC,H) or 
three bonds proton-proton spin-coupling constants (3JH,H).34In particular, the Murata 
method was developed based on the combined use of these data for solving acyclic 
structures stereochemistry having stereogenic carbons bearing hydroxyl, alkoxy, or 
methyl substituents.34,35 
Circular dichroism (CD) spectroscopy, Single Crystal X-ray Diffraction (SXRD), or other 
NMR-based methods such as the Mosher method helps in the determination. CD can 
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deduce the absolute stereochemistry of a compound only if the absolute stereochemistry 
of structurally related compounds havepreviously been solved. SXRD delivers the 
molecular structure along with relative stereochemical information although it is 
restricted to compounds whichare capable to appear in crystalline form. SXRD can 
provide absolute stereochemical configuration when heavy metal atom is present and is 
coordinated to the organic compound of interest. Mosher’s method can provide the 
absolute stereochemistry by reacting the compound of interest with Mosher’s esters, a 
pair of chiral derivatizing agents.36Stereochemical determination can also be achieved by 
organic synthesis involving chemical degradationor even by total synthesis of the 
compound of interest. 
2.1.2Lanthanide Chiral Shift Reagent (LCSR) for Absolute Stereochemistry 
Chemistry Determination and Kishi’s Method 
Lanthanide shift reagent (LSR) was first discovered by Hinckley in 1969.37 It was used 
for resolution of the 1H NMR spectrum of cholesterol in his original work. In addition to 
spectral resolution, lanthanide shift reagentswere reportedas a tool for determination of 
enantiomeric excess and stereochemical configuration. The first report of a chiral 
lanthanide NMR shift reagent (CLSR) was by Whitesides and Lewis in 1974. They use 
CLSR as a reagent for determining enantiomeric purity.38 
In a 2004 Kishi’s paper,39Tris[3-trifluoroacetyl-d-camphorato]praseodymium (III) or (R)-
Pr(tfc)3 (2.1) and Tris[3-trifluoroacetyl-l-camphorato]praseodymium (III) or (S)-Pr(tfc)3 
(2.2) were used to determine the absolute configuration of glisoprenin A (2.3), a natural 
product which contains four asymmetrical tertiary alcohols having a methyl group as one 
of the three groups on the chiral hydroxyl center.40 
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The group used the experimental data obtained from 21 different model alcohols, both 
secondary and tertiary and with known absolute stereochemistry at their hydroxyl chiral 
center, to develop a method for determination of absolute configuration of glisoprenin 
Ausing LCSR 2.1 and 2.2 with 13C NMR spectroscopy. Kishi introduced a new term, 
∆∆δ for the orientation of the hydroxyl group, which can be calculated as follow: 
∆∆δ = ∆δR – ∆δS 
Where ∆δRis the 13C chemical shift difference of the two α-carbons(CX and CY) in the 
presence of R-shift reagent 2.1reagent;∆δs is the 13C chemical shift difference of the α-
carbon in the presence of S-shift reagent2.2reagent. ∆∆δ is the mathematical difference 
between ∆δR and ∆δs.A positive value of ∆∆δ corresponds to the α-orientation of the 
hydroxyl chiral center. Similarly, a negative value of ∆∆δ suggests a β-orientation of the 
hydroxyl. 
Structures 2.1and 2.2are the chiral lanthanide tris β-diketone complex. Both 2.1 and 2.2 
induces upfield shiftsin the 13C NMR spectrum in respect to that with no shift reagent 
present. Several properties of CLSR make it particularly useful as NMR shift reagents: 
(1) CLSR is soluble in most organic NMR solvents such as chloroform, carbon 
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tetrachloride, carbon disulfide and benzene. (2) Lanthanide ions act as a hard Lewis acid 
and forms donor-acceptor complexes with hard Lewis base. (3) The shifts observed in 
NMR spectrum of a donor in the presence of LSR are highly predictable compare to the 
transition metal analogs.41 
Lanthanide series metals such as europium are paramagnetic and their induced shift may 
arise from two sources: contact or pseudocontact interactions.42The contact mechanism 
involves a finite probability of finding the unpaired electron of the metal at the nucleus 
whose NMR spectrum is being recorded. Praeseodymium based induce shifts operate 
primarily through a pesudocontact mechanism. Pseuodocontact, or through space, 
mechanism involves unpaired electrons exerting a magnetic field on a nucleus by a 
dipole-dipole interaction.43 
A praseodymium chiral shift reagent was chosen in the experiment because this shift 
caused by this reagent is through a pseudocontact mechanism. In 1H NMR 
spectroscopyin the presence of the Pr(tfc)3, line broadening makes spectrum difficult to 
interpret. Line broadening of 13C NMR spectral lines is less severe than that of the 1H 
NMR spectrum; therefore, it is easier to investigate the former. An upfield shift results in 
the presence of both Pr(tfc)3. The magnitude of the shift is dependent upon the moisture 
content of the LCSR, temperature and the concentration. 
2.1.3 Limits of Kishi’s Method and Natural Products 
Kishi was able to obtain a set of consistent ∆∆δ values that agrees with the absolute 
configuration from all his alcohol models with known configuration. However, the 
alcohols he used as models were limited to the secondary alcohol and simple tertiary 
alcohols with a methyl group as one of the groups on the chiral hydroxyl center. 
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Furthermore, there are three α-carbons that are adjacent to any the chiral hydroxyl center 
in atertiary alcohol, thusgiving rise to a total of three possible ∆∆δ data sets (Figure 2.1, 
α-carbons X and Y, X and Z, and Z and Y). Only one set of the chemical shifts of the two 
α-carbons was incorporated in Kishi’s calculation of ∆∆δ in his tertiary alcohols and the 
sign of ∆∆δ showed the right absolute configuration of that chiral hydroxyl center. For 
cyclic alcohols, Kishi has always chosen the α-carbon within the ring system. 
 
Figure 2.1.One of Kishi’s tertiary alcohols with alpha carbons shown (CX and CY). There are a three set of 
alpha carbon pairs (CX and CY; CX and CZ; CY and CZ) for tertiary alcohols. However, Kishi only used 
set a).  
 
Many bioactive natural products contain tertiary alcohol motifs in their complex 
structure; with erythromycin (2.4),integerrimine (2.5), harringtonine (2.6), K-252-a (2.7), 
zaragozic acid (2.8), cinatrin C1(2.9)and fostriecin (2.10), are onlya few representative 
examples.44Since tertiary alcohols areoften resistant to esterification on such as Mosher 
method, determining the stereochemistry of a tertiary alcohols are a challenging task.In 
natural products, the hydroxyl moiety of the molecule is often tertiary and contains 
groups that are more complex than the methyl group on the chiral hydroxyl centers 
shown in Figure 2.1. 
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2.2 The Goal of LCSR Method for Absolute Stereochemistry Determination 
The goal of this chapter was to determine empirical rules to the Kishi’s method of 
absolute stereochemistry determination; an attempt to solve the absolute stereochemistry 
of a number of synthesized tertiary alcohols using lanthanide chiral shift reagents was 
unsuccessful and will be discussed.If this goal were achieved, the LCSR could be used as 
a method for determining the absolute configuration of tertiary alcohols and eventually 
on naturally occurring tertiary alcoholsof marine natural products. One of the marine 
natural products isolated during the dissertation work, norselic acid A, contains one chiral 
hydroxyl center on its side chain attachedsteroidal D ring and one carboxylic acid on the 
steroidal ring skeleton.45Its stereochemistry was solved by SXRD since the LCSR method 
failed. (See Chapter 3) 
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2.3 Results and Discussion 
2.3.1 Kishi’s Method of Absolute Configuration Determination 
The tertiary alcohols (2.12-2.20) with known absolute configurationin Figure 2.2were 
synthesized by Grignard reaction from the corresponding ketones. They served as the 
models for validating the Kishi’s method of absolute configuration determination.(R)-
Pr(htc)3 (2.21) and (S)-Pr(htc)3 (2.22) were used with the LCSR experiments initially but 
(R)-Pr(tfc)3(2.1) and (S)-Pr(tfc)3(2.2) were synthesized later and were used for all 
experiments. 
 
 
Figure 2.2. Tertiary alcohol models synthesized with their 13C NMR carbon assignments. 
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No regular pattern of ∆∆δ was observed when theexperiment was conducted with LCSR 
2.21 and 2.22(Table 2.1). Therefore, 2.1 and 2.2, the LCSR used in Kishi’s paper were 
synthesized accordingly. Water could possibly coordinate to the LCSR and affect the 
outcome of the experimental data, therefore, all LCSR were all stored in a dessicator 
containing calcium chloride. The LCSR were moved to the freeze dryer over 
phosphorous pentoxide for extra desiccation. However, that was not efficient enough to 
dry the LCSR. The LCSR was stored at above 60ºC in a vacuum oven. The ∆∆δvalues 
were reported in Table 2.1 in the presence of 2.21 and 2.22. Table 2.2 summarized the 
∆∆δ calculated for the tertiary alcohols in the presence of 2.1 and 2.2. No consistencywas 
observed when 2.1 and 2.2were used as well. 
2.12-2.15were used as model tertaiary alcohol in the experiment initially, however no 
calculated ∆∆δvalue consistency could be obtained. Possible explanation to the 
inconsistency isthat the coordination of the alkene to the praseodymiumion might 
interfere with the result of the experiment. Therefore, aliphatic 2.16, 2.17, 2.19were 
synthesized and used in the experiment. In addition to camphoric tertiary alcohols, 
tertiary alcohols 2.18-2.20were synthesized from carvone and were used in the LCSR 
experiments as well. However, the experiments performed with 2.16-2.20yielded no 
regular pattern of ∆∆δ values that corresponded to the incorrect configuration. 
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Table 2.1.∆∆δ calculations of tertiary alcohols 2.12, 2.13 and 2.16 in the presence ofCLSR (R)-Pr(hfc)3 
(2.21) and (S)-Pr(hfc)3(2.22). 
 
Tertiary 
alcohol ∆δR = δCXR - δCYR ∆δS = δCXS - δCXS ∆∆δ = 
∆δR-
∆δS (α-Carbons) δCXR δCYR ∆δR δCXS δCYS ∆δS 
2.12 (D, G) 51.406 42.896 8.51 51.486 42.936 8.55 -0.04 
2.12 (A, G) 141.743 42.896 98.847 141.751 42.936 98.815 0.065 
2.12 (A, D) 141.743 51.406 90.337 141.751 51.486 90.265 0.072 
2.13 (F,G) 44.536 42.611 1.925 44.606 42.756 1.85 0.075 
2.13 (A,G) 141.355 42.611 98.744 141.504 42.756 98.748 -0.004 
2.13 (A, F) 141.355 44.536 96.819 141.504 44.606 96.898 -0.079 
2.16 (F, I) 52.746 44.355 8.391 52.803 44.44 8.363 0.028 
2.16(A, I) 144.731 44.355 100.376 144.818 44.44 100.378 -0.002 
2.16 (A, F) 144.731 52.746 91.985 144.818 52.803 92.015 -0.03 
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Table2.2.∆∆δ calculations of tertiary alcohols 2.12-2.20 in the presence ofCLSR (R)-Pr(tfc)3 (2.1) and (S)-
Pr(tfc)3(2.2). 
 
Tertiary 
alcohols (α-
Carbons) 
∆δR = δCXR - δCYR ∆δS = δCXS - δCXS 
∆∆δ =∆δR-
∆δS δCXR δCYR ∆δR δCXS δCYS ∆δS 
2.12 (D, G) 52.573 44.989 7.587 52.539 44.947 7.592 -0.08 (R) 
2.12 (A, D) 144.088 52.573 91.515 144.039 52.539 91.5 0.015 (S) 
2.12 (A, G) 144.088 44.989 99.099 144.039 44.947 99.092 0.007 (S) 
2.13 (F, G) 44.559 42.270 2.289 44.728 42.68 2.098 0.191 (S) 
2.13 (A, F) 140.767 44.559 96.208 141.283 44.728 96.555 -0.347 (R) 
2.13 (A, G) 140.767 42.270 98.497 141.283 42.63 98.653 -0.156 (S) 
2.14 (D, G) 54.028 45.233 8.795 54.032 47.238 6.794 2.001 (S) 
2.14 (D, H) 54.028 44.257 0.976 54.032 46.265 7.767 2.004 (R) 
2.14 (G, H) 45.233 44.257 0.976 47.238 46.265 0.973 0.003 (S) 
2.15 (F, I) 53.433 45.46 7.973 53.502 45.563 7.939 0.034 (S) 
2.15 (A, F) 146.451 53.433 93.018 146.589 53.502 93.087 -0.069 (R) 
2.15 (A, I) 146.451 45.46 100.991 146.589 45.563 101.026 -0.035 (S) 
2.16 (B, D) 52.029 45.796 6.233 52.012 45.775 6.237 -0.04 (S) 
2.16 (B, F) 52.029 42.076 9.953 52.012 42.048 9.964 -0.011 (R) 
2.16 (D, F) 45.796 42.076 3.720 45.775 42.048 3.727 -0.007 (S) 
2.17 (B, D) 52.038 45.197 6.841 51.932 45.145 6.787 0.054 (R) 
2.17 (B, F) 52.038 31.655 20.383 51.932 31.545 20.387 -0.004 (R) 
2.17 (F, D) 45.197 31.656 13.541 45.145 31.545 13.600 -0.059 (S) 
2.18(E, G ) 40.315 37.957 2.358 40.248 37.898 2.350 0.008 (S) 
2.18(D, E) 45.395 40.315 5.080 45.337 40.248 5.089 -0.009 (R) 
2.18(D, G) 45.395 37.957 7.438 45.337 37.898 7.439 -0.001 (S) 
2.19 (C, F) 35.985 30.576 5.409 36.331 30.948 5.382 0.027 (R) 
2.19 (C, D) 36.331 34.343 1.988 35.985 33.919 2.066 0.078 (S) 
2.19 (D, F) 33.919 30.576 3.343 34.343 30.948 3.395 0.052 (R) 
2.20(F, G) 36.474 35.081 1.393 36.405 34.994 1.411 0.018 (S) 
2.20(D, F) 42.237 36.474 6.763 43.154 36.405 6.749 0.014 (R) 
2.20(D, G) 43.237 35.081 8.156 43.154 34.994 8.160 -0.004 (R) 
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2.3.2 Discussion 
LCSR has been used for half a century for determination of enantiomeric excess; 
however, Kishi’s method for stereochemical determination in secondary and tertiary 
alcohol was first of its kind. Since the tertiary alcohols synthesized for the LCSR 
experiments were all synthesizedthrough theendo approach by the Grignard reaction from 
the corresponding ketone, the configurations of the tertiary alcohols were known as a 
result.R group with olefin and no olfefin were used in the LCSR experiments; however, 
inconclusive data were obtained from the experiments. Assuming chelating effect of 
olefin moiety of the tertiary alcohol to the praseodymium metal will interfere with the 
experimental result. 
Shimming was difficult due to the praseodymium being a lanthanide metal ion species 
and lock level drop was observed during the experiment. Slight line broadening observed 
on 13C NMR occasionally. This issue was alleviated by monitoring the lock level and 
shimming regularly during the experiment. 
All three available three alpha carbons pairswere taken into consideration for the ∆∆δ 
calculation.The priority of the alpha carbons were assigned following the Cahn-Ingold-
Prelog priority rules. No consistency or trend of the resulted configuration was observed 
even when the pair of two highest priority carbonswere picked as for ∆∆δ calculation. 
Nor the two other pairs with the lowest priority carbon included yielded any consistency. 
There are three alpha carbons to a tertiary hydroxyl chiral center. Two of them were 
taken into consideration for the each ∆∆δ calculation. As a result, there were three pairs 
of alpha carbons. 
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2.4 Summary and Conclusion 
Unfortunately, the LCSR experiments performed using (+)- and (-)-Pr(tfc)3 or (+) and (-)-
Pr(htc)3 had produced inconclusive data. One key advantage of Kishi’s method of 
stereochemical determination of is the less 13C NMR line broadening and lack of J 
coupling, allowing easier analysis compare to a 1H spectrum. Kishi’s method would help 
stereochemical determination for tertary alcohols that is incapable of crystal formation or 
that is challenging to esterify due to steric hinderance. 
Due to the inconsistent data obtained from the LCSR, empirical rule for Kishi’s method 
of stereochemical determination could not be determined.The methodcould not be 
applied to natural product, norselic acid A, or any other organic compounds containing 
secondary or tertiary alcohol moiety for determination their absolute 
stereochemistry.Alternative method for steroechemical determination on norselic acid A 
will be discussed in Chapter 3. 
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CHAPTER 3 
Anti-Lesihmanial and Antibiotic Activities of Norselic Acids A-E:NMR-guided 
Chemical Investigation Antarctic Sponge Crella sp. 
3.1 Leishmaniasis and BacterialInfectious Diseases 
3.1.1 Leishmaniasis Overview 
Leishmaniasis is a tropical disease epidemic to 88 countries with 72 of those countries 
being developing countries. According to the World Health Organization (WHO), 59,000 
people died of leishmaniasis and the disease affects more than 12 million people. Like 
most of neglected diseases, leishmaniasis creates a social burden for the developing 
countries, hence hindering the economy growth of the countries. The disease is 
transmitted by the insect vector, the female phlebotomine sandfly. There are three forms 
of leishmaniasis: cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), 
and visceral leishmaniasis (VL),46 with the visceral form being fatal if left untreated. 
Visceral leishmaniasis is caused by the intracellular protozoan Leishmania donovani in 
the Indian subcontinent, Asia and East Africa or L. infantum in Europe, North Africa and 
Latin America. Leishmania has two life cycles (Figure 3.1): One that resides in 
macrophages of the mammalian host; the other in the sandfly vector.The life cycle begins 
during sandfly stage when a female sandfly picks up amastigote-infected host 
macrophages from a mammalian host during a blood meal. The amastigotes then multiply 
and are transformed into promastigotes within the sandfly gut. Promastigotes then 
migrated to the foregut in the sandfly will be transmitted to another mammalian host by 
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subsequent blood meal. Promastigotes are ingested by macrophages and differentiate into 
amastigotes within the macrophages and could be persistent for several months, years, or 
even for the entire life of the host, resulting in disease. The life cycle begins again when 
another sandfly consumes a blood meal from the infected host.47 
 
Figure 3.1.The life cycle of leishmania (Image from Centers for Disease Control Public Health Image 
Library). 
 
Anti-fungal agent amphotericin B deoxycholate (3.1) (fungizone®) and liposomal 
formulations (AmBisome®) are currently used for the treatment against 
leishmaniasis.Miltefosine (3.2) is the first leishmania oral drug developed and has 
originally been developed as an antitumor drug. Sodium stibogluconate 
(pentostam®)(3.3) is only available for administration by injection intravenously or 
intramuscularly.48 Leishmanicidal is currently administered in low dose as commonly 
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used drugs exhibit severe side effects, and hence drug resistance can appear rapidly. 
There is also no vaccination for the disease currently.49 
 
 
3.1.2 Bacterial Infectious Diseases Overview 
Bacteria carry out certain random mutations at chromosomal level in response to the 
antibacterial compounds used for bacterial infections in humans.50Currently, there is an 
urgent need to discover and develop new antibiotics to treat microbial infectious diseases 
to overcome the growing problem of antibiotic resistance with the number of new 
approved drugs continues to decline.51For instance, hospital-acquired infections with 
Staphylococcus aureus and methicillin-resistant S. aureus(MRSA) infections are a major 
causes of illness and death and creating huge economic costs on patients and 
hospital.52Traditionally, antibacterial activity of marine natural products has been focused 
on biomedically-relevant strains (Table 3.1). The two bioassay techniques used for 
assessment of antibacterial activity are the disc diffusion method and the microdilution 
method.10Most antibacterials used clinically are either natural products or resembled 
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natural products and 74 out of 98 antibacterial small molecules marketed between 1981 
and 2005 contained structural motifs inspired by natural products.9,11 
Table 3.1. Common human pathogens used for laboratory assays (Adapted from reference 9). 
Bacterium Gram stain Disease Pathology 
Staphylococcus aureus + staph infections 
Streptococcus pneumoniae + pneumonia 
Streptococcus pyogenes + strep throat 
Enterococcus faecium + bacteraemia; endocarditis 
Micrococcus luteus + non-pathogenic 
Micrococcus nishinomiyaensis  non-pathogenic 
Listeria monocytogenes + listeriosis 
Mycobacterium tuberculosis + tuberculosis 
Escherichia coli - urinary tract infections; neonatral 
meningitis 
Pseudomonas aeruginosa - pulmonary and urinary tract 
infections 
 
3.2 The Chemical Investigation of Antarctic Sponge Crella sp. 
3.2.1 NMR-guided Isolation of Norselic Acids 
A huge diversity of marine invertebrates is collected from Antarctica for chemical 
investigation or ecology studies on a regular basis by the Baker laboratory. Crella sp., a 
bright orange encrusting sponge found at the 120 ft depth water at Norsel Point, near 
Palmer station Antarctica was first collected in 2004(Figure 3.2).The collected sponge 
was freeze-dried and extracted exhaustively with 1:1 DCM/MeOH to produce a lipophilic 
extract. The isolation of the norselic acids was NMR-guided. MPLC generated fractions 
(Scheme 3.1) were screened by1H NMR spectroscopy. Chemical investigation of 
fractions with signals resonated at key olefinic regions of the1H NMR spectrum were 
further pursued. Repeated HPLC separation afforded a series of five new steroids named 
norselic acids A-E. (3.4-3.8)  
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Figure 3.2Crella sp. found at Norsel Point, Antarctica. 
 
Scheme 3.1.Isolation scheme for norselic acids from the Antarctic sponge Crella sp. 
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3.2.2 Structure Elucidation of Norselic Acids A-E 
Norselic acids A-E (3.4-3.8) are a series of new highly oxidized steroids compared to 
other steroids, which are generally characterizedin the 1H NMR spectrum by their C-3 
hydroxyl methine signal between 3 and 4 ppm.Norselic acid A-E all exhibited the typical 
characteristic of steroids such as the upfield methyl signals and the busy overlapping 
signalsthroughout the aliphatic region of the 1H NMR spectrum.  
Norselic acid A (3.4) was found to have a molecular formula of C29H40O4by 
HRESIMSm/z 453.3000 [M+H]+ (calc’d for C29H40O4, 453.3005),corresponding to 9 
degrees of unsaturation. It was isolated as a yellow glassy solid. Repeated 
recrystallization of norselic acid A with hexane and DCM afforded norselic acid A as 
clear crystalline needles.The planar structure of norselic acid A was established by 
extensive NMR spectroscopy (1H, 13C, DEPT-135, gCOSY, gHSQC, gHMBC) (Figure 
3.3-3.7). 
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Figure 3.3.1H NMR spectrum of norselic acid A (3.4), 500 MHz, CDCl3. 
 
 
Figure 3.4.13C NMR and DEPT-135 of norselic acid A (3.4),125 MHz, CDCl3. 
 37 
 
 
 
Figure 3.5.gCOSY spectrum of norselic acid A (3.4), 500 MHz, CDCl3. 
 
Figure 3.6.gHSQC spectrum of norselic acid A (3.4), 500 MHz, CDCl3. 
 
Figure 3.7.gHMBC spectrum of norselic acid A (3.4),500 MHz, CDCl3. 
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DEPT-135 spectrum (Table 3.2) indicated seven quaternary carbons, ten methines, eight 
methylenes, and four methyl groups. The structural elucidation of the A ring of norselic 
acid A could be accomplished as the follows: a doublet resonated at δH7.03 (H-1) in the 
1H NMR spectrum of norselic acid A suggested the presence of a α,β-unsaturated proton 
in the molecule(Table 3.3).The δH 7.03 signal correlated to δC 186.6 (C-3)corresponding 
to α,β-unsaturated ketone according to the HMBC data. The proton δH7.03 also showed 
HMBC correlations to two more olefinic carbons at δC 163.4 (C-5) and 127.5 (C-2), as 
well asto the angular methyl carbon at δC 20.8 (C-19) and quaternary carbon at δC41.5 
(C-10). From the HMBC data, H3-19 in turn correlated to C-5, C-1 (δC 153.4), C-9 (δC 
48.4) and C-10. These assignments were supported by the COSY data, which showed a 
correlation between H-1 (δH 7.03)and H-2 (δH 6.25). 
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Table 3.2.13C NMR Spectral Data for Norselic Acid A-E (3.4-3.8)*. 
Pos A (3.17)   B (3.18) C (3.19) D (3.20) E (3.21) 
1 153.4  CH 158.4 CH 156.6 CH 35.8 CH2 153.2 CH 
2 128.3  CH 127.7 CH 127.8 CH 32.9 CH2 128.3 CH 
3 186.8  qC 200.4 qC 186.4 qC 200.0 qC 186.7 qC 
4 123.9 CH 41.2 CH2 124.2 CH 124.0 CH 123.9 CH 
5 163.1 qC 44.5 CH 43.7 qC 171.6 qC 162.9 qC 
6 127.9  CH 27.7 CH2 32.9 CH2 34.1 CH2 127.9 CH 
7 138.3  CH 31.3 CH2 36.5 CH2 31.9 CH2 138.0 CH 
8 40.3  CH 37.8 CH 37.0 CH 36.2 CH 40.2 CH 
9 48.4  CH 50.1 CH 52.3 CH 53.9 CH 48.4 CH 
10 41.5  qC 39.2 qC 169.2 qC 38.8 qC 41.5 qC 
11 24.0  CH2 23.4 CH2 29.1 CH2 23.1 CH2 23.9 CH2 
12 36.1  CH2 37.8 CH2 34.7 CH2 36.5 CH2 36.4 CH2 
13 57.3  qC 57.1 qC 57.2 qC 56.7 qC 57.3 qC 
14 54.6 CH 57.0 CH 56.5 CH 56.7 CH 54.6 CH 
15 24.6 CH2 23.4 CH2 25.1 CH2 28.7 CH2 28.4 CH2 
16 36.5 CH2 28.5 CH2 24.9 CH2 28.3 CH2 28.8 CH2 
17 56.4 CH2 56.7 CH 56.2 CH 56.4 CH 56.0 CH 
18 178.6 qC 177.9 qC 169.2 qC 171.6 qC 178.8 CH3 
19 20.8 CH3 13.2 CH3 18.8 CH3 17.5 CH3 20.8 CH3 
20 36.4 CH 36.5 CH 36.8 CH 37.4 CH 36.1 CH
 
21 19.0 CH3 19.1 CH3 18.6 CH3 19.1 CH3 19.3 CH3 
22 28.8 CH2 28.8 CH2 33.6 CH2 24.9 CH2 24.6 CH2 
23 36.5 CH2 36.0 CH2 30.9 CH2 30.0 CH2 30.5 CH2 
24 78.8 qC 78.5 qC 156.6 qC 78.6 qC 89.0 qC 
25 147.6 qC 148.0 qC 34.1 CH 147.8 qC 144.5 qC 
26 111.4 CH2 111.2 CH2 22.1 CH3 111.2 CH2 112.5 CH2 
27 19.9 CH3 19.9 CH3 22.2 CH3 19.9 CH3 19.1 CH3 
28 32.5 CH2 32.5 CH2 106.4 CH2 32.5 CH2 27.1 CH2 
29 7.6 CH3 7.6 CH   7.6 CH3 7.7 CH3 
30         170.1 qC  
31         22.1 CH3  
 
*Recorded at 125 MHz in CDCl3 
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Table 3.3.1H and 13C NMR Spectral Data for Norselic Acid A (3.4)*. 
Norselic Acid A   
Position δH Carbon δc HMBC COSY ROESY 
1 7.03 (d, 10,2) CH 153.4 2,3,5 2 2, 11a, 
19 
2 6.25 (dd, 10.1,1.8) CH 128.3 4 1 1 
3  qC 186.8    
4 6.01, dd (10.0, 2.9) CH 123.9 6,10  2 8 
5  qC 163.1    
6 6.21, dd (10.0, 2.9) CH 127.9 4,5,7,10 7  
7 6.07, dd (9.7, 1.4) CH 138.3 5,6,8,9 6 8 
8 2.35, m CH 40.3 6,7,9,14 9 4, 7, 19 
9 1.49 CH 48.4 8,10 8  
10  qC 41.5    
11a 1.87 m CH2 24 13 12 1 
11b 1.43, m   13 12  
12a 2.74, m CH2 36.1  11,14,17 21 
12b 1.31, m   9,13,14,17,18 11,14,17  
13  qC 57.3    
14 1.58, m CH 54.6 17,18 8  
15a 2.01, m CH2 24.6  16  
15b 1.46, m      
16 1.81, m CH2 36.5 22 17  
17 1.58, m CH 56.4 12,16,20,21 21  
18  qC 178.6    
19 1.09, s CH3 20.8 1,5,9,10  1, 8 
20 1.36, m CH 36.4 17,21,23 23  
21 0.98, d (6.5) CH3 19 17,20,22 20 8, 12a 
22a 1.95, m CH2 28.8 17,23 23  
22b 1.58, m    23  
23a 1.62, m CH2 36.5  22  
23b 1.31, m   22,24 22  
24  qC 78.8    
25  qC 147.6    
26a 4.87, s CH2 111.4 24,25,27 28  
26b 4.91, s    28  
27 1.62, s CH3 19.9 24,25,26   
28a 1.49, m CH2 32.5 24,29 29 29 
28b 1.58, m    29 29 
29 0.77, t (7.1) CH3 7.6 24,28 28 28 
1H recorded at 500 MHz and 13C recorded at 125 MHz in CDCl3 
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The assignments continued with H-6 (δH6.21) and H-7 (δH 6.07) on the B ring. 
Correlation was observedbetween H-6 and C-5, C-7 (δC 138.3) and C-4, andH-7 was 
correlated to C-5 and C-6.  H-6 and H-7 were correlated to each other by COSY.H-12a 
(δH1.31) and H-14 (δH 1.58) on the C ring correlated to downfield quaternary carbon C-18 
(δC 178.6) by HMBC. The mass spectroscopic data along with HMBC data supported C-
18 was a carboxylic acid carbon in place of the methyl group found in majority of other 
steroidal compounds.H-16a (δH1.81) of the D ring showed a long range correlation to C-
22 (δC 28.8) of steroidal side chain on HMBC. 
 
Several key HMBC correlations were observed on the steroidal side chain of norselic 
acid A. Olefinic protons on a terminal methylene H-26a/H-26b (δH4.86/δH 4.91), H-27 
(δH 1.62), H-28 (δH 1.49) and H3-29 (δH 0.77) all displayed correlation to the oxygen-
bearing quaternary carbon at δC78.8 (C-24). H2-23 showed correlation between C-24 and 
C-22 by HMBC. 
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The ROESY spectrum (Figure 3.8) revealed that the stereochemistry of the steroidal 
nucleus of norselic acid A resembled the typical steroidal nucleus stereochemistry 
oftrans/trans/transA/B/C/D relationship.ROESY correlation between H3-19, H-11β and 
H-8 and the absence of correlation with H-5 suggested the trans relationship of the B/C 
ring junction (Figure 3.9).Similarly, the ROESY correlation betweenH-12β and H-14 and 
H3-21 and H-20 to H-12 and the absence of correlation between H-8 and H-14 were the 
evidences for atrans/trans relationship between the B/C/D junctions. However, ROESY 
data alone was not sufficient for determining the configuration of C-24 on the steroid side 
chain.  
 
 
Figure 3.8.ROESY spectrum of norselic acid A (3.4), 500 MHz, CDCl3. 
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Figure 3.9. The molecular structure and relative stereochemistry of norselic acid A (3.17) as determined by 
SXRD. 
 
The relative configuration of norselic acid A (3.4) was elucidated by X-ray 
crystallography (Figure 3.9). Absolute stereochemistry of norselic acid A was initially 
attempted to be solved by the chiral lanthanide shift reagent (CLSR) method developed 
by Kishi and coworkers.39 However, the method was unsuccessful and yielded 
inconsistent data as discussed (See Chapter 2). The relative stereochemistry of norselic 
acid A was deduced by SXRD followed by the successful crystallization norselic acid A 
crystal using 1:1 hexane and DCM under slow evaporation condition. The 
stereochemistry of C-24 with respect to the steroidal ring was foundto be, give “R” 
configuration of the chiral tertiary alcohol center (Figure 3.9). 
Norselic acid B(3.5) was assigned the molecular formula of C29H44O4m/z 457.3312 
[M+H]+(calc’d457.3318 for C29H45O4)by HRESIMS and had two less elements of 
unsaturation(four mass units larger)than norselic acid A. 
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The 1H NMR spectrum (Figure 3.10)of norselic acid B displayed a similar doublet δH 
7.11 representing the H-1, slightly downfield than that of norselic acid A. This difference 
helped to distinguish the existence ofother norselic acid analogs in a MPLC fraction 
containing a mixture of norselic acid A with the others. 13C and DEPT-135 data revealed 
six quaternary carbons, eight methines, eleven methylenes, and four methyl groups 
(Figure 3.11 and Table 3.2).The structure of norselic acid B was elucidated by COSY, 
HSQC and HMBC data (Figure 3.12-3.14). The two fewer elements of unsaturation could 
be located in theA and B rings of norselic acid B as supported by the HMBC and COSY 
data. The H-1 (δH7.11) and H-2 (δH 5.86)were coupled to each other in COSY spectrum 
while H-1 correlated in the HMBC to C-2 (δC 127.7), C-3 (δC 200.4), C-5 (δC 44.5). Based 
on the 1H NMR spectrum, there were only four olefinic signals, with two,δH4.90 and 
4.94,representing the terminal methylene protons from the C-26/C-25 olefin; the other 
two olefin signals must correspond to H-1 and H-2 residing within the A ring. The 
ROESY data of norselic acid B (Figure 3.15) indicated the stereochemistry of steroidal 
nucleus was identical to that of norselic acid A and agreed with the configuration of the 
typical steroids.2D NMR data supported the remainder of norselic acid as being identical 
to norselic acid A. The 1H and 13C NMR data of norselic acid B was recorded in Table 
3.4. 
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Figure 3.10.1H NMR spectrum of norselic acid B (3.5), 500 MHz, CDCl3. 
 
 
Figure 3.11.13C NMR and DEPT-135 spectrum of norselic acid B (3.5), 125 MHz, CDCl3. 
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Figure 3.12.gCOSY spectrum of norselic acid B (3.5), 500 MHz, CDCl3. 
 
Figure 3.13.gHSQC spectrum of norselic acid B (3.5), 500 MHz, CDCl3. 
 
Figure 3.14.gHMBC spectrum of norselic acid B (3.5), 500 MHz, CDCl3. 
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Figure 3.15.gROESY spectrum of norselic acid B (3.5), 500 MHz, CDCl3. 
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Table 3.4.1H and 13C NMR Spectral Data for Norselic Acid B (3.5)*. 
Norselic Acid B 
Position δΗ Carbon δc HMBC COSY ROESY 
1 7.11, d (10.2) CH 158.4 1,2,3,5,9,10 2 2, 11a, 
19 
2 5.86, d (10.3) CH 127.7 4,10 1 1 
3  qC 200.4    
4a 2.22, m CH2 41.2 2,3,4,5,6  5 
4b 2.36, m      
5 1.94, m CH 44.5 19 6,7 4a, 9 
6 1.43, m CH2 27.7 8 5  
7a 1.83, m CH2 31.3 9  14, 19 
7b 1.61, m   9   
8 1.54, m CH 37.8 7,9,13 9,14  
9 1.54, m CH 50.1 11  5 
10  qC 39.2    
11a 1.92, m CH2 23.4 13  1 
11b 1.56, m   13   
12a 2.73, m CH2 37.8 11,13 11 21 
12b 1.16, m      
13  qC 57.1    
14 1.43, m CH 57 7,18 15 7a 
15a 1.91, m CH2 23.4 13,16 16  
15b 1.68, m   13,16 16  
16a 1.94, m CH2 28.5 13,14,15,18,17,19   
16b 1.68, m   13,14,15,18,17,19   
17 1.54 CH 56.7 16 16  
18  qC 177.9    
19 0.94, s CH3 13.2 1,5,9,10,19,21  1, 7a 
20 1.35, m CH 36.5  17  
21 1.02, d (6.4) CH3 19.1 17,22  12a 
22a 1.54, m CH2 28.8  23  
22b 0.89, m   24,25,28 22  
23a 1.61, m CH2 36 24,25,28 22  
23b 1.35, m      
24  qC 78.5    
25  qC 148    
26a 4.90, s CH2 111.2 26   
26b 4.94, s   26  27 
27 1.66, s CH3 19.9 25,26  26b 
28a 1.61, m CH2 32.5 24,29 26  
28b 1.54, m   24,29 29  
29 0.81, t (7.3) CH3 7.6 24,28,29     
1H recorded at 500 MHz and 13C recorded at 125 MHz in CDCl3 
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Norselic acid C (3.6) was the only one in the series that had no oxygen bearing side 
chain.The molecular formula of C28H40O3m/z 425.3082, [M+H]+(calc’d for C28H41O3, 
425.3056) as determined by HRESIMS, indicated norselic acid C was the only one in the 
series that had one less carbon count.  
 
The DEPT spectrum of norselic acid C indicated six quaternary, nine methines, nine 
methylene and four methyl carbons (Table 3.2 and Figure 3.17).The A ring of norselic 
acid C was identical to that of norselic acid A. The planar structure of norselic acid C was 
determined from extensive NMR data including 1H, 13C, DEPT-135, COSY, HSQC and 
HMBC (Figure 3.16-3.20). However, HMBC data revealed that the B ring of noselic acid 
Cwas more saturated than that of norselic acid A. The steroidal nucleus carbon count was 
the same as the other norselic acids, therefore the missing carbon must be on the steroidal 
side chain. There were two olefinic exomethylene proton signals resonating at δH 4.64 
and δH 4.72 which showed HMBC correlation to an olefinic quaternary carbon C-24 at δC 
156.6, methane carbon C-25 at δC 34.1 and methylene carbon C-23 at δC 30.9. The 
structure of norselic acid C was therefore assigned as shown in 3.6.1H and 13C NMR 
spectral data of norselic acid C was recorded in Table 3.5. The stereochemistry of 
norselic acid C was proved to be identical to that of norselic acid A by the ROESY data 
(Figure 3.21). 
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Figure 3.16.1H NMR spectrum of norselic acid C (3.6), 500 MHz, CDCl3. 
 
 
Figure 3.17.13C NMR and DEPT-135 spectrum of norselic acid C (3.6), 125 MHz, CDCl3. 
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Figure 3.18.gCOSY spectrum of norselic acid C (3.6), 500 MHz, CDCl3. 
 
Figure 3.19.gHSQC spectrum of norselic acid C (3.6), 500 MHz, CDCl3. 
 
Figure 3.20.gHMBC spectrum of norselic acid C (3.6), 500 MHz, CDCl3. 
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Figure 3.21.gROESY spectrum of norselic acid C (3.6), 500 MHz, CDCl3. 
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Table 3.5.1H and 13C NMR Spectral Data for Norselic Acid C (3.6)*. 
Norselic Acid C 
Position δΗ Carbon δc HMBC COSY ROESY 
1 7.03, d (11.0) CH 156.6 1,3,4,5,6,10,19 2 2 
2 6.25, d (10.3) CH 127.8 5 1 1 
3 qC 186.4 
4 6.09, s CH 124.2 2,4,5,6 6b 
5 qC 43.7 1,2,4,6,19 
6a 2.48, m CH2 32.9 4,6,8,9,10 4 
6b 2.37, m 4,6,8,9,10 4 
7a 1.21, m CH2 36.5 7,14 19 
7b 2.76,m 7,14 19 19 
8 1.74, m CH 37 7 7,9 19 
9 1.11, m CH 7 6,8 11a, 14 
10 qC 169.2 
11a 2.00, m CH2 29.1 12 11 21 
11b 1.68, m 
12a 1.56, m CH2 34.7 11,18 11,12 
12b 1.21, m 
13 qC 57.2 
14 1.56, m CH 56.5 7,14,18 9 
15a 1.87, m CH2 25.1 12 
15b 0.88, m 
16a 1.74, m CH2 24.9 14 14 
16b 1.53, m 
17 1.42, m CH 56.2 13,18 21 
18 qC 169.2 
19 1.17, s CH3 18.8 1,2,5,9,10,19 
20 1.42, m CH 36.8 17,21 19,23 
21 1.06, d (6.3) CH3 18.6 17,20,21 11a 
22a 2.06, m CH2 33.6 23 
22b 1.11, m 
23a 2.06, m CH2 30.9 22,24,28 20,28 
23b 1.87, m 
24 qC 156.6 
25 CH 34.1 23,28 26,27 
26 1.02, d (1.5) CH3 22.1 25,26,27,28 25 
27 1.01, d (1.5) CH3 22.2 17,25,26,28 25 
28a 4.64, s CH2 106.4 23,25,28 
28b 4.72, s     23,25,28     
1H recorded at 500 MHz and 13C recorded at 125 MHz in CDCl3 
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Norselic acid D (3.7) was isomeric to norselic Bbased on the HRESIMSm/z 457.3306 
[M+H]+(calc’d for C29H40O4, 457.3318) but with the different location ofunsaturation 
within the A ring.1H, 13C, DEPT, COSY, HSQC and HMBC spectrum was obtained to 
determine the planar structure of norselic acid D (Figure 3.22-3.26). Norselic acid D 
lacked the characteristic doublet that appeared in the rest of the norselic acids at close to 
7 ppm.The carbonyl carbon C-3of norselic acid D at δC 200.4 indicated there was less 
conjugation along the system compare to norselic acid A whose C-3 appeared at δC186.8. 
There were four olefinic protons observed in the 1H NMR spectrum, with two being at 
the terminal methylene at C-25/C-26 olefin identical to norselic acid B leaving one 
olefinic protonsfound at H-4 (δH5.73) in the A ring. Other key HMBC correlations in the 
A ring of norselic D included H-4 and H-2a (δH2.35) to C-3; H-1a (δH 1.98) and H-2b (δH 
2.28) to C-5 (δC171.6); and H-1b (δH 1.68) and H-2b to C-10 (δC38.8). The remainder 
steroidal nucleus structure and the steroidal side chain of norselic acid D were identical to 
norselic acid A and B.The relative stereochemistry of norselic acid D was deduced from 
the ROESY data and was found to be identical to norselic acid A (Figure 3.27). Detailed 
1H and 13C chemical shifts data of norselic acid D was listed in Table 3.6. 
 
 
 
 
 
 
 
 
 
 
 55 
 
 
Figure 3.22.1H NMR spectrum of norselic acid D (3.7), 500 MHz, CDCl3. 
 
 
Figure 3.23.13C NMR and DEPT-135 spectrum of norselic acid D (3.7), 125 MHz, CDCl3. 
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Figure 3.24.gCOSY spectrum of norselic acid D (3.7), 500 MHz, CDCl3. 
 
Figure 3.25.gHSQC spectrum of norselic acid D (3.7), 500 MHz, CDCl3. 
 
Figure 3.26.gHMBC spectrum of norselic acid D (3.7), 500 MHz, CDCl3. 
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Figure 3.27.gROESY spectrum of norselic acid D (3.7), 500 MHz, CDCl3. 
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Table 3.6.1H and 13C NMR Spectral Data for Norselic Acid D (3.20)*. 
Norselic Acid D 
Position δΗ Carbon δc HMBC COSY ROESY 
1a 1.98, m CH2 35.8 3,6,10 2  
1b 1.68, m   3,6,10 2  
2a 2.35, m CH2 32.9 1,2,4,5,10 1 4 
2b 2.28, m   1,2,4,5,10 1  
3  qC 200    
4 5.73, m CH 124 4  6, 2a 
5  qC 171.6    
6 2.35, m CH2 34.1 7 4,7 4 
7a 1.91, m CH2 31.9 9 6 14 
7b 1.05, m   9 6  
8 1.40, m CH 36.2 9,11  19 
9 0.95, m CH 53.9    
10  qC 38.8    
11a 1.40, m CH2 23.1 8,12,13 8  
11b 1.69, m      
12a 2.69, m CH2 36.5 11,14,17,18 21 19 
12b 1.14, m   11,14,17,18   
13  qC 56.7    
14 1.53, m CH 56.7 8,11,12,13,18  7a 
15a 1.87, m CH2 28.7 8 17  
15b 1.57, m   8 17  
16a 1.93, m CH2 28.3  20  
16b 1.22, m    20  
17 1.40, m CH 56.4 13,15,18,20   
18  qC 171.6    
19 1.10, s CH3 17.5 1,5,9,10,19  12a, 2a, 2b, 8 
20 1.68, m CH 37.4    
21 1.00, d (6.6) CH3 19.1 16,17,21,23 12a  
22a 1.83, m CH2 24.9 20   
22b 1.60, m    20   
23a 1.98, m CH2 36 22,24,25   
23b 1.68, m   22,24,25   
24  qC 78.6    
25  qC 147.8    
26a 4.93, s CH2 111.2 24,25,26  27 
26b 4.89, s   24,25,26  27 
27 1.65, s CH3 19.9 24,25,26,27  26a, 26b 
28a 1.53, m CH2 32.5 22,24,25,28  29 
28b 1.60, m    22,24,25,28  29 
29 0.79, t (7.4) CH3 7.6 24,28,29 28a, 
28b 
28a, 28b 
1H recorded at 500 MHz and 13C recorded at 125 MHz in CDCl3
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Norselic acid E (3.8) had the most carbon count and it was found to be acetylated at C-24 
oxygen of norselic acid A. HRESIMS determined its molecular formula to be C31H42O5  
(m/z 495.3124 [M + H]+, calc’d for C31H42O5 495.3110). The planar structure of norselic 
acid E was determined by 1H, 13C, DEPT, COSY, HSQC and HMBC (Figure 3.28-3.32). 
On the 1H NMR spectrum, the 3H singlet appeared at δH 2.04 suggested the presence of 
methyl protons of an acetyl group. These methyl protons were found to be correlating to a 
carbonyl carbon a δC170.1. The 13C NMR chemical shift of C-24 appeared at δC89.0, 
higher than that of norselic acid A δC78.8, indicating the presence of an acetate 
substitution on C-24 in place of a hydroxyl group. The relative stereochemistry of 
norselic acid E was determined from the ROESY data (Figure 3.33), which suggested 
identical relatively stereochemistry to norselic A. The 1H and 13C chemical shifts data 
was recorded in Table 3.7. 
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Figure 3.28.1H NMR spectrum of norselic acid E (3.8), 500 MHz, CDCl3. 
 
 
Figure 3.29.13C NMR and DEPT-135 spectrum of norselic acid E (3.8), 125 MHz, CDCl3. 
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Figure 3.30.gCOSY spectrum of norselic acid E (3.8), 500 MHz, CDCl3. 
 
Figure 3.31.gHSQC spectrum of norselic acid E (3.8), 500 MHz, CDCl3. 
 
Figure 3.32.gHMBC spectrum of norselic acid E (3.8), 500 MHz, CDCl3. 
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Figure 3.33.gROESY spectrum of norselic acid E (3.8), 500 MHz, CDCl3. 
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Table 3.7.1H and 13C NMR Spectral Data for Norselic Acid E (3.8)*. 
Norselic Acid E 
Position δΗ Carbon δc HMBC COSY ROESY 
1 7.04, d (10.3) CH 153.2 1,3 2 2, 6, 11a, 19 
2 6.27, dd (1.5, 
10.3) 
CH 128.3  1 1, 4 
3  qC 186.7    
4 6.02, s CH 123.9 2,6  2 
5  qC 162.9    
6 6.23, dd (2.9, 
9.9) 
CH 127.9 4,5,7  1 
7 6.08, d (9.2) CH 138 5,6,7,9,10,14   
8 2.35, m CH 40.2 6,9,13,14 6,9 19 
9 1.50, m CH 48.4 8,11 8  
10  qC 41.5    
11a 1.96, m CH2 23.9 9,13 12 1 
11b 1.66, m   9,13 12  
12a 2.77, m CH2 36.4 9,10,11,13,18 11,12 19, 21 
12b 1.15, m   9,10,11,13,18 11,12  
13  qC 57.3    
14 1.57, m CH 54.6 8,13,18 8  
15a 1.96, m CH2 28.4 16 16  
15b 1.77, m   16 16  
16a 0.93, m CH2 28.8 1,5,9,10,19 15,21  
16b 1.12, m   1,5,9,10,19 15,21  
17 1.57, m CH 56 15,20,22   
18  qC 178.8    
19 1.12, s CH3 20.8 1,5,9,10,19  1, 8, 12a 
20 1,43, m CH 36.1    
21 1.01, d (6.8) CH3 19.3 20,21 20 12a 
22a 1.81, m CH2 24.6    
22b 1.57, m      
23a 1.96, m CH2 30.5 22,25   
23b 1.81, m      
24  qC 89    
25  qC 144.5    
26a 4.93, s CH2 112.5 24,25,26  27 ,29 
26b 4.96, s   24,25,26  27, 29 
27 1.65,s CH3 19.1 24,25,26 26 26 
28a 1.81, m CH2 27.1 25 29 29 
28b 2.06, m   25 29 29 
29 0.73, t (7.6) CH3 7.7 24,28  26a, 26b, 28a, 
28b, 31 
30  qC 170.1    
31 2.04, s CH3 22.1 24,30   29 
1H recorded at 500 MHz and 13C recorded at 125 MHz in CDCl3 
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3.3 Bioactivity Screening of the Norselic Acids 
(Antimicrobial assay conducted by Wyeth Research; Antimalaria assay conducted 
by Dennis Kyle from USF Department of Public Health; and Amphipod and Seastar 
bioassay conducted by James McClintock and Charles Amsler from University of 
Alabama at Birmingham Department of Biology) 
 
Norselic acids A-E were screened against leishmania, malaria and several bacteria 
including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive S. 
aureus (MSSA), vancomycin-resistant Enterococcus faecium (VRE) and Candida 
albicans.The bioactivities of norselic acids A-E (3.4-3.8) against these microbes were 
evaluated with zone of inhibition (ZOI) and are summarized in Table 3.8. Norselic acid A 
displayed mild activity against the microbes while norselic acids B-E displayed no 
activities. Norselic acid A-E exhibited activity against the leishmania parasite Leishmania 
donovania, which low micromolar activity among the series ranging from 2.0 to 3.6 µM 
(Table 3.9). However, they were virtually inactive when tested against Plasmodium 
falciparum, the parasite responsible for tropical disease malaria. 
Table 3.8.Antimicrobial bioactivity (ZOI in mm) of norselic acids A-E. (AC=almost clear (resistant) H= 
hazy (bacteriostatic) VH=very  hazy ( test material showed a hint of inhibition)) 
Infectious Microbes Norselic acid A 
(3.4)(200µg) 
Oxacillin 
(1 unit) 
Kanamycin 
(30 µg) 
Vancomycin 
(30 µg) 
Amoxicillin + 
clavulanic acid 
(30 µg) 
Rifampin 
(5 µg) 
S. aureus 375 (MSSA) 8VH 18:22H 15 19 30:41H nt 
S. aureus 310 (MRSA) 9H 0 0 15 15 nt 
E. faecium 379 (VREF) 8H 0 10 0 14 nt 
E coli 442 0 0 nt nt nt 6 
E coli 389 (imp) 0 8H 21:37H 17:25H 24:30H 20 
C. albicans54 8 0 0 0 0 0 
 
Table 3.9.Norselic acid A-E activity against leishmaniasis and malaria. 
3.4 3.5 3.6 3.7 3.8 
Tropical Diseases IC50 (µM)  
Leishmaniasis (L. donovania) 2.5 2.4 2.6 2 3.6 
Malaria (P. falciparum) 1660 7116 10246 3802 2554 
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In addition to the anti-infective properties, norselic acid A was shown to deter 
mesograzer predation and is ecologically important compound for chemical defense 
against predation of amphipods. Norselic acid A reduced the consumption of artificial 
foods by the amphipod Gondogeneia antarctica by 9% at natural sponge tissue 
concentration and 18% when it is three times the natural concentration of norselic acid A. 
Feeding by sea star Odontaster validalus was not deterred by three times the natural 
concentration of norselic acid A but did significantly deter sea star feeding at ten times 
the natural concentration.Crella sp. was one of the two sponge species displaying feeding 
deterrent by Gondogeneiaantarctica when similar bioassays were conducted to both 
lipophilic and hydrophilic extracts from 12 randomly selected sponges species at Palmer 
Station.53 
3.4Discussion 
The only similar class of compounds previously isolated from marine sponge genius 
Crella is of the crellastatin familycollected from the temperate water at Vanuatu Island. 
Thirteen Crellastatins, crellastatin A-M (3.9-3.21), are reported up-to-date (Figure 
3.34).54,55They are all cytotoxic nonsymmetric dimeric steroids and display antitumor 
activity against human bronchopulmonary non-small-cell lung carcinoma cell lines 
(NSCLC) with IC50 values in the range of 2-10 µg/mL. Crellastatins are among the few 
reports of naturally occurring dimeric steroid which displayed cytotoxicity against cancer 
cell line. Although norselic acids and crellastatin shared the common steroidal tetracyclic 
core, they each have similar but unique structural features. Norselic acids and 
creallastatins were both highly oxidized within the A ring of the steroidal backbone, with 
norselic acids having additional oxidized C-18 as carboxylic acid, while majority of 
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crellastatinswere oxidized at C-19 as a hemiacetal bridge to C-3. As for the steroidal side 
chain, norselic acids were oxidized at C-24 (oxygenated or olefinated) whereas the two 
monomers of the crellastatins were united by steroidal side chain as an oxgenated seven-
membered ring.  
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Figure 3.34.Structures of crellastin A-M (3.9-3.21).  
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Norselic acids were not the first steroids known to exhibit anti-leishmanial activity. 
Acitivity displayed by steroids against Leishmania donovanihad been previously reported 
in variousliteratures. Other naturally occurring steroidal derivatives such as steroidal 
alkaloids and saponins isolated from plant were potent inhibitor of L. donovani.56-58 In 
addition to its antileishmanial activity (IC50 = 1.3 µM), a steroidal glycoside pandaroside 
G (3.22) displayed potent activity against Trpanosoma brucei rhodesiense (IC50 = 0.78 
µM), which is another protozoan kinetoplastid flagellate parasite59,60 Pandaroside G was 
isolated from marine sponge Pandaros acanthifolium collected from the Martinique 
Island. 
 
3.5Summary and Conclusion 
In conclusion, five new highly oxidized steroids, norselic acids A-E, had successfully 
been isolated from the Antarctic sponge, Crella sp.Their structures closely resembled to 
their dimeric steroid, Crellastatins, which were isolated from the closely related species 
collected in the temperate water. The bioactivity of the norselic acids were assessed with 
antimicrobial assay, tropical diseases assay, including leishmania and malaria assay, and 
feeding deterrent assay. Norselic acid A displayed modest antibacterial activity against 
MSSA and C. albicans, as well as drug resistant bacteria including MRSA and VRE. 
Norselic acid was not active against E coli, a Gram-negative bacteria. The discovery of 
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norselic acid A supported the diversity of cold water chemistry discussed in Chapter 1 
and justify the important role of cold water marine natural products in drug discovery. 
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CHAPTER4 
Natural Products Drug Discovery against Malaria 
4.1 Introduction to Malaria 
4.1.1 Malaria Overview 
Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus 
Plasmodium. There are four types of human malaria: P. falciparum, P. vivax, P. 
malariae, and P. ovale, with P. falciparum and P. vivax being the most common and P. 
falciparum is being the most deadly.61 Malaria is endemic in many countries around the 
world. There are estimated 300-500 million cases each year, giving rise to 1.5-2.7 million 
of deaths around the globe.62 The disease is responsible for high mortality and morbidity 
each year in low-income countries.63 Ninety percent of cases and death occur in sub-
Saharan Africa, South East Asia and South America,with most deaths happening in 
children under the age 5 years and in pregnant women.64 Symptoms of malaria include 
fever, headache, and vomiting. Left untreated, the disease can be lethal by disrupting the 
blood supply to vital organs. 
Malaria is both a cause and a consequence of poverty. It slows the economic growth rates 
by about 1.3% in countries with high disease rates. The average per-capita gross domestic 
product (GDP) in malarious countries in 1995 was US$ 1,526, compared with US$ 8,268 
in countries without intensive malaria. Where malaria prospers most, human societies 
have prospered least.63 
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4.1.2 Life Cycle of Malaria 
The malaria life cycle includes the mosquito stage, human liver stage and the human 
blood stage. (Figure 3.1)Plasmodium has a very complex life cycle in both mosquito and 
human hosts. In human hosts, the cycle begins when the sporozoite form is injected by 
the mosquito, which migrates to liver cells. After extensive replication, merozoites are 
released into the bloodstream, entering the blood stage. Once in the blood stage, the 
parasite feeds by degrading hemoglobin in its acidic food vacuole. 
 
Figure 4.1.The life cycle of malaria (Image from Centers for Disease Control Public Health Image 
Library). 
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4.1.3 Current Clinical Treatment and Drug Resistance 
Currently, the few limited classes of malaria drugs have included quinines (e.g. 
chloroquin (4.1) and mefloquine (4.2)), endoperoxides (e.g. artesunate (4.3)), 
andatovaquone (e.g. atovaquone (4.4)) (Figure 4.2). Drug resistance developed because 
microorganism, in general, can employ a range of mechanisms to overcome drug 
challenge by evolving and mutating. A new generation of drugs called the artemisinin-
based combination therapies (ACTs) is effectively reducing the death toll.ACTs are 
composed of an artemisnin derivative and blood schizontoicidal medicine(s) for treating 
uncomplicated falciparum malaria. Artesunate-sulfaxdoxine/pyrimethamine, artesunate-
amodiaquine, artesunate-mefloquin, artemether-lumefantrine, and dihydroartemisnin-
piperaquine are the currently used ACTs. The use of combination of drugs has offered the 
advantages of higher thearapeutic efficacy and lowering the potential for development for 
resistance. However, since the adoption of ACTs by WHO in 2001, evidenceof drug 
resistance to ACTs has been reported at the Thai-Cambodia border region and in 2009 
and resistance was further observed in Southeast Asia.If the ACTs should fail, there is no 
solid backup plan. This urges the need for new and affordable drugs.65, 66 
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Figure4.2.First line malaria drugs. 
4.1.3.1Quinolines 
Quinolines are historically the most important anti-malarial drugs. Quinine from the 
barkof the Andean Cinchona tree is a natural remedy first used to combat malaria more 
than 350 years ago but is quite toxic. Chloroquine is a less toxic, safer and 
cheapersynthetic relative that was first developed in 1947.However, resistance to 
chloroquin (4-aminoquinoline)was reportedin Thailand in 1957.67The mode of action of 
chloroquin is believed to sequestration of harmfulβ-hematinwhich are polymers of 
haemozoin produced as a by-product of hemoglobin digestion by the parasite.68 
4.1.3.2 Artemisinin and Its Derivatives 
Artemisinins are sesquiterpene endoperoxides that were derived from the Chinese herb 
qinghao (Artemisia annua) used in traditional Chinese medicine for the treatment of 
fevers over two millennia.Ever since the structure of artemisnin (4.5)was resolved in 
1997, many of its derivatives have been synthesized.Sodium artesunate (4.6), artemether 
(4.7), and arteether (4.8)(Figure 4.3) are artemisnin derivativepro-drugs that can 
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metabolized to dihydroartemisinin4.9.69Other semisynthetic (4.10-4.11) derivatives are 
made to combat drug resistance (Figure 4.4).The highly reactive endoperoxide moiety 
within the 1,2,4-trioxane system of artemisinin is essential for the activity of the drug. 
Some studies suggest that the mechanism of action of these artemisinin related 
compounds involve the heme-mediated decomposition of the endoperoxide bridge to 
produce carbon-centered free radicals, which can in turn modify proteins and other 
molecules.67,70,71 
 
Figure 4.3.Clinically used artemisinin derivatives used in ACTs 
 
Figure 4.4.Othersemisynthetic derivatives of artemisinin. 
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4.1.3.3 Atovaquone 
Atovaquone (4.4) is a parasite-selective mitochondrial inhibitor which acts as a structural 
analogue of coenzyme Q in the electron transport chain and thus collapses the organellar 
membrane potential, thus stopping parasite respiration and pyrimidine biosynthesis. It 
was found in the 1940s but resistance was rapidly observed when it was administered in 
monotherapy due to point mutation in the cytochrome b gene. Atvovaquone is used in 
combination with proguanil since 1997.70 
4.1.3.4Antifolates 
The main antifolate drugs are pyrimethanmine (4.12), proguanil (4.13), the sulfonamides, 
such as sulfadoxine (4.14) and sulfalene (4.15) and the sulfone, dapsone 
(4.16).67Pyrimethamine and proguanil were initially used alone in the 1940s/50s, 
combination of pyrimethamine and sulfadoxine were used after the development of the 
resistance. The mechanism of action of antifolates involves inhibitionwith the folate 
pathway of the parasite by inhibiting essential enzymes, with pyrimethamine and 
cycloguanil targeting dihydrofolate reductase (DHFR) and the sulfa drugs inhibiting 
dihydropteroate synthetase (DHPS). Antifolate drugs are forumlated with artemisnin-
based drugs as ACTs. 
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4.1.4Other Potential Antimalaria Drug Candidates from Natural Products 
Among the currently used malaria clinical drugs described, many of them were obtained 
from a natural origin although many synthetic derivatives have been produced to combat 
drug resistance. Other new potential ongoing malaria drug discovery has been conducted 
over the years from natural products. For example, a series of diterpene isocyanates, 
isothiocyanates, and isonitriles (4.17-4.24) were isolated from the tropical marine sponge 
Cymbastelahooperi.72This series of diterpene demonstrated significant and selective in 
vitro antimalarial activity (Figure 4.5). By application of 3D-QSAR with receptor 
modeling methodology,73 the study revealed that the activity of diisocyanoadociane and 
axisonitrile-3 is by inhibiting the decomposition of H2O2 , the peroxidative destruction of 
free heme (FP), and the GSH-mediated breakdown of FP, and by interfering with β-
hematin formation.  The study suggested that the active isonitrile compounds exert their 
antiplasmodial activity by the same mechanism. A total synthesis of compound 4.18 has 
been reported.74 
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Figure 4.5.Diterpene isocyanates, isothiocyanates, and isonitriles from the tropical marine sponge 
Cymbastelahooperi and their associating IC50 values against P. falciparum strain D6 (with the most 
promising IC50 circled in red). 
 
4.2 Medicine for Malaria Venture(MMV) 
4.2.1 The Collaboration and Project Goals 
Medicine for Malaria Venture (MMV) is a non-profit private organization whose mission 
is to reduce the burden of malaria in disease-endemic countries by discovering and 
facilitating delivery of new effective and affordable anti-malarial drugs.6It is funded by 
the Bill and Melinda Gates foundation, several government agencies, international 
organizations, and many other private individuals.  As one of the research teams funded 
by MMV, Dr. Bill Baker’s lab collaborates with several principal investigators fromother 
academic laboratories as well as private companies in the hope of finding for the “needle 
in a haystack”, or the drug leadsof early stage discoveryto cure the tropical disease 
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malaria from a natural product source.The specific goals trying to achieve are (1) to 
screen 70,000 organism extracts with low nM IC50against Plasmodium falciparum (2)to 
analyze 700 active organism extractsand isolate the compounds responsible for the 
activity (3)to identify small molecule drug leads with molecular weight in the range of 
accepted value 360-414guided with high-throughput bioassay. (Refer to Lipinski rule of 
five in Chapter 1) because molecules with higher molecular weights are often too costly 
and complex to synthesize.(4)To fully characterize the early drug leadsusing 
spectroscopic methods and other wet chemistry methods if applicable. 
The Baker lab in the chemistry department of University of South Florida is responsible 
for the chemistry aspectsof this project. Our laboratory collaborates with biologists from 
City University of Hong Kong (CUHK), Mycosynthetix, and Magellan Bioscience, to 
discover the new drug leads for curing disease. 
Dr. Dennis Kyle from the College of Public Health at University of South Florida will 
perform all anti-malaria activity screening, including the in vitro antiplasmodial bioassay 
and in vivo antimalarial efficacy test when applicable. In addition, cytotoxicity 
screeningwill be performed and cytostaticity properties will be monitored to rule out the 
drug leadthat is not suitable drug candidates at early stage during the project. 
Prof. Lilian Vrijmoed’s group from CUHK is responsible for isolating endophytic fungi 
from mangrove plants collected around the world (including different ecosystems in the 
arctic, temperate, and tropical regions) and providing scale up cultivation on the active 
samples from the preliminary screen. They can isolate up to 500 endophytic fungi strains 
from a typical branch of a mangrove tree.  
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Dr. Cedric Pearce from Mycosynthetix, Inc.will provide terrestrial fungal samples. The 
company has an extensive library of fungi. It will also provide any scale-up cultivation of 
the active samples. 
Drs. Todd Daviau and John Cronan from Magellan Bioscience will provide marine cave-
eubacteria. Magellan Bioscience offers diverse library of microorganisms and fungi from 
the ocean although only marine-cave eubacteria will be provided and screened in this 
project. 
4.2.2 Endophytic Fungi as a Source of Bioactive Compounds 
Our laboratory was responsible for finding small molecules drugs of natural origin to 
combat the disease. This dissertation work has focused on searching for active-
antimalarials from the endophytic fungal collection from the CUHK. The entophytic 
fungi were collected from Mai Po Nature Reserve from Hong Kong. 
4.2.3 Bioassay-guided isolation of active anti-malarials 
Freeze-dried endophytic fungi samples prepared by the CUHK were extractedat USF 
with 1:1 DCM and MeOH. The crude extract produced from the extraction was sent to 
Kyle’s lab for preliminary malaria assay. The active antimalarial crude extract was 
subjected to normal phase MPLC by gradient elution (100% hexane to 100% to EtOAc to 
100% MeOH) for the first round of fractionation. The MPLC-generated fractions were 
prepared for the antimalarial and cytotoxicity screening by plating 30 mg/mL of each 
fraction in 96-well plates. Another chromatographic separation was performed on the 
fully (>67% inhibition, high priority) and partially active fractions (33-67% inhibition, 
low priority) that exhibit anti-malarial activity. Cytostatic property was observed in the 
cytotoxicity assay when the cells tested stopped dividing. The fractions were 
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resubmittedto Dr. Kyle laboratory for a second round of bioassay. Active fractions again 
would be further purifiedinto pure compounds for the final bioassay.  
4.2.4Compounds Characterization and Known Compound Identification 
Known compounds from marine and microbial source database, Antimarin,was used to 
help identifying known compounds isolated throughout the project. Isolated pure 
compounds were subjected to search using the database using either molecular mass data, 
or 1H or 13C NMR chemical shift data.A complete NMR data set (1H, 13C, COSY, 
HMBC, HSQC, ROESY) was obtained for potential new compounds whose structure 
was not found in the database.NMR data sets were obtained for all compounds before the 
Antimarin database was purchased. All compounds isolated and identified were given 
chemist code (Wai) with number in the order of discovery. 
4.3 Active Anti-malarials Identified 
4.3.1 Cytochalasins 
The Cytochalasinsare a class of mycotoxin which binds to actin in cells and prevents its 
polymerization and elongation. As a consequence of this action, cytochalasins halt 
cellular process such as cell division. They were first isolated by Aldridge and Turner at 
Imperial Chemical Industries and Tamm in Zurich in the 1960s.75,76Cytochalasins stop 
the cell’s ability to divide and ultimately promote apoptosis. Cytochalasins were 
commonly found in several fungi including Helminthosporium sp.,Phoma sp.,Xylaria 
sp.,Hypoxylon sp. and Chalara sp.25Aspochalasins from Aspergillus flavipesare known to 
display anticancer activity by inhibiting actin polymerization within the cytoskeleton. 
There is a largenumber of cytochalasins reported up-to-date. The structural features of 
cytochalasins are diverse among different subgroups of cytochalasins. Nevertheless, 
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cytochalasins are generally characterized by the presence of a hydrogenated and highly 
substituted bicyclic isoindolone unit fused to a macrocylic ring (Figure 4.6)23The 
structure of the macrocyclic ring varies widely within the cytochalasins. It can be a 
lactone, a carbonate, or carbocycle; whereas the C-3 of the hydrogenated isoindoloneis 
most commonly substituted with an isopropyl, benzyl or an indole group.77 The structure 
verification of known cytochalasins is often challenging because many cytochalasins 
were reported in the older literature where their NMR data is not clearly provided. 
 
Figure 4.6. Nomenclature of the cytochalasin scaffolds. 
4.3.1.1 Wai-1and Its Relative Stereochemistry 
Wai-1 (4.25) was isolated from the CY 5331 extract after repeated chromatographic 
fractionation and purificationsteps (Scheme 4.1). CY 5331 was later identified as Xylaria 
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sp..Extensive NMR and mass spectroscopic data revealed the planar structure of Wai was 
identical to that of cytochalasin Q reported in the literature.78 
 
 
Scheme 4.1.The separation scheme of CY5331. 
Upon comparison of the 1H and 13C NMR data between Wai-1 and cytochalasin Q, slight 
discrepancies of a few NMR chemical shifts were found (Table 4.1), and different 
stereochemistry for Wai-1 is suspected than that reported for cytochalasin Q. 
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Table 4.1.1H and 13C chemical shifts of Wai-1 (4.25) and that reported for the cytochalasin Q(chemical 
shift discrepancies in red). 
  Wai-1 (4.25)   Cytochalasin Q72   
Position  1Ha 13Cb 1Ha 13Cb 
1  174.6  174.4 
2 (NH) 6.06   5.69  
3 3.55 (m) 54.1 3.55 (t, 7.3) 54.0 
4 2.08 (dd, 5.9, 2.1) 50.5 2.08 (dd, 5.7, 2.3) 50.7 
5 1.66 (m)  36.7 1.69 (dq, 7.3, 5.7) 36.8 
6  57.0  57.0 
7 2.68 (d, 5.6)  62.5 2.70 (d, 5.6) 62.5 
8 2.50 (dd, 10.0, 5.6)  45.1 2.50 (dd, 10.0, 5.6) 45.1 
9  55.1  55.0 
10 2.78 (m)  45.8 2.75 (d, 7.2) 45.9 
11 0.79 (d, 7.3) 12.5 0.96 (d, 7.3) 12.6 
12 1.14 (s) 19.3 1.16 (s) 19.3 
13 5.81 (dd, 15.7, 10.0) 131.7 5.81 (dd, 15.7, 10.0) 131.8 
14 5.22 (ddd, 15.7, 10.8, 
5.2) 
131.8 5.23 (ddd, 15.7, 10.8, 5.2) 131.8 
15 2.43 (m) 37.9 2.45 (ddd, 11.6, 11.1, 11.1) 37.9 
 1.97 (m)   1.97 (ddt, 13.0, 5.3, 1.0)  
16 2.70 (m) 42.2 2.71 (m) 42.3 
17  210.4  210.4 
18  77.7  77.7 
19 6.06 (dd, 15.7, 2.5) 130.8 6.06 (dd, 15.7, 2.5) 130.9 
20 5.08 (dd, 15.7, 2.4) 127.6 5.09 (dd, 15.7, 2.4) 127.7 
21 5.77 dd, 2.5, 2.4) 76.0 5.77 (dd, 2.5, 2.4) 75.9 
22 1.17 (d, 6.8)  19.6 1.17 (d, 6.9) 19.6 
23 1.46 (s) 24.2 1.47 (s) 24.2 
24  169.7  170.7 
25 (OAc) 2.20 (s) 20.7 2.20 (s) 20.8 
1’  136.9  137.0 
2’, 6’ 7.30 (m) 129.2 7.31 (m) 129.1 
3’, 5’ 7.14 (m) 128.9 7.14 (m) 129.0 
4’ 7.22 (m) 127.1 7.24 (m) 127.4 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
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In order to verify and elucidate the stereochemistry of Wai-1, a ROESY NMR spectrum 
was acquired (Figure 4.7). The H-3 (δH 3.55) did not showed a correlation to H-4 (δH 
2.08) according to the ROESY spectrum, indicating they are in a trans relationship.The 
presence of correlation between H-3 withH-11 (δH 0.79) and with H-12 (δH1.14)agreed 
with thesyn relationship of that in cytochalasin Q. H-11 showed no correlation to H-10 
(δH 2.78), which further supported the assigned syn relationship between H-3, H-11 and 
H-12. H-5 correlated to H-8 ()H-4 displayed ROESY correlation to H-21 (δH5.77). H-22 
(δH 1.17) displayed no correlation to H-23 (δH 1.46), indicating that they were in trans 
relationship.The identity of Wai-1 was cytochalasin Q, with identical stereochemistry. 
 
 
 
 
 
 
 
 
Figure4.7.ROESY spectrum (500 MHz, CDCl3) and 3D diagram of Wai-1 (4.25). 
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4.3.1.2 Other Known Cytochalasins Identified 
Many other similar cytochalasins have been isolated and identified from the CUHK 
extracts after the initial isolation of cytochalasin Q (4.25), including cytochalasin C (Wai- 
5 4.26), R (Wai-6 4.27), D (Wai-7 4.28), N (Wai-8 4.29), 19,20-epoxycytochalasin C 
(Wai-9 4.30), cytochalasin H (Wai-10 4.31),and J (Wai-15 4.32) (See Tables4.2-4.8 for 
NMR data of the isolated cytochalasins and the reported data from the literature).They 
were isolated from CY 5368 and CY 5286 (Scheme 4.2 and 4.3). CY 5368 was identified 
as Verticillium sp. while CY 5286 was found to be Diaporthe sp.All cytochalasins 
isolated belong to the [13] cytochalasin scaffold. Their structures varied by the olefin and 
epoxidation between C-6 and C-7, C-13 and C-14, or C-19 and C-20. Moreover, the 
carbonyl moiety on C-17 that was present on majority of the cytochalasins obtained were 
missing for cytochalasin H and J. Due to the cytostatic property of cytochalasins, they are 
poor drug candidates. 
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Scheme 4.2.The separation scheme of CY 5286. 
 
 
CY 5368 (4.2g)
-6(1:1 CH2Cl2:MeOH)
1.98g
Silica MPLC
100% MeOH
1 2 3 4 5 6 7 8 9 10 11
50%EtOAc/Hexane
4 mg 16mg 31mg 56mg 11mg 42mg 128mg 176mg 375mg
12
27mg 21mg 299mg
combined based on similar 1H NMR spectrum
and TLC showing the fractions all containing
similar components
1 2 3
100% EtOAc 100% MeOH
Flash Column
41mg
NP silica HPLC
1.5%MeOH/DCM
Wai-7 (4.28)
Cytochalasin D
(1mg)
Wai-8 (4.29)
5,6-Dihydroxycytochalasin C
(1 mg)
Wai-9 (4.30)
19,20-epoxycytochalasin C
(1 mg)
 
 
Scheme4.3.The separation scheme of CY 5368.  
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Table 4.2.1H and 13C chemical shifts of Wai-5 (4.26) and that reported for cytochalasin C. 
  Wai 5 (4.26) Cytochalasin C 
Position  1Ha 1Hb79 13Cc79 
1    170.9 
2 (NH)     
3 3.69 (m) 3.69 (ddt, 7.5, 7.5, 1.5) 50.7 
4 2.88 (d, 1.4) 2.88 (d, 1.5) 50.7 
5    126.9 
6    134.1 
7 4.45 (m) 4.40-4.51 (m) 61.1 
8 3.07 (dd, 10.3, 10.1) 3.09 (dd, 10.0, 10.0) 50.7 
9    53.8 
10 3.16 (m) 3.16 (dd, 13.0, 7.5) 43.4 
 3.22 (m) 3.22 (dd, 13.0, 7.5)  
11 1.94 (s) 1.95 (s) 17.2 
12 1.40 (s) 1.41 (s) 19.5 
13 6.59 (m) 6.59 (ddd, 15.4, 10.0, 1.0) 132.8 
14 5.53 (m) 5.54 (ddd, 15.4, 10.0, 5.5) 133.5 
15 1.94 (m) 1.93-1.96 (m) 38.2 
 2.66 (m) 2.60-2.75 (m)  
16 2.66 (m) 2.60-2.75 42.5 
17    210.9 
18    78.6 
19 5.65 (dd, 15.4, 2.3) 5.66 (dd, 15.5, 2.5) 130.0 
20 6.84 (dd, 15.5, 2.3) 6.84 (dd, 15.5, 2.5) 133.5 
21 6.41 (m) 6.41 (dd, 2.5, 2.5) 76.4 
22 1.05 (d, 6.2) 1.05 (d, 6.3) 14.9 
23 1.58 (s) 1.58 (s) 24.8 
24    175.7 
25 
(OAc) 
2.38 (s) 2.38 (s) 
20.7 
Ar-H 7.22-7.34 (m) 7.22-7.34 (m) 139.0 
    129.1 
    128.6 
      127.0 
aRecorded at 500 MHz in C5D5N 
bRecorded at 400 MHz in C5D5N 
cRecorded at 100 MHz in C5D5N 
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Table 4.3.1H and 13C chemical shifts of Wai-6 (4.27) and that reported for cytochalasin R. 
  Wai 6 (4.27) Cytochalasin R 
Position  1Ha 13Cb 1Hc78 13Cd79 
1  174.5  174.2 
2 (NH) 9.6 (s)   9.7 (s)  
3 3.96 58.5 3.96 (ddd, 7.0, 7.1, 2.0) 54.3 
4  51.2 2.40 (dd,5.7, 2.0) 51.0 
5  37.1 1.85 (dq, 5.7, 7.3) 36.8 
6  54.6  55.7 
7 3.39 (d, 5.8) 61.5 3.39 (d, 5.7) 61.2 
8  44.2 1.98 (dd, 8.6, 5.7) 44.0 
9  56.0  54.5 
10  46.2 2.84 (dd, 13.2, 7.7) 45.9 
    3.11 (dd, 13.2, 6.4)  
11 0.72 (d, 7.4) 12.8 0.71 (d, 7.3) 12.6 
12 1.21 (s) 19.8 1.20 (s) 19.5 
13 4.36 (dd) 54.5 4.37 (dd, 8.6, 2.0) 58.2 
14  61.8 3.0-3.12(m) 61.5 
15  38.1 1.95-2.09 (m) 37.9 
    2.12 (dd, 12.4, 1.5)  
16  38.0 3.0-3.12 (m) 37.7 
17  212.7  212.5 
18  77.8  77.6 
19  129.3 6.22 (dd, 12.5, 2.6) 131.4 
20  131.7 7.18 (dd, 12.5, 2.6) 129.1 
21 6.25 (s) 75.6 6.25 (s) 75.3 
22 1.06 (d, 6.8)  20.6 1.03 (d, 6.8) 20.3 
23 1.63 (s) 24.5 1.62 (s) 24.2 
24  169.8  169.6 
25 
(OAc) 
 21.0 Not listed 20.7 
1’ Ar-5H=7.20-7.38(m) 137.0 Ar-5H=7.20-7.38 (m) 136.8 
2’, 6’  129.3  129.1 
3’, 5’  128.3  129.1 
4’  127.5  127.3 
Assignment of position 3 and 13 may be reversed 
aRecorded at 500 MHz in C5D5N 
bRecorded at 125 MHz in CDCl3 
cRecorded at 400 MHz in C5D5N 
dRecorded at 100 MHz in CDCl3  
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Table 4.4.The 1H and 13C chemical shifts of Wai-7(4.28) and that for cytochalasin D. 
Wai-7 (4.28) Cytochalasin D80,81 
Position 1Ha 13Cb 1Ha 13Cb 
1 173.6 173.6 
2 (NH) 4.65 (brs) 4.64 (brs) 
3 3.23 (m) 53.5 3.22 (m) 53.5 
4 2.84 (m) 47.0 2.84 (m) 47.0 
5 2.15 (t, 4.19) 50.0 2.14 (t) 50.0 
6 147.5 147.5 
7 3.81 (d, 10.4) 69.8 3.80 (d) 69.8 
8 2.83 (m) 32.6 2.83 (m) 32.6 
9 53.3 53.2 
10 2.76 (m) 45.3 2.76 (m) 45.3 
11 0.95 (d, 6.72) 13.6 0.94 (d) 13.6 
12 5.09 (s) 5.30 (s) 114.5 5.08 (s) 5.29 (s) 114.5 
13 5.33 (m) 134.1 5.33 (m) 134.1 
14 5.69 (dd, 15.7, 9.75) 130.6 5.69 (dd) 130.6 
15 
2.03 (dd, 10.6, 5.34) 
2.51 (dd, 23.1, 11.1)  37.7 2.02 (dd) 2.51 (dd) 37.7 
16 2.73 (m) 42.3 2.73 (m) 42.3 
17 210.2 210.2 
18 77.7 77.7 
19 5.14 (d, 15.8) 127.1 5.14 (d) 127.1 
20 6.11 (dd, 15.7, 2.61) 132.3 6.11 (dd) 132.3 
21 5.62 (m) 77.2 5.62 (m) 77.3 
22 1.19 (d, 6.84) 19.4 1.20 (d) 19.4 
23 1.50 (s) 24.2 1.51 (s) 24.2 
24 169.7 169.7 
25 (OAc) 2.26 (s) 20.8 2.26 (s) 20.8 
1’ 137.2 137.2 
2’ 6’ 7.13 (d, 7.03) 129.1 7.13 (d) 129.1 
3’ 5’ 7.28, (m) 128.9 7.28 (m) 128.9 
4’ 7.28 (m) 127.6 7.28 (m) 127.6 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
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Table 4.5.1H and 13C chemical shifts of Wai-8 (4.29) and that reported for cytochalasin N. 
  Wai 8 (4.29) Cytochalasin N  
Position  1Ha 1Hb79 13Cc79 
1    174.9 
2 (NH) 9.52 (s) 9.55 (s) 
3 4.55 (m) 4.55 (ddd, 7.0, 7.0, 2.0) 56.8 
4    49.0 
5    65.7 
6    63.4 
7 4.15 (m) 4.15 (dd, 10.5, 6.0) 70.2 
8 3.81 (m) 3.81 (dd, 10.5, 6.0) 42.4 
9    55.6 
10 3.15 (d, 6.8) 3.16 (d, 7.0) 45.4 
11 1.58 (s) 1.59 (s) 20.2 
12 1.25 (s) 1.25 (s) 19.4 
13 6.60 (dd, 14.7, 10.0) 6.61 (dd, 15.5, 10.5) 129.0 
14 5.45 (m) 5.47 (ddd, 15.5, 10.5, 4.5) 130.0 
15 1.94 (m) 1.95 (ddd, 11.5, 5.5, 1.0) 38.7 
 2.64 (m) 2.58-2.75 (m) 
16 2.64 (m) 2.58-2.75 (m) 44.5 
17    210.9 
18    78.5 
19 5.64 (dd, 15.8, 2.2) 5.65 (dd, 16.0, 2.5) 131.2 
20 6.75 (dd, 15.7, 2.2) 6.76 (dd, 16.0, 2.5) 131.2 
21 6.22 (m) 6.22 (dd, 2.5, 2.5) 76.2 
22 1.02 (d, 6.2) 1.02 (d, 6.5) 14.8 
23 1.56 (s) 1.56 (s) 24.6 
24    170.7 
25 (OAc) 2.37 (s) 2.38 (s) 20.7 
Ar-H 7.29-7.38 (m) 7.29-7.38 (m) 127.4 
    128.2 
    129.0 
      138.4 
aRecorded at 500 MHz in C5D5N 
bRecorded at 400 MHz in C5D5N 
cRecorded at 100 MHz in C5D5N 
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Table 4.6.1H and 13C chemical shifts of Wai-9 (4.30) and that reported for 19,20-epoxycytochalasin C. 
 Wai-9 (4.30) 19,20-epoxycytochalasin C78 
Position 1Ha 13Cb 1Hc 13Cd 
1  174.1  174.0 
2 (NH) 5.61 (brs)  5.56 (brs)  
3 3.34 (m) 60.7 3.33 (dd, 8.2, 6.7) 60.6 
4 2.54 (brs) 50.7 2.52 (brs) 50.7 
5  126.5  126.5 
6  131.3  131.3 
7 3.81 (d, 9.2) 68.0 3.78 (d, 9.8) 68.0 
8 2.26 (dd, 10.0, 9.8) 49.2 2.26 (dd, 10.2, 9.8) 49.2 
9  51.4  51.4 
10 3.06 (dd, 15.1, 7.6), 
2.99 (dd, 13.5, 9.0) 
44.7 3.06 (dd, 13.5, 6.0), 2.99 
(dd, 13.5, 9.2) 
44.7 
11 1.43 (s) 14.0 1.41 (s) 13.9 
12 1.65 (s) 17.1 1.65 (s) 17.1 
13 6.13 (dd, 15.7, 10.4) 133.9 6.13 (dd, 15.7, 10.2) 133.9 
14 5.73 (m) 131.6 5.70 (ddd, 15.8, 9.9, 6.1) 131.6 
15 2.68 (m) 37.4 2.67 (ddd, 12.6, 10.1, 
10.0), 2.09 (m) 
37.4 
16 3.22 (m) 41.8 3.22 (ddq, 10.8, 6.7, 1.2) 41.8 
17  215.2  215.2 
18  76.3  76.3 
19 3.20 (d, 1.93) 59.9 3.19 (d, 2.0) 59.9 
20 3.42 (m) 53.0 3.42 (dd, 2.0, 0.8) 53.0 
21 5.76 (brs) 71.9 5.74 (brs) 71.9 
22 1.21 (d, 6.7) 19.2 1.18 (d, 6.7) 19.2 
23 1.50 (s) 21.9 1.50 (s) 21.9 
24  170.1  170.1 
25 (OAc) 2.14 (s) 20.8 2.14 (s) 20.8 
1'  137.5  137.5 
2' 6' 7.32 (m) 128.1 7.31 (m) 129.1 
3' 5' 7.22 (m) 128.9 7.19 (m) 128.9 
4' 7.25 (m) 127.0 7.25 (m) 127.0 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
cRecorded at 400 MHz in CDCl3 
dRecorded at 100 MHz in CDCl3 
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Table4.7.1H and 13C chemical shifts of Wai-10 (4.31) and that reported for cytochalasin H. 
 Wai-10 (4.31) Cytochalasin H82,83 
Position 1Ha 13Cb 1Hc 13Cd 
1  174.2  174.3 
2 (NH) 5.30 (s)  5.6  
3 3.25 (m) 53.7 3.23 (m) 53.8 
4 2.13 (t, 4.4) 50.5 2.12 (t) 50.3 
5 2.77 (m) 32.9 2.77 (m) 32.8 
6  147.9  148 
7 3.83 (d, 10.9) 69.7 3.82 (d) 69.7 
8 2.94 (t, 10.3) 47.2 2.93 (t) 47.2 
9  51.8  51.5 
10 2.86 (dd, 13.5), 2.64 (m) 45.6 2.85 (dd), 2.64 (dd) 45.6 
11 1.00 (d, 6.74) 14.1 1.00 (d) 14.1 
12 5.11 (s), 5.35 (s) 114.1 5.15 (s), 5.35 (s) 114.1 
13 5.73 (dd, 15.6, 9.7) 125.9 5.75 (ddd) 125.9 
14 5.40 (m) 138.1 5.40 (ddd) 138.1 
15 1.78 (m), 2.03 (m) 42.7 1.77 (m), 2.00 (m) 42.8 
16 1.80 (m) 31.2 1.80 (m) 31.1 
17 1.56 (dd, 14.3, 2.7), 1.88 
(dd, 14.3, 3.0) 
53.7 1.56 (dd), 1.86 (dd) 53.8 
18  74.3  74.3 
19 5.56 (m) 127.1 5.56 (dd) 127.0 
20 5.86 (dd, 16.5, 2.8) 138.7 5.86 (dd) 138.6 
21 5.55 (m) 77.5 5.55 (dd) 77.5 
22 1.04 (d, 6.4) 26.4 1.05 (d) 26.5 
23 1.34 (s) 28.4 1.32 (s) 28.4 
24  170.1  170.1 
25 (OAc) 2.24 (s) 20.9 2.23 (s) 20.9 
1’  137.4  137.4 
2’ 6’ 7.14 (d, 7.0) 129 7.14 (d) 128.9 
3’ 5’ 7.30 (m) 128.9 7.30 (dd) 128.9 
4’ 7.25 (t) 127.1 7.25 (t) 127.0 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
cRecorded at 400 MHz in CDCl3 
dRecorded at 100 MHz in CDCl3 
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Table4.8.1H and 13C chemical shifts Wai-15 (4.32) and that reported for cytochalasin J. 
Wai-15 (4.32) Cytochalasin J84 
Position 1Ha 1Ha 13Cb 
1 178.5 
2 (NH) 7.69 (s) 7.69 (s) 
3 3.09 (m) 3.09 (m) 53.2 
4 2.54 (m) 2.55 (m) 48.1 
5 2.45 (m) 2.47 (m) 33.6 
6 151.9 
7 3.54 (m) ca. 3.55 71 
8 2.72 (m) 2.71 45.3 
9 53.8 
10a 2.72 (m) ca. 2.71 44.1 
10b 2.63 (m) 2.63 (dd) 
11 0.57 (d) 0.57 (d) 13.7 
12a 4.80 (s) 4.80 (s) 111.7 
12b 5.05 (s) 5.04 (s) 
13 5.48 (dd) 5.47 (dd) 131.2 
14 5.02 (ddd) 5.02 (ddd) 134.8 
15a 1.83 (m) 1.85 (m) 43.6 
15b 1.56 (m) ca. 1.56 
16 1.68 (m) ca. 1.68 28.3 
17a 1.62 (dd) 1.62 (dd) 54.2 
17b 1.37 (dd) 1.37 (dd) 
18 73.2 
19 5.75 (dd) 5.76 (dd) 129.3 
20 5.65 (dd) 5.65 (dd) 137.2 
21 5.10 (d) 5.10 (d) 75.2 
22 0.93 (d) 0.95 (d) 26.7 
23 1.14 (s) 1.14 (s) 31.6 
1' 137.9 
2' 6' 7.22 (d) 7.22 (d) 130.5 
3' 5' 7.29 (dd) 7.29 (dd) 128.7 
4' 7.21 (t) 7.21 (t) 127 
aRecorded at 400 MHz in d-DMSO
 
bRecorded at 100 MHz ind-DMSO 
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4.4Other Inactive Compounds Identified 
4.4.1 (2E,4E)-dimethyldeca-2,4-dienoic acid 
Wai-2, (2E,4E)-dimethyldeca-2,4-dienoic acid (4.33), was a new compound isolated 
along with the other active anitmalarial cytochalasins from CY 5331 but was inactive 
against malaria (IC50>2500µM). 
 
HRESIMI indicated the [M + H]+ ion for Wai-2 at m/z 197.1545, which suggested 
themolecular formula of C12H20O2(calc’d for C12H21O2, 197.1542). The structure of Wai-
2 was determined by extensive 1D- and 2-D NMR data (Figure 4.8-4.12). 
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Figure 4.8.1H NMR spectrum of Wai-2 (4.33), 500 MHz, CDCl3. 
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Figure 4.9.a) DEPT and b)13C NMR spectrum of Wai-2 (4.33), 500 MHz, CDCl3.  
a) 
b) 
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Figure 4.10.COSY spectrum of Wai-2 (4.33), 500 MHz, CDCl3. 
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Figure 4.11.HSQC spectrum of Wai-2 (4.33), 500 MHz, CDCl3. 
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Figure 4.12.HMBC spectrum of Wai-2 (4.33), 500 MHz, CDCl3.  
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The structure elucidation of Wai-2 began at C-1. The 13C NMR chemical shift indicated 
the chemical shift C-1 at δC 172.5 ppm, which corresponded to the carboxylic moiety of 
Wai-2. H-2 (δH5.82) showed correlations toC-1 and C-4 (δC 126.5) by HMBC. With the 
addition correlation observed in COSY between H-3 (δH 7.37) with H-2 and with H-4 (δH 
6.60), it is reasonable to deduce that C-1 through C-4 were connected in straight chain. 
H-4 was further correlated to H-5 (δH6.04) by COSY. H-5, in turn, showed HMBC 
correlation to C-3 (δC 147.7), C-4 (δC 126.5), C-6 (δC 35.0), C-7 (δC 43.8), and C-11 (δC 
18.9).The straight hydrocarbon chain was substituted with a methyl groups at C-6 (δC 
35.0) and C-8 (δC 32.0). As suggested by DEPT, C-11 is a methyl and H-11 correlated to 
C-5 (δC 152.0), C-6 and C-7.it must be a substituent on C-7 because it also displayed 
COSY correlation to C-6. Similarly, C-12 (δC 12.09) is a methyl group substituted on C-8 
supported by the COSY correlation between H-12 (δH 0.85) and H-8 (δH 1.83). DEPT 
NMR data further indicated C-7 (δC 43.8) and C-9 (δC 29.9) were the methylene carbons 
spaced between C-6, C-8 (δC 32.0), and C-10 (δC11.2). The terminal methyl protons H-10 
(δH 0.85) correlated to C-8 (δH 1.83) and C-9 (δH 1.83, 1.14) by HMBC. The key COSY 
and HMBC correlation of Wai-2 was illustrated in Figure 4.13. 
 
Figure 4.13.Key COSY and HMBC correlations of Wai-2 (4.33). 
The relative stereochemistry of Wai-2 was deduced by coupling constants. The coupling 
constant between the vinyl protons H-2 and H-3 and H-3 and H-4 implied that both 
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double bonds are in trans relationship (J2,3= 15.3 Hz and J3,4 =15.2 Hz). The detailed 1H 
and 13C NMR chemical shifts of Wai-2 were reported in Table 4.9. 
Table 4.9. The 1H and 13C chemical shifts of Wai-2 ((2E,4E)-dimethyldeca-2,4-dienoic acid) (4.33). 
Wai-2 ((2E,4E)-6,8-dimethyldeca-2,4-dienoic acid) 
(4.33) 
Position 1Ha 13Cb 
1 172.5 
2 5.82 (d, 15.4) 118.2 
3 7.37 (dd, 15.3, 10.9) 147.7 
4 6.20 (dd, 15.2, 10.9) 126.5 
5 6.04 (dd, 15.2, 8.3) 152.0 
6 2.38 (m) 35.0 
7 1.83 (m), 1.14 (m) 43.8 
8 1.83 (m) 32.0 
9 1.83 (m), 1.14 (m) 29.9 
10 0.85 (d, 7.3) 11.2 
11 1.03 (d, 6.6) 18.9 
12 0.85 (d, 7.3) 20.9 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
 
4.4.2 Ergosterol peroxide 
Wai-3, or ergosterol peroxide (4.34) was a presumed product of the H2O2-dependent 
enzymatic oxidation of ergosterol,85and was isolated from CY 5331. The identity of the 
isolated Wai-3 was verified by 1H and 13C NMR (Table 4.10) Although ergosterol 
peroxide contains the endoperoxide moiety, it lacked the potent antimalarial activity that 
artemisinin has. However, ergosterol peroxide was reported to exhibit 
immunosuppressive, anti-inflammatorgy, antiviral and antitumor activities. In particular, 
ergosterol peroxide strongly inhibited the growth of human leukaemia (HL60) cells.86 
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Table4.10.1H and 13C chemical shifts of Wai-3 compared to that for ergosterol peroxide (4.34). 
Wai-3 (4.33) Ergosterol Peroxide85 
Position 1H a 13C b 1Hc 13Cd 
1  34.7  34.7 
2  30.1  30.0 
3 3.97 (m) 66.5 3.97 (m) 66.2 
4  36.9  36.8 
5  79.4  79.3 
6 6.27 (d, 8.51) 135.2 6.25 (d) 135.0 
7 6.53 (d, 8.49) 130.7 6.52 (d) 130.5 
8  82.1  82.1 
9  51.2  51.0 
10  39.3  39.3 
11  20.6  20.6 
12  39.3  39.3 
13  44.5  44.5 
14  51.7  51.6 
15  23.4  23.4 
16  28.6  28.6 
17  56.2  56.1 
18 0.82 (s) 12.9 0.82 (s) 12.8 
19 0.89 (s) 18.2 0.89 (s) 18.1 
20  39.7  39.6 
21 0.99 (d,  6.6) 20.9 1.00 (d) 20.8 
22 5.21 (dd, 15.3, 8.0) 135.2 5.23 (dd) 135.3 
23 5.14 (dd, 15.3, 8.0) 132.3 5.15 (dd) 132.1 
24  42.7  42.7 
25  33.1  33.0 
26 0.82 (d, 6.9) 19.6 0.82 (d) 19.6 
27 0.83 (d, 6.9) 19.9 0.84 (d) 19.9 
28 0.91 (d, 6.8) 17.5 0.91 (d) 17.5 
aRecorded at 500 MHz in CDCl3 
bRecorded at 125 MHz in CDCl3 
cRecorded at 400 MHz in CDCl3 
dRecorded at 100 MHz in CDCl3  
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4.5 Discussion 
 
Cytochalasin is a common fungal mycotoxin produced by many endophytic fungi. Ten 
cytochalasins (with two was not identified) and two inactive compounds that were 
discovered during the MMV project were discussed in this chapter. Many other 
cytochalasins have been isolated and identified from many other MMV endophytic fungi 
samples by fellow workers in the Baker’s laboratory. Cytochalasins is a known to bind to 
actin filaments in cells and block polymerization and elongation of actin. The cytostatic 
nature of cytochalasin has prevented it from progressing onto the next stage of the study 
because the cytostatic activity is not selective. 
The antimalarial activity of cytochalasin has been reported previously. Cytochalasin B-
exerts its antimalarial activity by allowing the malaria parasite only attachingto the red 
blood cells but not being able to move or enter the red blood cells.87In a more recent 
study, the mode of action of cytochalasin D was investigated. Since cytochalasin D is 
well-known to prevent actin elongation and promotes the dispersion of existing actin 
filaments, the study suggested that actin is required for endocytic trafficking in 
Plasmodium falciparum. Cytochalasin D promote actin filament of the parasite to 
depolymereize and inhibits haemoglobin digestion as a result of disrupted endocytosis 
within the parasite.88 
Fungal fatty acids from the endophytic fungi studied during the MMV project were found 
to be abundant component present in the lipophillic (1:1 DCM/MeOH) fungal extract. 
Many fungi produce the same common fatty acids.89 However, Wai-2 was produced in 
small quantity. It is common for endophytic fungi to produce unsaturated fatty acid. 
Several issues needed to be address with thehigh throughput screening. The most active 
compound in a MPLC fraction might only exist trace amount predominated by inactive 
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compounds. The small amount of compound responsible for the activityfor the entire 
fraction might not be isolated because it is easily lost during the multiple 
chromatographic separations.Also, lost of preliminary activity of the MPLC fractions was 
observed occastionally as the fractionswere purifiedinto pure individual compounds and 
it posed a problem in high throughput screening technique. This problem demonstrate 
good separations of compound is crucial because it leads to more pure  
Since MPLC fractions were dried and redissolved in DMSO for malaria assay, the 
occasional low solubility of some MPLC fractions in DMSO was  problematic. DMSO 
was the solvent of choice because of its non-toxic property and it is an universal solvent 
to dissolve most compounds that need to be tested. 
Since cytochalasin is a common fungal metabolite and is a bad drug lead, LCMS can be 
employed for identifying known cytochalasins rapidly from the active MPLC fractions 
without further characterization. Identification of cytochalasins was often a challenging 
task since many cytochalasins were reported in early literature, in which NMR data was 
not clearly reported. 
Related fungal strains isolated from the closely-related mangrove trees might be 
responsible forobtaining the similar types of natural products throughout the MMV 
project. This issue could be avoided by collecting fungal samples from different species 
of mangrove plants.Diversity of fungal metabolite can be increased significantly if the 
organism were collected at different ecosystems around the globe. 
4.6Summary and Conclusion 
In a nutshell, Ten identified and characterized compounds were discussed in this chapter. 
Eight compounds isolated were cytochalasins, two inactive compounds, and several more 
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dimeric and chromone compounds will be discussed in the next chapter.Most of these 
compounds were known but their antimalarial activities werenever reported. One inactive 
compound was isolated from an active extract of CY 5331.All compounds isolated during 
the MMV project with the associated antimalarial activities and molecular structures 
were summarized in Table 4.11 and Figure 4.14 respectively. 
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Table 4.11. MMV compounds summary and the associated anti-malarial activity against Plasmodium falciparum W2 and cytotoxicity against J 594 cells (newly 
discovered compounds in green). 
Sample Compound Name MW 
(g/mol) 
 Antimalariala 
Activity   
(IC50) 
Cytotoxicityb 
(IC50) 
CY5331-6-Fr2-fr4-HPLC2-8-HPLC3 (Wai-1) Cytochalasin Q (4.25)  507  26.4nM > 10 µM 
CY5331-6-Fr2-fr1-HPLC2-4 (Wai-2) (2E,4E)-6,8-dimethyldeca-2,4-
dienoic acid (4.33) 
196  >2500nM > 10 µM 
CY5331-6-Fr2-fr2-HPLC14 (Wai-3) Ergosterol peroxide (4.34) 428  >2500nM > 10 µM 
Wai-4 (Same as Wai-1) Cytochalasin Q (4.25) 507  26.4nM > 10 µM 
CY5331-6-Fr4-HPLC9n10-HPLC3(Wai-5) Cytochalasin C (4.26) 507  136nM > 10 µM 
CY5331-6-Fr4-HPLC5-HPLC9n10-HPLC2 (Wai-6) Cytochalasin R (4.27) 524  290nM ND 
CY5368-6-Fr3-5-fr1-3-HPLC12 (Wai-7) Cytochalasin D (4.28) 507  25.8nM ND 
CY5368-6-Fr3-5-fr1-3-HPLC10 (Wai-8) Cytochalasin N (4.29)   ND ND 
CY5286-6-Fr3-5-fr1-3-HPLC11 (Wai-9) 19,20-epoxycytochalasin C (4.30) 524  ND ND 
CY5286-6-Fr4-HPLC22n23-HPLC9-11 (Wai-10) Cytochalasin H (4.31) 493  ND ND 
CY5286-6-Fr5-HPLC9-HPLC6 (Wai-11) Not identified   ND ND 
Wai-12 Cytochalasin H (4.31) 493  ND ND 
CY5286-6-Fr4-HPLC17 (Wai-13) Not identified   ND ND 
CY5286-6-Fr5-HPLC19-HPLC9  
(Wai-15) 
Cytochalasin J (4.32) 452  ND ND 
CY5188-6-Fr5-HPLC16 (Wai-16) Dicerandrol B (5.1) 708  41.9nM > 150 µM 
CY5188-6-Fr5-HPLC6 (Wai-17) Dicerandrol D (5.2) 708  630nM 7.8 µM 
CY5286third-Fr4-HPLC18n19-HPLC2-HPLC5 (Wai-18) Chromone Compound (5.3) 582  89.8nM ND 
CY5286third-Fr4-HPLC18n19-HPLC3-5-HPLC6 (Wai-19) Chromone Compound (5.4) 582  81.9nM ND 
        
a
 W2 Plasmodium falciparum 
bJ 594 cytotoxicity 
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Cytochalasin family: 
 
Non-active compounds: 
 
Figure 4.14. Structures of the cyctochalasins (4.25-4.32) and other non-active compounds (4.33-4.34) 
isolated from the MMV funded project. 
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Quantity of the compound isolated is a problem but it was relieved by the development of 
the latest NMR technology such as the cryoprobe for delivering improved signal-to-noise 
ratio and faster experiment time for milligram scale of compound. Furthermore, the 
organism source is renewable and the active compounds can be harvested repeatedly if 
needed. Culturing condition, such as the media of choice, pH and temperature, was an 
important factor in the types of compound an endophytic fungal sample produced. For 
instance, CY 5286 has produced majority cytochalasin but has produced chromone type 
compounds predominantly under different cultivation condition.  
Dicerandrol B and D, as well as two novel chromone compounds, which were 
alsoisolated as part of the MMV funded project will be discussed in Chapter 5. 
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Chapter 5 
Dimeric Xanthone and Chromone Derivatives as Malaria Treatments 
5.1 Introduction to Xanthone/Chromone Derivatives 
The xanthone structuresare considered to be “privileged structures” and are very 
interesting because they display a wide variety of pharmacological activities due to their 
tricyclic scaffolds.23Privileged Structures are molecular scaffolds with versatile binding 
properties and is a class of compounds that are represented in the bioactive compounds 
which displayed a wide range of biological activity. It serves as a starting point which 
allows medicinal chemist to design combinatorial chemistry or parallel synthesis 
libraries.90 More complex xanthone and chromone natural products were decorated with 
moieties such as glycosides, prenyl groups, and many others upon the basic scaffold 
(Figure 5.1).91 
 
 
Figure 5.1. Basic xanthone and chromone scaffolds. 
Xanthone derivatives targets many enzyme and cellular systems including aromatase, 
cyclooxygenases, and prostaglandin receptors, glutathione S-transferease, and quinine 
reductase, as well as various kinases and protease.91,92Xanthones derivatives can be 
monomeric, dimeric or trimeric.93 
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Isolated from an unidentified endophytic fungus of the endangered mint Dicerandra 
frutescens, dicerandrols are dimers of a class of mycotoxins termed xanthones and are 
structurally related to ergochromes and secalonic acids.94 Reported dicerandrols are 
symmetric or asymmetric. The malaria bioassay guided isolation of dicerandrols B and D, 
as well as two new dimeric chromones will be discussed in this chapter. 
5.2 Isolation and Characterization of Dicerandrols 
Wai-16 (5.1) and Wai-17 (5.2) were isolated as bright yellow solids from endophytic 
fungus sample CY 5188. CY 5188 was later identified to be Diaporthe sp. 
 
They eluted at different retention times from the same 2% MeOH/DCM NP silica gel 
HPLC analysis (Scheme 5.1). 
 
Scheme 5.1.The separation scheme for CY 5188. 
 
Wai-16 had a molecular weight, determined by HRESIMS [M+H]+m/z709.2124 (calc’d 
for C36H37O15 709.2133). The molecular formula suggested Wai-16 had 19 elements of 
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unsaturation. Most of the signals of Wai-16 in the 1H and 13C NMR spectrum (Figures 
5.2 and 5.3) appeared in pairs, due to the very similar but slightly asymmetric dimeric 
skeleton. 
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Figure 5.2.1H NMR spectrum of dicerandrol B (Wai-16) (5.1), 500 MHz, CDCl3. 
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Figure 5.3.13C NMR spectrum, of dicerandrol B (Wai-16) (5.1) 125 MHz, CDCl3. 
 
There were 32 carbon signals present on 13C NMR spectrum for 38 carbons. DEPT 
(Figure 5.4) spectrum indicated the molecule had 19 quarternary carbons, 8 methines, 4 
methylenes and 5 methyls. The detailed 1H and 13C data was recorded in Table 5.1. 
 
Figure 5.4.a) DEPT spectrum of Wai-16 (5.1), 125 MHz, CDCl3. b) 13C spectrum of Wai-16 for reference, 
125 MHz, CDCl3  
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Table5.1.1H and 13C chemical shifts of Wai-16 (5.1) and those reported from dicerandrol B. 
Wai-16 (5.1) Dicerandrol B 
Position 1Ha 13Cb 1Ha94 13Cc94 
1, 1' 
 
159.5 159.3 
 
160.3 160.3 
2,2' 
 
117.7 118.0 
 
118.9 118.5 
3,3' 7.38 (d, 8.5) 140.1 140.1 7.39 (d, 8.5) 141.0 141.0 
4,4' 6.43 (d, 8.5), 6.36 
(d, 8.5) 
107.8 107.8 6.43 (d, 8.5), 6.37 
(d,8.5) 
108.9 108.7 
4a, 4a' 
 
157.4 157.0 
 
158.9 158.5 
5,5' 5.59 (d, 1.5), 5.53 
(d, 1.6) 
70.4 70.2 5.61 (d, 1.5), 5.54 (d, 
1.5) 
71.8 71.6 
6,6' 2.34 (m) 27.7 27.7 2.35 (m) 28.5 28.5 
7,7' 2.47 (m) 33.4 33.4 2.47 ( m) 34.1 34.1 
8,8' 
 
178.0 177.8 
 
180.1 180.0 
8a,8a' 
 
100.8 100.4 
 
102.3 101.4 
9,9' 2.07 (s) 187.7 187.7 2.03 (s) 189.0 189.0 
9a,9a' 
 
108.2 107.9 
 
107.3 107.3 
10,10' 
      
10a, 10a' 
 
82.4 80.5 
 
83.8 82.0 
11,11' 1.01 (d, 6.4), 1.00 
(d, 6.4) 
17.6 17.6 1.01 (d, 6.0), 1.00 (d, 
6.0) 
17.8 17.7 
12,12' 4.48 (d, 13.0), 4.19 
(d, 13.0), 3.87 (dd, 
5.5, 13.0), 3.55 
(dd, 7.5, 13.0) 
65.5 65.3 4.49 (d, 13.0), 4.19 (d, 
13), 3.90 (dd, 5.5, 
13.0), 3.55 (dd, 7.5, 
13.0) 
66.0 65.8 
13,13' 
 
170.6 170.4 
 
171.4 171.3 
14,14' 2.02 (s) 20.9 20.7 2.00 (s) 21.0 21.0 
15' 
  
170.3 
  
171.1 
16' 2.04 (s) 
 
20.9 2.03 (s) 
 
20.9 
Enolic OH 14.01 (s), 13.97 (s) 
  
13.97 (brs), 13.97 
(brs) 
  
Phenolic OH 11.80 (s), 11.74 (s) 
  
11.82 (s), 11.76(s) 
  
CH2-OH 3.33 (d, 5.9), 3.31 
(d, 6.1) 
  
3.36, (t, 6.5) 
  
aRecorded at 500MHz in CD3CN  
bRecorded at 125MHz, in CDCl3 
cRecorded at 125MHz in CD3CN 
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COSY (Figure 5.5) and HMBC (Figure 5.6) experiments established the connectivity of 
the compounds. HSQC (Figure 5.7) revealed the direct connectivity between carbon 
atoms and protons. 
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Figure 5.5.COSY spectrum of Wai-16 (5.1), 500 MHz, CDCl3. 
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Figure 5.6.HMBC spectrum of Wai-16 (5.1), 125 MHz, CDCl3. 
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Figure 5.7.HSQC spectrum of Wai-16 (5.1), 500 MHz, CDCl3. 
Three spin systems were observed from the comprehensive NMR data.The aromatic 
protons H-3/3’(overlapping signal at δH7.52) and H-4/4’(δH6.53 and 6.48) were the only 
two protons belonging to the first spin system (Figure 5.8a) 
 
Figure 5.8a.First spin system of Wai-16 (5.5). 
They were attached a tetrasubstituted aromatic ring. COSY correlationssupported the fact 
that H-3/3’ and H-4/4’ were attached to the adjacent aromatic carbons C-3/3’ and C-
4/4’.C-1/1’ (both at δC 178.0) were the carbons substituted with their hydroxyl group as 
determined by their downfield 13C chemical shift. The HMBC correlation between H-3/3’ 
and oxygen-bearing quaternary carbon C-4a/4a’ (δC 157.0/157.4) and aromatic quaternary 
carbon C-9a/9a’ (both at δC 108.17) confirmed the membership of the last two carbons in 
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the aromatic ring.In addition, the phenolic proton on C-1/1’(δC 157.0, 157.4) showed 
correlation to C-1/1’, C-4/4’,and C-2/2’ The two monomers could be joined together in a 
2-2’ fashiontocomplete the assignment of the first spin system (Figure 5.8b).HMBC 
correlation between carbonyl carbon C-9/9’ (both at δC 187.7) and H-4/4’ established the 
connectivity between the aromatic ring and the second six-membered ring. 
 
Figure 5.8b. Completed first spin system of Wai-16 (5.1). 
The different substituents on C-12/-12’ (both at δC 65.3)was the sole difference between 
the two monomers. Methylene protonsH-12α, 12β/12’α, 12’β (δH4.12/3.56 and δH 
4.52/4.19) displayed two or three bonds HMBC correlation to C-10a/10a’ (δC82.5 and 
80.5), C-5/5’ (δC 70.4 and 70.2), and C-8a/8a’ (δC 100.8 and 100.4) (Figure 5.9a)with H-
12’specifically displaying HMBC correlation to acetyl carbon C-15’ (δC 170.4). 
Hydroxylated C-12 or acetylated C-12’ on each monomer represented the second spin 
system (Figure 5.9b), which H-5 (δH5.58), and H-5’ (δH 5.77) correlated to respectively. 
 
Figure 5.9. Second spin system of the a) monomer contains a hydroxyl group on C-12 and b) monomer 
contains the acetyl group on C-12’ of Wai-16 (5.1). 
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The last spin system of Wai-16 (Figure 5.10) consisted of the most number ofprotons and 
was separated by the middle six-membered ring from the first. The enolic protons (δH 
14.01 and 13.97) correlated to C-7/7’ (δC 33.4), C-8/8’ (δC 178.0), and C-8a/8a’ (δC 
100.39 and 100.81). TheHMBC spectrum also indicated correlation between H-5/5’ and 
C-13/13’ (δC 170.4 and 170.54). This completed tricyclic monomer assignment. 
 
Figure 5.10.Last spin system of Wai-16 (5.1). 
The relative stereochemistry of Wai-16 was deduced from the 1H-1H coupling constants 
and ROESY spectrum (Figure 5.11). 
Figure 5.11.ROESY spectrum of Wai-16 (5.1), 500 MHz, CDCl3.  
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The coupling constants J6,7α= 11.0 Hz and J6,7β= 6.5 Hz suggested a trans-diaxial 
relationship between H-6 and H-7β.The ROESY correlation between H-5/5’(δH 
5.59/5.53) and H-12/12’(δH 4.48, 3.87/ 4.19, 3.55) suggested that they are in a trans 
relationship as well.Comparison of the chemical shifts of 1H NMR chemical shifts to that 
of dicerandrol B confirmed the proposed structure of Wai-16 was identical to that of 
dicerandrol B (Table 5.1 and Figure 5.12). 
 
Figure 5.12.3D diagram the monomer of Wai-16 (5.1). 
As for Wai-17 (5.2), HRESIMS indicated a [M + H]+ ion at m/z709.2137(calc’d for 
C36H37O15 709.2133), which corresponded to  molecular formulaC36H36O15 and was 
isomeric to Wai-16.Wai-17 shared very similar chemical shifts in the1H NMR spectrum 
with Wai-16(Table 5.2).Wai-16 and Wai-17 differ only in stereochemistry at C-10a. 
ROESY (Figure 5.13) indicated no correlation between H-5 (δH5.82) and H-12 (δH5.02 
and 3.39) on Wai-17. Therefore the trans relationship between H-5 and the is deduced 
ROESY correlation between H-12 (δH 5.02 and 3.62) and H3-14 (δH 2.20) was also 
present to support the proposed stereochemistry (Figure 5.13).Wai-17, as an epimer of 
Wai-16, was a novel natural product. 
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Table 5.2.The 1H and 13C chemical shifts of isolated dicerandrol D (Wai-17) (5.2). 
Wai-17 (Dicerandrol D) (5.2) 
Position 1Ha 13Cb 
1, 1'  161.5 161.3 
2,2'  115.1 115.0 
3,3' 7.41 (d, 8.7), 7.31 (d, 8.7) 141.6 141.1 
4,4' 6.57 (d, 8.8), 6.52 (d, 8.8) 109.8 108.8 
4a, 4a'  154.1 154.1 
5,5' 5.82 (s), 5.60 (s) 70.0 70.0 
6,6' 2.56-2.29 (m) 28.1 27.7 
7,7' 2.56-2.29 (m) 33.4 33.4 
8,8'  177.6 177.1 
8a,8a'  101.0 99.7 
9,9'  187.9 187.5 
9a,9a'  106.2 106 
10,10'    
10a, 10a'  82.8 80.9 
11,11' 1.07 (d, 6.3), 1.04 (d, 5.8) 17.7 17.6 
12,12' 5.02 (d, 12.8), 3.62 (d, 12.8), 4.01 (dd, 
13.6, 5.1), 3.39 (dd, 13.5, 10.0) 
65.2 65.4 
13,13'  170.8 169.9 
14,14' 2.20 (s), 2.28 (s) 21.1 21.0 
15'   169.8 
16' 1.63 (s)  20.1 
enolic OH 14.23 (s), 13.98 (s)   
phenolic OH 11.98 (s), 11.68 (s)   
CH2-OH Not observed   
aRecorded at 500MHz in CDCl3 
bRecorded at 125MHz, in CDCl3 
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Figure 5.13.a) ROESY NMR spectrum of Wai-17 (5.2), 600 MHz, CDCl3. b) Expanded ROESY spectrum. 
a) 
b) 
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Figure 5.14.3D diagram the monomer of Wai-17 (5.2). 
5.3 Isolation and Characterization of Wai-18 and Wai-19 
 
Wai-18 (5.3) and Wai-19 (5.4), both with the molecular formula of C30H30O12, 
determined byHRESIMS m/z [M + H]+ 583.1837 [M + Na]+605.1546 (calc’d for 
C30H31O12 583.1816);  and HRESIMS m/z [M + H]+ 583.1842 [M + Na]+605.1630 
(calc’d for C30H31O12 583.1816) respectively. Wai-18 and Wai-19 were isolated from the 
second and third batch CY 5286 (Scheme 5.2).  
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Scheme 5.2.The separation scheme forCY5286 third batch. 
 
Unlike Wai-16 and -17, there was no acetyl group on Wai-18 and Wai-19 as deduced 
from the 1H and NMR 13C data (Table 5.3). 
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Table 5.3.The 1H and 13C chemical shifts of Wai-18 (5.3) and Wai-19 (5.4). 
 
  Wai-18 (5.3) Wai-19 (5.4) 
Position 1Ha 13Cb 1Ha 13Cb 
1, 1'  196.7 195.9 197.3 197.1 
2, 2' 3.22 (d, 17.1), 3.05 (d, 18.2), 2.90 
(m), 2.90 (m) 
38.2 37.9 
3.24 (d, 13.7) 3.21 (d, 13.7) 38.8 38.3 
3, 3'  83.0 82.9 83.5 83.3 
4, 4'     
4a, 4a'  158.1 158.1 158.7 155.8 
5, 5' 6.49 (dd, 5.37, 1.46) 106.9 106.9 6.59 (d, 8.8) 140.2 140.1 
6, 6' 7.47 (dd, 8.5, 1.5), 7.46 (d, 8.3) 140.9 140.7 7.29 (d, 8.3), 7.25 (d, 8.8)  109.9 107.4 
7, 7' 6.48 (dd, 5.5, 1.5)  117.2 117.2 6.50 (d, 8.3) 118.6 115.2 
8, 8'  159.0 159.0 161.9 158.7 
8a, 8a'  107.1 107.1 107.0 106.8 
9, 9' 4.39 (dd, 4.4, 1.46), 4.35 (dd, 4.4, 
1.5) 
86.5 86.4 
4.33 (d, 3.9), 4.22 (d, 3.9) 87.6 86.9 
10, 10' 2.90 (m) 29.9 29.4 3.10 (m), 2.88 (m) 29.6 29.2 
11, 11' 2.90 (m) ,2.90 (m), 2.82 (m), 2.24 
(d, 4.48) 
36.6 36.4 2.84 (m), 2.35 (m), 2.02 (d, 5.4), 1.99 
(d, 5.4) 36.4 36.2 
12, 12'  175.8 175.6 176.0 175.3 
13, 13'     
14, 14' 3.93 (m), 3.86 (m) 62.8 62.3 3.90 (m), 3.82 (m) 63.2 62.9 
15, 15' 1.30 (d, 6.8), 1.27 (d, 6.8) 20.8 20.6 1.30 (d, 6.8), 1.10 (d, 6.8) 20.8 20.5 
phenolic OH 12.04 (s), 12.01 (d, 1.5)     12.28 (s), 11.73 (s)     
 
aRecorded at 500MHz in CDCl3 
bRecorded at 125MHz, in CDCl3 
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The molecular mass of Wai-18 and Wai-19 were significantly lower than that of Wai-16 
(5.1) and Wai-17 (5.2), 709.2130. CY 5286 was also identified as Diaporthe sp., the 
same genus as CY 5188. Hence, it is reasonable to speculate CY 5286 and CY 5188 
biosynthesize similar dimeric xanthone derivatives. The characteristic chelated phenolic 
protons (δH12.0) were observed on the 1H NMR spectrum (Figure 5.15). The enolic 
protons which were observedapproximately at 14 ppm on Wai-16 and Wai-17 were 
absent, although the appearance of such signal is concentration-dependent. 
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Figure 5.15.1H NMR Spectrum of Wai-18 (5.7), 500 MHz, CDCl3. 
Upon careful examination on the 13C spectra from Wai-18 and -19, similar pairing pattern 
of resonances observed on that of Wai-16 and-17 was observed as they depicted 30 
resonances. The monomers of Wai-18 and Wai-19 were deduced to be the structure of 
dimeric chromones. DEPT spectra (Figure 5.16a and 5.16b) of Wai-18 and Wai-19 
revealed that there were ten quaternary, six methylene, eight methine, and two methyl 
carbons in the structure.  
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a) 
 
 
b) 
 
Figure 5.16. DEPT spectrum of a)Wai-18 (5.3)  and b)Wai-19 (5.4), 500 MHz, CDCl3. 
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The structure of Wai-18 was established using HSQC, HMBC and COSY data (Figure 
5.17-5.19). 
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Figure 5.17.HSQC spectrum of Wai-18 (5.3), 500 MHz, CDCl3. 
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Figure 5.18.HMBC spectrum of Wai-18 (5.3), 500 MHz, CDCl3. 
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Figure 5.19.COSY spectrum of Wai-18 (5.3), 500 MHz, CDCl3. 
The 1H NMR spectrum indicated aromatic signals on each monomer (δH 7.46 and δH6.49; 
δH7.47 and 6.48), where COSY data confirmed the correlation to each other and therefore 
be in ortho positions to each other. The monomers are connected through C-7’-C-5 
linkage as determined by the HMBC correlation between H-6’ (δH7.47) to C-5 (δC106.9) 
and H-6 (δH 7.46) to C-7’ (δC 117.2). H-6 and H-7 (δH6.48) were the only aromatic 
signals on the 1H NMR.H-6 also showed correlation to the carbon bearing the hydroxyl 
group, C-8 (δC 159.0), on the aromatic ring. HMBC correlations were also observed 
between C-14 (δC 62.8) and H-2α (δH3.22) and H-2β (δH 2.90) and the same correlations 
were observed for the other monomer unit. The HMBC correlation between C-3 (δC 82.9) 
and H-9 (δH 4.35) established the connection between the pyran ring and the five-member 
lactone unit. H-9 also correlates to C-10 (δC 29.4) and C-15 (δC 20.6). The correlations 
with the correlation between H-11α,β(δH 2.90 and 2.11) and C-12 (δC 175.6) confirmed 
the presence of the five-member lactone unit (Figure 5.20). 
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Figure 5.20.Key  HMBC (curved arrows) and COSY(bold bonds) correlations of Wai-18 (5.3) and Wai-
19.(5.4). 
 
13C and DEPT NMR spectra suggested that there were the same number and typesof 
carbon and optical rotation and CD suggested that they rotated light in different 
directions,depicting their different stereochemistry within their three stereocenters on 
each monomer.The NMR data of Wai-18 and was very closely similar to that of Wai-19 
with a few exception such as 13C chemical shifts were slightly different. The structure of 
Wai-19 was solved by 1H, 13C, COSY, HSQC, and HMBC data (Figure 5.21-5.25). 
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Figure 5.21.1H NMR Spectrum of Wai-19 (5.4), 500 MHz, CDCl3. 
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Figure 5.22.13C NMR Spectrum of Wai-19 (5.4), 125 MHz, CDCl3. 
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Figure 5.23.COSYspectrum of Wai-19 (5.4), 500 MHz, CDCl3. 
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Figure 5.24.HSQC spectrum of Wai-19 (5.4), 500 MHz, CDCl3. 
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Figure 5.25.HMBC spectrum of Wai-19 (5.4), 500 MHz, CDCl3. 
The stereochemistry was investigated by spectroscopic measurements including optical 
rotation and Circular Dichroism (CD) analysis.CD spectra and optical rotation data of 
was obtained for analyzing the chiralityfor Wai-18 and Wai-19. Wai-18 and -19 were 
both optically active with optical rotation of opposite sign (+24.113 and -84.396 
respectively) indicated different stereochemistry of the two dimeric xanthone derivatives. 
Axial chirality has been reported in dimeric chromones, a similar class of compounds.95 
5.4 Discussion 
 
Wai-16-19 (5.1-5.4) displayed potent activity against Plasmodium falciparum, at 41.9 
nM, 630 nM, 89.8 nM and 81.9 nM, respectively. It has been suggested that it is possible 
that a synthetic 4,5-dihydroxyxanthone exerts its activity by binding to heme and form a 
complex in the parasite’s acidic vacuole. It acted as inhibitors of spontaneous heme 
aggregation, and eventually preventing hemozoin formation.961H NMR study showed that 
the carbonyl moiety coordinated with the iron of heme.97It is possible that structurally 
related Wai-16-19 inhibited the parasite in a similar manner although the mode of action 
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of Wai-16-19 was not investigated during this work. It is also reported that xanthones are 
active against leishmaniasis, although in vitro assay. 
Wai-16-19 were dimmers isolated from The structural elucidation of the dimeric 
xanthone and chromones compounds were difficult but an intriguing process due to the 
pairing and overlapping of the 13C NMR signals. In addition to the antimalarial activity 
that was discovered during this work, dicerandrol B (Wai-16 5.1) was reported to display 
antibacterial activity against Staphylococcus aureus and Bacillus subtilus, although it was 
inactive against the fungus Geotrichum candidum and the yeast Saccharomyces 
cerevisiae at 300 µg/disk.94 
Axial chirality existed in Wai-18 and Wai-19 due to the restriction to rotation of the bond 
connecting caused by the hydroxyl groups between the two monounits. They displayed 
positive and negative Cotton effect.Phomopsis-H76 A (5.5), the asymmetrical dimeric 
chromone isolated from the endophytic fungus Phomopsis sp., was found to be 
structurally very closely related in to Wai-18 and -19, only differed from the substitution 
pattern of the aromatic rings.98 
 
In addition to Phomopsis-H-76 A, the Knoig’s group has isolated dimierc chromone 
monodictyochromes A (5.6) and B (5.7) from the marine algicolous fungus Mondodictys 
putredinis (Monodictys was an underexplored genus belonging to the ascomycetes).95 
The two monomers units of momodictyochromes A and B were spectulated to 
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connectedthrough a regioselective phenol oxidative coupling involving two activated 
sites of the aromatic moiety of each monmer. Also the connection was likely to be 
stereoselectively controlled since CD spectroscopy had revealed momnodictyochrome A 
and B were two atropisomers.95 5.6 and 5.7 were shown to demonstrate cancer 
chemopreventive potential by inhibiting cytochrome P450 1A and cultured mouse Hepa 
1c1c7 cells. 
 
Not surprisingly, the momomers produced by the same marine algicolous fungal strain 
Monodictys putredinis isolated from the inner tissue of an unspecified marine green 
collected in Tenerife, Spain displayed similar anticancer activity exhibited by their 
dimeric analogs.93 
 
Antimalarial activity was observed from four xanthones (5.11-5.14) when they were first 
isolated from the roots of Andrographis paniculata99, The xanthones were later reported 
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to display in vitroantiprotozoal activity against Trpanosoma brucei brucei, Trpanosoma 
cruzi and Leishmania infantum.45 Wai-16-19 could be active against the leishmania 
parasite if tested. 
 
5.5 Summary and Conclusions 
Interesting antimalarial dimeric xanthone and chromonefungal natural products were 
isolated as part of the MMV funded project in addition to the cytochalasins described in 
the previous chapter.Since endophytic fungi can be conveniently cultivate, active 
xanthone and chromone compounds could be produced repeatedly as desired although 
extra attention is needed to ensure chemicalconsistency by cultivating scale-up culture 
under the identical conditions for different batches. 
Xanthone and chromone targets inflammatory mediators, enzymes including kinases and 
proteases and receptors such as monoamine oxidase B (MAO-B). As mentioned, 
xanthone structure exhibits many interesting pharmacological activities. While Wai-16-
19 displayed potent antimalarial activities,they need to be tested against a diversity of 
cell-based and target-based assays to discover their therapeutic potential. 
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Chapter 6 
Summary and Concluding Remarks 
Natural product has been used by human over the course of history to cure diseases. 
Natural products are proven to be a rich source and structurally diverse compounds that 
were biosynthesized by organisms designed to bind to certain specific enzymes and is 
often a more effective drug. Despite the downfall of natural product in the pharmaceutical 
world over the last 20-30 years,100 natural product has continued to be a source of 
structurally diverse and bioactivenew molecular entities. From this dissertation, diverse 
classes of bioactive natural products were isolated from Antarctic invertebrates and 
mangrove endophytic fungi and they were found to be display growth inhibition against 
bacteria and tropical diseases including leishmania and malaria. 
In conclusion, number of new compounds and previously reported natural products were 
isolated during the dissertation work. Norselic acids were a series of steroid isolated from 
the Antarctic marine sponge Crella sp. Cytochalasins, xanthone and chromone 
compounds were isolated as active anti-malarials by bioassay guided method. 
From chapter 3, the discovery of norselic acids A-E were reported as novel natural 
product that is potent anti-leshmanial and antibiotic. Since they are steroids, they are not 
the best drug candidate because steroidal drugs tend to be the usual side effect.  
Natural product has been playing a crucial role in malaria and leishmaniasis therapy 
historically. The plant alkaloid quinine and artemisinin, both are natural products, have 
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been successful in treating malaria until resistant has been developed. Paromycin is a 
example of natural product produced by bacteria for treatment against visceral 
leishmaniasis.101From chapter 4, eightcytochalasins, (2E, 4E)-6, 8-dimethyldeca-2, 4-
dienoic acid, and ergosterol peroxide were isolated in the drug discovery project against 
malaria during the MMV-funded project. In chapter 5, two dimeric xanthone and two 
dimeric chromones were isolated, both structure were challenging to elucidate because of 
the overlapping or repeating 1H and 13C NMR resonances. Xanthone and chromones 
displayed activity against different biological targets. 
Strategy must be developed to screen out common metabolites or recurring compounds 
such as cytochalasins and to discovery better drug leads.Compounds display inhibition 
against malaria has to go through additional cytoctoxcity and cytostaticity evaluation as 
part of the preliminary screening process.Natural product drug discovery is traditionally a 
time-consuming process and contains a number of steps including extraction, purification 
and structure elucidation. Better separation of crude material will also provide better 
screening results. 
Discovery of common cytotoxic fungal metabolites that are not suited to develop into a 
drug can be avoided by building mass spectral library of such compounds. By screening 
the active hit fractions at the early stage of the compounds available in the library, 
dereplication can be carried out at the early stageto save time and resources for any 
further work on these hit fractions could be saved at the early stage. The use of known 
compound database also helps with quickly identifying unwanted compounds, avoiding 
time and cost spent on fully characterizing such compounds. 
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Although compound supply is a major obstacle to advancing a natural product lead into 
drug development. Compounds produced by microorganisms such as bacteria, or 
endophytic fungi investigated in this dissertation can be scale-up produced by repeat 
fermentation. Compounds generate by macroorganism such as marine invertebrates can 
be synthesized by organic synthesis or biosynthesis through genetic engineering. Organic 
synthesis and biosynthesis also plays an important role in drug lead optimization. 
The potential of natural product as a therapeutic treatment is not limited to against 
tropical diseases, but also as a cure to the diseases such as cancer, cardiovascular, 
neurological and metabolic diseases in the developed countries. As time elapse, 
pathogens will evolve and new diseases will emerge. New drugs are needed to treat new 
diseases and combat drug-resistance against diseases. 
There are plenty of marine natural products in the preclinical pipeline or in clinical trials. 
If traditional natural product research can couple with the effective separation and 
screening strategy, new powerful NMR technologies, advanced organic synthesis 
methodology and theconstantly improving genomicknowledge which enhance the 
discovery and screening of natural products, natural products research represents the 
endless opportunities for the new drug discoveryin the future. 
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Chapter 7 
Experimental 
 
7.1 General Experimental Procedures 
Optical rotations were measuredon an Autopol IV automatic polarimeter using a Na lamp 
at 25 °C with a 10 cm cell. Circular Dichroism data was recorded at room temperature on 
the AVIV Model 215 Circular Dichroism spectrometer in 1 cm cuvettes. UV-visible data 
were obtained on a Perkin-ElmerLambda 900 UV-vis/NIR spectrometer. Infrared spectra 
were obtainedwith a Nicolet Avatar 320 FT-IR spectrometer. 1H, 13C, DEPT 135,1H-1H 
COSY,1H-1H ROESY, HSQC, and HMBC spectra were obtained on a VarianInova 500 
instrument operating at 500 MHz for 1H and 125 MHz for13C. HPLC was performed with 
a Shimadzu LC-8A multisolventdelivery system connected to a Shimadzu SPD-10A UV-
vis tunableabsorbance detector using a YMC Pack ODS-AQ C-18 analyticalcolumn (250 
× 10 mm)for reversed phase, Phenomenex Sphereclone (250 × 10 mm), SunFire Prep 
silica column (250 × 10 mm)for normal phase, or YMC Pack CN preparative column 
(250 × 20 mm).Teledyne Isco Combiflash Companion MPLC with Teledyne Isco silica 
gel cartridges.Thin layer chromatography (TLC) was performed using Whatman normal 
phase silica gel 60Å Partisil®or reversed phase C-18 plate. TLC plates were stained with 
5% phosphomolybdic acid in EtOH and heating and visualized under UV light source. 
EMScience silica gel 60 of 230-400 mesh was used in flash columnchromatography. 
Mass spectroscopic data were obtained from AgilentTechnologies LC/MSD TOF. The 
crystal structure measurements wereperformed using a Bruker Smart APEX CCD 
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diffractometer usinggraphite-monochromated Cu KR radiation (λ ) 1.54178 Å) with 
ahemisphere scan mode at 100(2) K in the range 3.21° <θ < 65.13°.The structure was 
solved by direct methods with SHELXS-97. All nonhydrogenatoms were refined 
anisotropically. Hydrogen atoms wereplaced in calculated positions with fixed thermal 
parameters riding onthe parent atoms. The final refinement was performed by full-
matrixleast-squares methods on F2 by SHELXL-97. 
7.2 Supporting Informationfor Chapter 2 
Experimental Procedures 
Synthesis of Tris[3-trifluoroacetyl-l-camphorato]praseodymium (III) (2.1) 
Synthesis of 3-trifluoromethylhydroxymethylene-l-camphor ligand 
 
Attempts had been made for synthesizing 2.1following the literature procedure initially. 
The ligand of Pr(III) ion, 3-trifluoromethylhydroxymethylene-l-camphor was prepared by 
following procedure.102 Triisopropylamine was pre-dried using sodium sulfate and was 
distilled with calcium hydride. It was then dissolved in 10 mL of freshly distilled 
anhydrous diethyl ether in a round bottom flask under nitrogen which was cooled down 
to -78 °C. Six milliliter of BuLi was added to the stirring solution 1.0 M 1.00g of (S)-(-) 
camphor, ethyl trifluroacetate and was characterized by 1H (Figure 7.1) and 13C NMR 
(Figure 7.2) and its mass was verified by GC-MS (Figure 7.3).1H NMR (500 MHz, 
CDCl3) δ ppm2.89 (m, 1H), 2.09 (m, 1H), 1.78 (m, 1H), 1.46 (m, 2H), 1.01 (s, 3H), 0.97 
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(s, 3H), 0.84 (s, 3H);13C NMR (125 MHz, CDCl3) 214.2, 148.3, 120.5, 118.3, 117.7, 
58.1, 47.1, 30.1, 26.6, 20.4, 18.2, 8.4. 
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Figure 7.1.1H NMR spectrum of 13C NMR spectrum of 3-trifluoromethylhydroxymethylene-l-camphor 
((-)-tfc) ligand(CDCl3, 400MHz). 
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Figure 7.2.13C NMR spectrum of 3-trifluoromethylhydroxymethylene-l-camphor ((-)-tfc) 
ligand(CDCl3, 100 MHz).  
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Figure 7.3.GCMS chromatogram oftrifluoromethylhydroxymethylene-l-camphor(tfc). 
 
Coordination of the 3-trifluoromethylhydroxymethylene-l-camphor ((-)-tfc) Ligands 
to the Praseodymium (III) Ion 
3-Trifluoromethylhydroxymethylene-l-camphor ((-)-tfc) (392 mg, 0.444 mmol, 3equiv) 
was dissolved in 4 mL of reagent grade methanol in a round bottom flask. Sodium 
methoxide (24.0 mg, 0.444 mmol, 3 equiv), in 0.4 mL of methanol was added to the 
stirring reaction mixture. The reaction was stirred for 20 min before 52.6 mg of 
PrCl3·6H2O (0.148mmol, 1 equiv) in 1.2 mL of methanol was added to the stirring 
reaction mixture. The reaction was stirred at 40 °C for a further 20 min. The reaction was 
quenched by 5 mL of water and the reaction mixture was extracted with pentane three 
times. The combined organic layers were washed with water and concentrated. The solid 
residue was freeze-dried for 24 h. The solid was recrystallized from hot hexane. The 
synthesized (-)- Pr(tfc)3 was characterized by IR and NMR spectroscopy (Figure 7.4-
7.5).(+)-Pr(tfc)3 was prepared with the identical procedures.  
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-)-Pr(tfc)3(MeOD, 500 MHz). 
-)-Pr(tfc)3 (MeOD, 125 MHz). 
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Analysis of Tertiary Alcohols in the Presence of Lanthanide Shift Reagent 
Experiment  
The chiral tertiary alcohols were synthesized by Grignard reaction either using a 
commercially available Grignard reagent or from de novo preparation from the 
appropriate alkyl bromide.  
The 2D data (gCOSY, gHSQC and gHMBC) of the tertiary alcohols was collected 
through the Varian Inova 400 for the purpse of making carbon assignment. A Varian 
Inova 400 spectrometer was used to collect the 13C NMR data initially. However, the 400 
MHz spectrometer was unable to provide spectrum with signals having low enough 
signal to noise ratio at a reasonable time frame. A Varian Inova 500 spectrometer was 
used to collect all the 13C NMR data afterwards (Figure 7.6-7.10). Non-coordinating 
NMR solvent, CDCl3 or C6D6, used in the LCSR experiment was anhydrous and was 
stored in ampoules for single use only. Tertiary alcohol was prepared in NMR solvent at 
0.05M in the presence of 15 mol % of Pr(htc)3with respect to the tertiary alcohol. 
 
 
Figure 7.6.13C NMR spectra of tertiary alcohol(2.13) with a) 15 mol % (-)-Pr(tfc)3, b) 15 mol % (+)-
Pr(tfc)3 and c) no LCSR at 0.05M (C6D6, 500 MHz). 
OH
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Figure7.7.13C NMR spectra of tertiary alcohol (2.14) with a) 15 mol % (-)-Pr(tfc)3, b) 15 mol % (+)-
Pr(tfc)3 and c) no LCSR at 0.05M (C6D6, 500 MHz). 
 
Figure7.8.13C NMR spectra of tertiary alcohol (2.15)with a) 15 mol % (-)-Pr(tfc)3, b) 15 mol % (+)-Pr(tfc)3 
and c) no LCSR at 0.05M (C6D6, 500 MHz). 
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.  
Figure7.9.13C NMR spectra of tertiary alcohol (2.16) with a) 15 mol %(-)Pr(tfc)3, b) 15 mol % (+)Pr(tfc)3 
and c) no LCSR at 0.05M (C6D6, 500 MHz). 
 
 
Figure 7.10.13C NMR spectra of tertiary alcohol (2.17) with a) 15 mol %(-)Pr(tfc)3, b) 15 mol % (+)Pr(tfc)3 
and c) no LCSR at 0.05M (C6D6, 500 MHz). 
  
OH
2.16
a) 
 
b) 
 
c) 
a) 
 
b) 
 
c) 
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7.3 Supporting Information for Chapter 3 
Biomass Collection 
Crella sp. was typically collected from 30 to40 m depth at Norsel Point, Gamage Point, 
Janus Island, and HermitIsland, Antarctica, in 2001, 2003, and 2004. A voucher specimen 
wasidentified by Dr. Robert Van Soest, University of Amsterdam, wherethe voucher is 
held as ZMA17112. 
Extraction and Isolation of the Norselic Acids 
The freeze-dried biomass (193 g) wasextracted by MeOH/DCM (1:1 × 3 1 L). The 
resulting extract (34.0g, only 13.2 g was used) was partitioned between EtOAc and H2O. 
The EtOAc partition (5.7 g) was concentrated in vacuo and was loadedon a 60g self-pack 
silica gel flash column (EMScience silica gel 60 of 230-400 mesh). The EtOAc residue 
was fractionated witha step gradient from 100% hexane to 100% EtOAc to 100% MeOH. 
The 70% EtOAc/hexane fraction (792mg) containing crude norselic acid A(3.4)was 
concentrated in vacuo, followed by purification by recrystallization in 1:1 DCM and 
hexane for threedays to allow slow crystal formation yielding310 mg of crystal. Crude 
norselic acid B-E (3.5-3.8)(426mg) eluted with 60% EtOAc/hexane from the flash 
column. The fractionwas loaded on a second silica gel flash column. The 50% EtOAcand 
hexane fraction (245 mg) was subjected to an isocratic elution onanalytical NP HPLC 
column (Phenomenex Sphereclone (250 × 10 mm)) with 40% EtOAc/hexane to afford 
pure norselic acid B (3.5)(32 mg).The 40% EtOAc/hexane fraction (120 mg) eluted from 
the second flash column was further purified by HPLC on YMC pack preparative CN 
column(250 × 20 mm)to afford norselic acid B (3.6)(4mg), norselic acid C (3.7)(7.5 mg), 
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and (3.8)(8.3 mg). Additional norselic acid C (3.7)(2 mg) was obtainedafter further 
analytical RP HPLC using 80% aqueous methanol. 
Norselic Acid A (3.4): white, crystalline needles (from 1:1 hexane/CH2Cl2); mp 157-158 
°C; [α]20D +53 (c 0.2 CHCl3); UV (CH3OH)λmax (log ε) 299 (3.83) nm; IR (thin film) νmax 
3500, 1706, 1648 cm-1;1H and 13C NMR data, see Table 3.2; HRESIMSm/z 453.3000 [M 
+ H]+(calc’d for C29H41O4, 453.3005). 
Single-Crystal X-ray Crystallographic Data of Norselic Acid A(3.4)(conducted by 
the USF X-Ray Facility) 
Formula C29H40O4; MW 452.61; orthorhombic P212121; a )6.646(2) Å, b ) 17.261(5) Å, 
c ) 22.793(6) Å, V ) 2614.6(13) Å3, Z) 4, density(calculated) ) 1.150 mg m-3; crystal size 
0.45 × 0.16 ×0.12 mm3. The total number of reflections collected was 7788, of 
which3305 independent reflections were measured with an R(int) ) 0.0665. The final 
indices were R1) 0.0629, wR2) 0.1586, S ) 1.056.Crystallographic data have been 
deposited in the Cambridge CrystallographicData Centre (deposition number CCDC 
736592). These datacan be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif, or by e-mailing data_request@ccdc.cam.ac.uk, or 
by contacting TheCambridge Crystallographic Data Centre, 12 Union Road, 
CambridgeCB2 1EZ, UK; fax +44 1223 336033. 
Norselic Acid B (3.5): yellow, crystalline solid; mp 201 °C; [α]20D +42 (c 0.2 CHCl3); 
UV (CH3OH) λmax (log ε) 277 (2.51) nm; IR (thinfilm) νmax 3462, 1653, 1671 cm-1; 1H 
and 13C NMR data, see Table 3.5; HRESIMS m/z 457.3312 [M + H]+ (calc’d457.3318 for 
C29H45O4); m/z 439.3203 [M + H - H2O]+ (calc’d forC29H43O3, 439.3212). 
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Norselic Acid C (3.6): white, amorphous solid; [α]20D +43 (c 0.2CHCl3); UV (CH3OH) 
λmax (log ε) 267 (3.78) nm; IR (thin film) νmax1675, 1653; 1H and 13C NMR data, see 
Tables 3.4;HRESIMS m/z 425.3082 [M + H]+ (calc’d for C28H41O3, 425.3056). 
Norselic Acid D (3.7): yellow, glassy solid; [α]20D +54 (c 0.1 CHCl3);UV (CH3OH) λmax 
(log ε) 242 (4.00) nm; IR (thin film) νmax 3290,1670, 1655 cm-1; 1H and 13C NMR data, 
see Table 3.5; HRESIMS m/z 457.3306 [M + H]+ (calc’d for C29H45O4,457.3318). 
Norselic Acid E (3.8): yellow, glassy solid; [α]20D +57 (c 0.1 CHCl3);UV (CH3OH) λmax 
(log ε) 299 (3.70) nm; IR (thin film) νmax 3450,1622, 1615; 1H and 13C NMR data, see 
Table 3.6;HRESIMS m/z 495.3124 [M + H]+ (calc’d for C31H43O5, 495.3110). 
Antimicrobial Assays (conducted by Wyeth Pharmaceuticals) 
In Vitro antimicrobial activities againstmethicillin-sensitive (MSSA, strain 375) and -
resistant (MRSA, strain310) Staphylococcus aureus, vancomycin-resistant Enterococci 
faecium(VREF, strain 379), E. coli (strain 442), E. coli imp (strain 389, a mutantstrain 
with increased permeability to large molecular weight compounds),and Candida albicans 
(strain 54) were determined by an agardiffusion method. Media used were Difco nutrient 
agar (pH 6.8) for S.aureus, LB (Luria-Bertani) agar for E. faecium and E. coli, and 
YM(yeast maltose) agar for C. albicans. Assay plates (9 in. × 9 in.,Sumilon) were 
prepared by pouring a 125 mL volume of agar medium(tempered at 50 °C) inoculated 
with an overnight broth culture of thetest organisms (adjusted to approximately 106 cells 
per mL). Sampleconcentrations of 200 µg in 10 µL aliquots were spotted onto the 
agarsurface, and the plates were incubated at 37 °C for 18 h. The zone ofgrowth 
inhibition was measured using a hand-held digital caliper andrecorded in mm (digits) of 
either clear zone (reported with no caveat),almost clear (AC) or resistant colonies, when 
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the test material resultsin quick resistance colonies, hazy (H), usually used when the 
testmaterial is bacteriostatic and does not kill 100% of the cells, or very 
hazy (VH), when the test material shows a hint of inhibition, whichmay occur when the 
test material is highly nonpolar and insoluble. 
Leishmania bioassay (conducted by USF Department of Public Health) 
Leishmania bioassay was performed using the following procedures. Initially, norselic A-
E (3.4-3.8) were prepared in 1mg/1mL of DMSO solutions on a 96-well plate. Serial 
dilutions were made by using HBSS. 90uL of parasite was transferred to each well of the 
daughter assay plate after the dilutions. Stain was added to each well to react with a 
dehydrogenase enzyme in the parasite. Biotek plate reader to quantify the amount of live 
parasite by the absorbance. 
IC50 for Leishmania bioassay. Norselic acid A(3.4): 1.1 µg/mL. Norselic acid B (3.5):1.1 
µg/mL. Norselic acid C (3.6):1.1 µg/mL. Norselic acid D (3.7):0.9 µg/mL. Norselic acid 
E (3.8):1.8 µg/mL. 
7.4 Supporting Information for Chapter 4 
Fungal Material103(conducted by City University of Hong Kong (CUHK)) 
The endophytic fungi CY 5331, CY 5286 and CY 5368 was isolated and collected from 
the mangrove tree Avicennia marinain Mai Po Nature Reserve, Hong Kong in July and 
August 2009. CY 5331, CY 5286 and CY 5368were later identified as Xylaria 
sp.,Diaporthe sp., and Verticillium sp. respectively. From each tree, a branch (with 
leaves) well above the high tide mark, but below the canopy apex, was selected. All 
samples were taken to the lab-oratory in clean plastic bags. In the laboratory, each branch 
(excluding the leaves) was divided into 4 portions (A, B, C, and D) of different diameter, 
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and each portion was separated by at least 3–5 mm. The diameters of the portions were 
A: 13–17 mm, B: 7–11 mm, C: 3–7 mm, D: 2.5–4 mm. 
 
Figure 7.11. Portions divided on mangrove tree branch (Image adapted from reference 103). 
From each branch portion, a 20-mm segment was removed. The segments were briefly 
washed in running water, and surface-dried with clean paper towels. Each segment was 
then surface-sterilized by immersion in 75% ethanol for 1 min and 5% sodium 
hypochlorite solution for 0.5 min, followed by rinsing with sterile distilled water and 
finally, surface-dried with sterilized paper towel. With a sterile razor blade, the ends of 
these segments (ca. 1 mm thick) were removed and discarded while four 2-mm-thick 
cross sections (A1–A4,B1–B4,C1–C4,D1–D4, Figure 1) were cut. The bark of each cross 
section was then separated from the woody/xylem tissue. The bark (thus separated) was 
sized into a number of ca. 2 mm2 pieces. Ten of these bark pieces were randomly selected 
and subsequently plated. Concurrently, each de-barked cross section (i.e., wood tissue) 
was further divided into 4–8 wedges, depending on its diameter. These wedges were then 
sliced into a number of ca. 2 mm3 pieces, and 10 pieces were randomly selected for 
plating out. Hence, from each segment on the branch of a tree, 40 bark pieces and 40 
wood pieces were sampled. Accordingly, a total of 160 bark pieces and 160 wood pieces 
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were sampled from each tree branch. This procedure had been tested prior to the main 
experiment and found to be rigorous. Four mature leaves from the end of each branch 
were also sampled for endophytes, three 1 cm2 portions were cut from the middle section 
of each leaf, including the mid-vein. These leaf portions were surface-sterilized following 
the procedures described earlier. Leaf portions were then sliced into a number of ca. 2 
mm2 pieces and 10 pieces chosen at random to plate out. Hence, a total of 40 leaf pieces 
from each tree was examined. All tissue samples (i.e., bark, wood, and leaf) were plated 
onto Petri dishes (87 mm in diameter) containing 2% malt-extract agar (Oxoid, 
Basingstoke, UK) supplemented with 0.5 g/L of penicillin G and streptomycin sulphate. 
Plates were incubated at room temperature (ca. 22–25oC) on the open bench in the 
laboratory, and subject to light and dark periods of approximately 14 and 10 h per day, 
respectively. Fungal growth was examined every day for two weeks and then twice a 
week for at least one month. A hypha growing out from the incubated bark, wood, or leaf 
tissues was cut out and transferred to a fresh malt- extract agar plate. 
Preparation for Scale-up Fungal Culture (conducted by CUHK) 
Two agar plugs (6 mm) made from the growing edge of the fungal colonies were then 
inoculated into 25 ml YEP freshwater medium in Falcon tubes containing 10 g/L glucose, 
2 g/L peptone and 1 g/L yeast extract. Inoculated tubes were incubated in an orbital 
shaker on 100 rpm at 25°C for 3 weeks. Flask contents (medium and mycelium) in 
Falcon tubes were freeze-dried and the subsequent freeze-dried residue mass was used for 
bioassay of microbial extracts. 
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Extraction and Isolation of the Cytochalasins 
Freeze driedCY 5331, CY 5286 and CY 5368 were received by USF chemistry from 
CUHK and were extracted with 1:1 DCM/MeOH upon arrival. The extraction was 
evaporatedin vacuo and the resulting dried extract was prepared in a solution of DMSO 
for malaria and cytotoxicity bioassay. Separation on the active extractswas further 
pursued by chromatographic techniques including MPLC and HPLC. Thin Layer 
Chromatography (TLC) served as a tool to determine the solvent system used in HPLC. 
Wai-1, Wai-2, Wai-3, Wai-5 and Wai-6 were all obtained from CY 5331. 
Wai-1 (Cytochalasin Q) (4.25): White amorphous solid. [α]D20-25.1 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 7.30 (m, 2H), 7.22 (m, 1H), 7.14 (m, 2H), 6.05 (dd,J= 
15.7, 2.5 Hz, 1H), 6.06 (s, NH),5.80 (dd, J = 15.7, 10.0 Hz, 1H), 5.76 (m, 1H), 5.22 
(ddd,J = 15.7, 10.8, 5.2 Hz, 1H),  5.08 (dd, J = 15.7, 2.4 Hz, 1H), 3.55(m, 1H), 2.78 (m, 
2H), 2.75 (m, 1H), 2.70 (d, J = 6.4 Hz, 1H), 2.50 (dd, J = 10.0, 5.6 Hz, 1H), 2.43 (m, 
1H), 2.20 (s, 3H), 2.08 (dd, J = 5.9, 2.1 Hz, 1H),1.97 (m, 1H), 1.66 (m, 1H), 1.46 (s, 3H), 
1.16 (d, J = 6.9 Hz, 3H), 1.14 (s, 3H), 0.79 (d, J = 7.3 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ ppm 210.4, 174.6, 169.7, 137.0, 131.8, 131.7, 130.8, 129.2, 128.9, 127.6, 127.1, 
77.7, 76.0, 62.5, 57.0, 55.1, 54.1, 50.5, 45.8, 45.1, 42.2, 37.9, 36.7, 24.2, 20.7, 19.6, 19.3, 
12.5; HRESIMS m/z [M+H]+508.2690 [M + Na]+ 530.2517 (calc’d for C30H38NO6, 
508.2699). 
Wai-2((2E,4E)-6,8-dimethyldeca-2,4-dienoic acid) (4.33): Yellow oil. [α]D20-20.1 (c 
0.1 CHCl3);1H NMR (500 MHz, CDCl3) δppm 7.37 (dd, J = 15.3, 10.9 Hz, 1H), 6.20 
(dd, J = 15.2, 10.9 Hz, 1H), 6.04 (dd, J = 15.2, 8.3 Hz, 1H), 5.82 (d, J = 15.4 Hz, 1H), 
2.38 (m, 1H), 1.83 (m, 3H), 1.14 (m, 2H), 1.03 (d, J = 6.6 Hz, 3H), 0.85 (d, J =7.3 Hz, 
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3H), 0.85 (d, J =7.3 Hz, 3H); 13C NMR (125Hz, CDCl3) δ ppm 172.5, 152.0, 147.7, 
126.5, 118.2, 43.8, 35.0, 32.0, 29.9, 20.9, 18.9, 11.2;13C NMR (125 MHz, CDCl3) δ ppm 
172.5, 152.0, 147.7, 126.5, 118.2, 48.8, 35.0, 32.0, 29.9, 20.9, 18.9, 11.2; HRESIMS 
m/z[M+H]+197.1545[M + Na]+ 219.1365 (calc’d for C12H21O2, 197.1542). 
Wai-3 (Ergosterol peroxide) (4.34): White amorphous solid. [α]D20-9.0 (c 0.1 CHCl3)1H 
NMR (500 MHz, CDCl3) δ ppm 6.53 (d, J = 8.5 Hz, 1H), 6.27 (d, J = 8.5 Hz, 1H), 5.21 
(dd, J = 15.3, 8.0 Hz, 1H), 5.14 (dd, J = 15.3, 8.0 Hz, 1H), 3.97 (m, 1H), 2.14 (ddd, J = 
13.8, 5.1, 1.9 Hz, 1 H), 2.03 (m, 1H), 1.98-1.93 (m, 3H), 1.92, (m, 1H), 1.86 (m, 2H), 
1.72 (m, 2H), 1.61 (m, 1H), 1.57 (m, 2H), 1.52 (m, 2H), 1.46-1.31 (m, 2H), 1.29-1.19 (m, 
3H), 0.99 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.8, 3H), 0.89 (s, 3H), 0.83(d, J = 6.9, 3H), 
0.82 (d, J = 6.9, 3H), 0.82 (s, 3H);13C NMR (125 MHz, CDCl3) δ ppm 135.2, 135.2, 
132.3, 130.7, 82.1, 79.4, 66.5, 56.2, 51.7, 51.2, 44.5, 42.7, 39.7, 39.3, 39.3, 36.9, 34.7, 
33.1, 30.1, 28.6, 23.4, 20.9, 20.6, 19.9, 19.6, 18.2, 17.5, 12.9; HRESIMS m/z 
[M+H]+429.3372 [M + Na]+ 451.3187(calc’d for C28H45O3, 429.3369). 
Wai-4 (4.25): Same as Wai-1. 
Wai-5 (Cytochalasin C) (4.26): White amorphous solid. [α]D20-10.0 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 7.34 (t, J = 7.5 Hz, 2H), 7.27 (m, 1H), 7.19 (d, J = 6.8 
Hz, 2H), 6.02 (dd, J = 15.8, 2.4 Hz, 1H), 5.91 (m, 1H), 5.35 (m, 1H), 5.35 (m, 1H), 5.18 
(dd, J = 15.6, 2.2 Hz, 1H), 4.69 (s, NH), 3.80 (d, J = 9.5 Hz, 1H), 3.35 (m, 1H), 2.98 (m, 
2H), 2.75 (m, 1H), 2.54 (m, 1H), 2.46 (m, 2H), 2.27 (s, 3H), 2.02 (dd, J = 12.1, 6.7 Hz, 
1H), 1.71 (s, 3H), 1.53 (s, 3H), 1.47 (s, 3H), 1.22 (d, J = 6.8 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ ppm 209.9, 174.3, 169.9, 137.5, 134.1, 131.9, 131.6, 131.2, 129.0, 
128.9,128.1, 127.0, 126.3, 77.8, 75.1, 68.0, 60.2, 52.4, 50.2, 49.6, 44.6, 42.3, 37.7, 24.3, 
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20.9,19.4, 17.2, 14.0;HRESIMS m/z [M+H]+ 508.2700[M + Na]+ 530.2521 (calc’d for 
C30H38NO6, 508.2699). 
Wai-6 (Cytochalasin R) (4.27): White amorphous solid. [α]D20-13.1 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm7.34 (m, 2H), 7.28 (m, 1H), 7.16 (m, 2H), 6.41 (dd, J = 
15.6, 2.5 Hz, 1H), 5.81 (m, 1H), 5.80 (dd, J = 15.6, 2.5 Hz, 1H), 5.64 (dd, J= 15.6, 2.5 
Hz, 1H) 4.61 (s, NH), 3.63 (m, 2H), 2.99 (m, 1H), 2.93 (m, 1H), 2.78 (m, 2H), 2.65 (td, J 
= 10.0, 2.2 Hz, 1H), 2.20 (s, 3H), 2.10 (m, 1H),1.65 (m, 1H), 1.60-1.50 (m, 1H), 1.55 (s, 
3H), 1.45 (m, 1H), 1.20 (s, 3H), 1.19 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 7.3 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ ppm 212.7, 174.5, 169.8, 137.0, 131.7, 129.3, 129.3, 129.3, 
127.5, 77.8, 75.6, 61.8, 61.5, 58.5, 56.0, 54.5, 54.6, 51.2, 46.2, 44.2, 38.1, 38.0, 37.1, 
24.5, 21.0, 20.6, 19.8, 12.8;HRESIMS m/z [M+H]+524.2647[M + Na]+ 546.2463 (calc’d 
for C30H38NO7, 524.2648). 
Wai-7 (CytochalasinD) (4.28): White amorphoussolid. [α]D20-16.1 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 7.28 (m, 2H), 7.28 (m,1H), 7.13 (d, J = 7.03 Hz, 2H), 
6.11 (dd, J = 15.7, 2.6 Hz, 1H), 5.69 (dd, J = 15.6, 9.8 Hz, 1H), 5.62 (m, 1H), 5.33 (m, 
1H), 5.30 (s, 1H),5.14 (d, J = 15.8, 1H), 5.09 (s, 1H), 4.65 (brs, NH), 3.81 (d, J = 10.4 
Hz, 1H), 3.23 (d, J = 4.7 Hz, 1H), 2.84 (m, 2H), 2.76 (m, 2H), 2.73 (m, 1H), 2.51 (dd, J 
= 23.1, 11.1 Hz, 2H), 2.26 (s, 3H), 2.15 (t, J = 4.2 Hz, 1H), 2.03 (dd, J = 10.6, 5.3 Hz, 
1H), 1.50 (s, 3H), 0.95 (d, J = 6.7 Hz, 3H), 1.19 (d, J = 6.8 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ ppm 210.2, 173.6, 169.7, 147.5, 137.2, 134.1, 132.3, 130.6, 129.1, 128.9, 
127.6, 127.1, 114.5, 77.7, 77.2, 69.8, 53.5, 53.3, 50.0, 47.0, 45.3, 42.3, 37.7, 32.6, 24.2, 
20.8, 19.4, 13.6; HRESIMS m/z [M+H]+508.2697 [M + Na]+ 530.2522 (calc’d for 
C30H38NO6, 508.2699). 
 152 
Wai-8 (Cytochalasin N) (4.29):White amorphoussolid. [α]D20-21.1 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 7.33 (m, 2H), 7.27 (m, 1H), 7.18 (m, 2H), 5.96 (15.6, 2.4 
Hz, 1H), 5.90 (m, 1H), 5.72 (m, 1H), 5.37 (m, 1H), 5.19 (dd, J = 15.6, 2.4Hz, 1H), 4.67 
(brs, NH), 3.60 (m, 1H), 3.49 (d, J = 10.7Hz, 1H), 3.10 (s, 1H), 3.09 (m, 1H), 3.00(m, 
1H), 2.88 (dd, J = 13.8, 9.3 Hz, 1H), 2.51 (m, 2H), 2.31 (s, 3H), 2.03 (dd, J = 13.5, 4.4 
Hz, 1H) 1.51 (s, 3H), 1.40 (s, 3H), 1.25 (s, 3H), 1.20 (d, J = 6.8 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ ppm210.1, 173.6, 170.2, 137.0, 135.9, 131.8, 129.5, 129.0, 128.9, 128.9, 
128.1, 127.3, 127.0, 77.8, 75.3, 68.3, 64.2, 62.9, 56.1, 48.4, 45.0, 44.8, 43.8, 37.9, 24.2, 
19.8, 19.3, 14.2; HRESIMS m/z [M + Na]+546.2466 (calc’d for C30H37NO6Na, 
546.2468). 
Wai-9 (19, 20-epoxycytochalasin C) (4.30): White amorphoussolid. [α]D20-3.0 (c 0.1 
CHCl3);1H NMR (500 MHz, CDCl3) δ ppm 7.32 (m, 2H), 7.25 (m, 1H), 7.22 (m, 2H), 
6.13 (dd, J = 15.7, 10.4 Hz, 1H), 5.76 (brs, 1H), 5.73 (m, 1H), 5.61 (NH), 3.81 (d, J = 
9.2 Hz, 1H), 3.42 (m, 1H), 3.34 (m, 1H), 3.22 (m, 1H) 3.20 (d, J = 1.93 Hz, 1H), 3.06 
(dd, J = 15.1, 7.6 Hz, 1H), 2.99 (dd, J = 10.0, 9.8 Hz, 1H), 2.68 (m, 2H), 2.54 (brs, 1H), 
2.26 (dd, J = 10.0, 9.8 Hz, 1H), 2.14 (s, 3H), 1.65 (s, 3H), 1.50 (s, 3H), 1.43 (s, 3H),1.21 
(d, J = 6.7 Hz, 3H);13C NMR (125 MHz, CDCl3) δ ppm 215.2, 174.1, 170.1, 137.5, 
133.9, 131.6, 131.3, 128.9, 128.1, 127.0, 126.5, 76.3, 71.9, 68.0, 60.7, 59.9, 53.0, 51.4, 
50.7, 49.2, 44.7, 41.8, 37.4, 21.9, 20.8, 19.2, 17.1, 14.0; HRESIMS m/z [M + Na]+ 
530.2523 (calc’d for C30H37NO6Na, 530.2513). 
Wai-10 (Cytochalasin H) (4.31): White amorphoussolid. [α]D20-9.2 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 7.30 (m, 2H), 7.25 (m, 1H), 7.14 (d, J =7.0 Hz, 2H), 
5.86 (dd, J = 16.5, 2.8 Hz, 1H), 5.73 (dd, J = 15.6, 9.7 Hz, 1H), 5.56, (m, 1H), 5.55 (m, 
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1H), 5.40 (m, 1H), 5.35 (s, 1H), 5.30 (brs, NH), 5.11 (s, 1H), 3.83 (d, J = 10.9 Hz, 1H), 
3.25 (m, 1H), 2.94 (t, J = 10.3 Hz, 1H), 2.86 (dd, J = 13.5, 4.5 Hz, 1H), 2.77 (m, 1H), 
2.64 (m, 1H), 2.24 (s, 3H), 2.13 (t, J = 4.4 Hz, 1H), 2.03 (m, 1H), 1.88 (dd, J = 14.3, 3.0 
Hz, 1H), 1.80 (m, 1H), 1.78 (m, 1H),  (m, 2H), 1.56 (dd, J = 14.3, 2.7 Hz, 1H), 1.34 (s, 
3H), 1.04 (d, J = 6.4 Hz, 3H), 1.00 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 
ppm 174.2, 170.1, 147.9, 138.7, 138.1, 137.4, 129.0, 128.9, 127.1, 127.1, 125.9, 114.1, 
77.5, 74.3, 69.7, 53.7, 53.7, 51.8, 50.5, 47.2, 45.6, 42.7, 32.9, 31.2, 28.4, 26.4, 20.9, 
14.1;HRESIMS m/z [M+H]+494.2901 (calc’d for C30H40NO5, 494.2907). 
Wai-11(unidentified/not fully characterized due to insufficient material): White 
amorphoussolid. 1H NMR (500 MHz, CDCl3) δ ppm 7.35 (t, J = 7.3 Hz, 2H), 7.29 (d, J 
= 6.2 Hz, 1H), 7.18 (d, J = 6.9 Hz, 2H), 5.44 (d, J = 28.9 Hz, 1H), 5.35-5.16 (m, 1H), 
4.19-4.04 (m, 1H), 3.82 (s, 1H), 3.79-3.66 (m, 1H), 3.41-3.29 (m, 1H), 3.10-2.90 (m, 
2H), 2.74-2.61 (m, 1H), 2.60-2.44 (m, 3H), 2.42-2.30 (m, 1H), 2.05-1.94 (m, 1H), 1.92-
1.81 (m, 1H), 1.42 (d, J = 11.6 Hz, 1H), 1.13 (d, J = 7.15 Hz, 3H), 1.26-1.21 (m, 5H), 
1.28 (s, 3H). 
Wai-12 (4.30):See Wai-10 (Cytochalasin H). 
Wai-13 (unidentified/not fully characterized due to insufficient material):White 
amorphous solid. 1H NMR (500 MHz, CDCl3) δ ppm 7.34 (m, 2H), 7.27 (m, 1H), 7.16 
(m, 2H), 5.39 (m, 1H), 5.22 (m, 1H), 5.21 (m, 1H), 4.65 (m, 1H), 4.08 (dq, 13.6 Hz, 2.6 
Hz, 1H), 3.69, (m, 2H), 3.02 (m, 3 H), 2.00 (1H), 1.82 (m, 1H), 1.40 (m, 1H), 1.26 (s, 
3H), 1.21, (d, 6.1 Hz, 3H), 1.12 (d, 7.5 Hz, 3H). 
Wai-15 (Cytochalasin J) (4.32):White amorphoussolid. [α]D20-21.1 (c 0.1 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm7.34 (t, J = 7.7 Hz, 2H), 7.28 (m, 1H), 7.18 (d, J = 
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7.8Hz, 2H), 6.07 (dd, J = 16.7, 2.4 Hz, 1H), 5.76 (dd, J = 15.4, 9.8 Hz, 2H), 5.52 (brs, 
NH), 5.37 (m, 1H), 5.36 (s, 1H), 5.14 (s, 1H), 4.14 (s, 1H), 3.93 (s, 1H), 3.85 (d, J = 10.9 
Hz, 1H), 3.32 (m, 1H), 2.99-2.86 (m, 2H), 2.67-2.54 (m, 2H), 2.04 (m, 1H), 1.93 (dd, J = 
14.3, 3.0 Hz, 1H), 1.87-1.72 (m, 2H), 1.59 (dd, J = 14.2, 2.9 Hz, 1H), 1.38 (s, 3H), 1.14 
(d, J = 6.7 Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H)13C NMR (125 MHz, CDCl3) δ ppm 175.6, 
148.4, 137.9, 137.5, 137.0, 137.0, 131.2, 129.1, 128.9, 127.8, 127.1, 113.8, 74.5, 69.9, 
53.8, 53.8, 52.9, 50.3, 45.9, 45.6, 42.6, 33.0, 31.2, 28.5, 26.5, 14.0; HRESIMS m/z [M + 
H]+452.2804 (calc’d for C28H38NO7 452.2801). 
Malaria Bioassay (conducted by USF Department of Public Health) 
The transgenic P. falciparum clone 3D7 expressing luciferase was grown in continuous 
culture using the method outlined by Trager and Jenson.104 Briefly, parasites were grown 
in RPMI 1640 media without phenol-red and contained 10% heat-inactivated type A+ 
human plasma, sodium bicarbonate (2.4g/L), HEPES (5.94g/L) and 4% washed human 
type A+ erythrocytes. Cultures were gassed with a 90% N2, 5% O2 and 5% CO2 mixture 
followed by incubation at 37°C. P. falciparum 3D7 cultures at ≥4% parasitemia and 
having >70% of parasites in the ring-stage were used in the assay. Parasites were diluted 
to 0.5% parasitemia and 1.5% hematocrit using the RPMI 1640 media described above. 
Test compounds were diluted to a final concentration of 100 µg/mL and then serially 
diluted in duplicate over 11 concentrations using a Beckman Coulter Biomek 3000. The 
final test compound concentrations ranged from 100 µg/mL to 0.098 µg/mL. In 96-well 
microtiter plates a volume of 90µl/well of 0.5% parasitized erythrocytes at 1.5% 
hematocrit was added on top of 10µL/well of the test compound. A separate 96 well plate 
containing chloroquine, dihydroartemisinin and atovaquone was added to each set of 
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assay plates as control drugs. The Beckman Coulter Biomek 3000 was used to dispense 
test compounds, control drugs and parasitized erythrocytes into the microtiter plates.  
Positive and negative controls were included in each microtiter plate. Positive controls 
consisted of drug-free parasitized erythrocytes and negative controls consisted of 
parasitized erythrocytes dosed with a high concentration of chloroquine or 
dihydroartemisinin that ensured 100% parasite death. Assay plates were placed into a 
plastic gassing chamber and equilibrated with a 90% N2, 5% O2 and 5% CO2 mixture 
then incubated at 37°C for 72 hours. After 72 hours of incubation excess culture media 
was aspirated off of each well using the Biomek 3000. Plates were then frozen at -20°C 
until later processed for parasite growth determinations. For processing, assay plates were 
removed from -20°C and allowed to thaw at room temperature. Assay plates were 
processed using Luciferase Assay System reagents purchased from Promega. Briefly, 50 
µL of Promega’s Cell Culture Lysis Reagent was added to each well of the 96 well 
microtiter plate. Plates were then shaken for a minimum of 5 minutes to lyse the red 
blood cells. Subsequently, 50 µL of Promega’s Luciferase Assay Substrate was then 
added to each well. Relative Luminescence units (RLU) were read using a Perkin Elmer 
Topcount NXT Microplate Scintillation and Luminescence Counter. RLU’s were 
captured for each well using an integration time of 5 seconds. Data analysis was 
performed using a custom database manager (Dataspects, Inc). Non-linear regression 
analysis was used to calculate EC50. 
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Cytotoxicity Assay 
Cell line A-549 (adenocarcinomic human alveolar epithelial cells) was cultured in F-12K 
Nutrient Mixture (Kaighn’s Modification) media containing L-glutamine, supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin. For the assay, the A-549 
cells were diluted to 1.33 x 105 cells/mL in DMEM F12 media with L-glutamine, without 
HEPES or phenol red, and supplemented with 2 % fetal bovine serum and 1% penicillin-
streptomycin. The A-549 cells were dispensed into 96 well plates at a volume of 90 
µL/well giving a final concentration of 12,000 cells per well. Plates were incubated for 
24 hours at 37°C and 5% CO2. After 24 hours, 10 µL’s of the test compounds were added 
to the 96 well plates containing A-549 cells followed by 72 hours of incubation at 37°C 
and 5% CO2. A Beckman-Coulter Biotek NX 3000 was used to dispense cells and 
prepare and dispense test compounds to the 96 well plates. Positive and negative controls 
were included on each assay plate. After the incubation period, cell proliferation was 
assessed using Promega’s CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
reagent. Into each well 20 µL’s of reagent was added followed by incubation for 1 hour at 
37°C and 5% CO2. A Biotek plate reader was used to read absorbance at 490 nM and 
IC50 values were determined for each test compound. 
6.5 Supporting Information for Chapter 5 
Fungal Material 
The endophytic fungus CY 5188 (Diaporthe sp) and CY 5286 (Diaporthe sp.) was 
isolated and collected from the mangrove tree foliar endophyte of Sonneratia caseolaris 
in Mai Po Nature Reserve, Hong Kong.  
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Extraction and Malaria Bioassay-guided Isolation of Dicerandrol B (5.1) and D (5.2) 
Nine grams of freezed-dried CY 5188 was extracted with 1:1 DCM/MeOH exhaustively 
and to yield 3g of crude extract after solvent removal using a rotary evaporator. The 
crude extract was dissolved in DMSO at concentration of 30 mg/mL and 120 µL of 
which was transferred to a 96-well plate for malaria and cytotoxcity bioassay. (See 
section 6.4 for malaria and cytotoxicty bioassay procedures) The crude extract was 
subjected to MPLC NP12 g silica gel column (silica cartridge, Isco Combiflash 
Companion) and volumetric fractions were collected usinga 100% hexane to 100% 
EtOAc to 100%MeOH gradient. DMSO solution of the MPLC fractions concentrated in 
vacuo was prepared for furtherbioassay.Successive HPLC was performed on theactive 
fraction with NP (SunFire prep silica column 250 × 10 mm) and had resulted 1 mg of 
dicerandrol B (5.5) and 1 mg of dicerandrol D (5.6). (see Scheme 5.1)  
Extraction and Malaria Bioassay-guided Isolation of Wai-18 (5.3) and Wai-19 (5.4) 
Nine grams of freezed-dried third batch CY 5286 was extracted exhaustively with 1:1 
DCM/MeOH. The extraction had produced 3 g of crude extract. Since malaria bioassay 
indicated the crude extract of CY 5286 exhibited more than 67% inhibition on 
Plasmodium falciparum. The crude extract was chromatographed on a MPLC 12 g NP 
silica column (silica cartridge, Isco Combiflash Companion) using a 100% hexane to 
100% EtOAc to 100% MeOH gradient elution. Volumetric MPLC fractions were 
prepared in DMSO solution for malaria bioassay. The active MPLC fraction was further 
purified by repeated NP (SunFire prep silica column 250 × 10 mm) and RP HPLC (YMC 
Pack ODS-AQ C-18 250 × 10 mm analytical column) and had led to pure Wai-18 (1 mg) 
and Wai-19 (1 mg). (see Scheme 5.2) 
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Wai-16 (Dicerandrol B) (5.1):Yellowamorphous solid. [α]D20-8.3 (c 0.04 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm 14.06 (s, 1H),  14.00 (s, 1H), 11.90 (s, 1H), 11.86 (s, 
1H), 7.42 (m, 2H), 6.53 (d, J = 8.5 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 5.77 (s, 1H), 5.58 
(s, 1H), 4.52 (d, J = 12.8 Hz, 1H), 4.19 (d, J = 12.8 Hz, 1H), 4.12 (d, J = 13.2 Hz, 1H), 
3.56 (d, J = 13.14 Hz, 1H), 2.45 (m, 6H), 2.12 (s, 9H), 1.09 (t, J = 5.39 Hz, 6H); 13C 
NMR (125 MHz, CDCl3) δ ppm 187.7, 187.7, 178.8, 178.0, 170.6, 170.4,170.3, 159.5, 
159.3, 157.4, 157.0, 140.1, 140.1, 118.0, 117.7, 108.2, 107.9, 107.8, 107.8, 100.8, 100.4, 
82.4, 80.5, 70.4, 70.2, 65.5, 65.3, 33.4, 33.4, 27.7, 27.7, 20.9, 20.9, 20.7, 17.6, 17.6; 
HRESIMS m/z [M+H]+709.2124(calc’d for C36H37O15 709.2133). 
Wai-17 (Dicerandrol D) (5.2): Yellowamorphous solid. [α]D2012.6 (c 0.02 CHCl3);1H 
NMR (500 MHz, CDCl3) δ ppm14.23 (s, 1H), 13.98 (s, 1H), 11.68 (s, 1H), 11.65 (s, 1H), 
7.42 (d, 8.8 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.57 (d, J = 8.8 Hz, 1H), 6.52 (d, J = 8.78 
Hz, 1H), 5.82 (s, 1H), 5.60 (s, 1H), 5.02 (d, J = 12.8 Hz, 1H), 4.01 (dd, J = 13.6, 5.1 Hz, 
1H), 3.62 (d, J = 12.8 Hz, 1H), 3.39 (dd, J = 13.5, 10.0 Hz, 1H), 2.56-2.29 (m, 6H), 2.20 
(s, 3H), 2.18 (d, J = 6.15 Hz, 3H), 1.63 (s, 3H), 1.07 (d, J = 6.33 Hz, 3H), 1.04 (d, J = 
5.75 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ ppm187.9, 187.5, 177.6, 177.1, 170.8, 
169.9, 169.8, 161.5, 161.3, 154.1, 154.1, 141.6, 141.1, 115.1, 115.0, 109.8, 108.8, 106.2, 
106.0, 101.0, 99.7, 82.2, 80.9, 70.0, 70.0, 65.4, 65.2, 33.4, 33.4, 28.1, 27.7, 21.1, 21.0, 
17.7, 17.6, 20.1; HRESIMS m/z [M+H]+ 709.2137 [M + Na]+ 731.1967 (calc’d for 
C36H37O15 709.2133). 
Wai-18 (5.3):Yellowamorphous solid.[α]D20-24.1 (c 0.1 CHCl3);CD (c 0.01, MeOH) λmax 
nm (∆ϵ) 250 (+14.1), 293 (4.2);1H NMR (600 MHz, CDCl3)δ ppm 12.04 (s, 1H), 12.01 
(d, 1.5 Hz, 1H) 7.47 (dd, J = 8.5, 1.5 Hz, 1H), 7.46 (d, 8.3 Hz, 1H), 6.48 (dd, J = 5.5, 1.5 
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Hz, 1H), 6.48 (dd, 5.5, 1.5 Hz, 1H), 4.39 (dd, J = 4.3, 1.5 Hz, 1H), 4.35 (dd, J = 4.4, 1.5 
Hz, 1H), 3.93 (m, 2H), 3.86(m, 2H), 3.22 (d, J = 17.1 Hz, 1H), 3.05 (d, J = 18.6 Hz, 1H), 
2.90 (m, 5H), 2.82 (m, 1H) 2.24 (m, 2H), 1.30 (d, J = 6.8 Hz, 3H), 1.27 (d, J=6.8 Hz, 
3H); 13C NMR (125 MHz, CDCl3) δ ppm 196.7, 195.9, 175.8, 175.6, 159.0, 159.0, 158.1, 
158.1, 140.9, 140.7,117.2, 117.2, 107.1, 107.1, 106.9, 106.9, 86.5, 86.4, 83.0, 82.9, 62.8, 
62.3, 38.2, 37.9, 36.6, 36.4, 29.9, 29.4, 20.8, 20.6; HRESIMS m/z[M+H]+ 
583.1837[M+Na]+605.1546(calc’d for C30H31O12583.1816). 
Wai-19(5.4):White amorphous solid.[α]D20-84.6 (c 0.1 CHCl3);CD (c 0.01, MeOH) λmax 
nm (∆ϵ) 245 (-30.5), 286 (-22.7);1H NMR (500 MHz, CDCl3) δ ppm12.28 (s, 1H), 11.73 
(s, 1H), 7.29 (d, J= 8.3 Hz, 1H), 7.25 (d, J= 8.8 Hz, 1H), 6.59 (d, J = 8.8 Hz, 1H), 6.50 
(d, J = 8.3 Hz, 1H), 4.33 (d, J = 3.9 Hz, 1H), 4.22 (d, J = 3.9 Hz, 1H), 3.90 (m,  2H), 
3.82 (m, 2 H), 3.24 (d, 13.7 Hz, 2H), 3.21 (d, 13.7 Hz, 2H), 3.10 (m, 1H), 2.88 (m, 1H), 
2.84 (m, 1H),2.35 (m, 1H), 2.22(m, 1H), 2.02 (d, 5.4 Hz, 1H), 1.30 (d, J = 6.9 Hz, 3H), 
1.10 (d, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ ppm 197.3, 197.1, 176.0, 175.3, 
161.9, 158.7, 158.7, 155.8, 140.2, 140.1, 118.6, 115.2, 109.9, 107.4, 107.0, 106.8, 87.6, 
86.9, 83.5, 83.3, 63.2, 62.9, 38.8, 38.3, 36.4, 36.2, 29.6, 29.2, 20.8, 20.5; HRESIMS m/z 
[M+H]+583.1842[M+Na]+605.1630 (calc’d for C30H31O12 583.1816). 
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Appendix A: NMR Data for Chapter 3 
 
 1H NMR Spectrum of Norselic Acid A (3.4), 500 MHz, CDCl3 
 
x 
x 
x 
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13C NMR Spectrum of Norselic Acid A (3.4), 125 MHz, CDCl3
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DEPT Spectrum of Norselic Acid A (3.4), 125 MHz
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gCOSY Spectrum of Norselic Acid A (3.4), 500 MHz, CDCl3 
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gHSQC Spectrum of Norselic Acid A (3.4), 500 MHz, CDCl3 
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gHMBC Spectrum of Norselic Acid A (3.4), 500 MHz, CDCl3 
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ROESY Spectrum of Norselic Acid A (3.4), 500 MHz, CDC13 
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1H NMR Spectrum of Norselic Acid B (3.5), 500 MHz, CDCl3 
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13C NMR Spectrum of Norselic Acid B (3.5), 125 MHz, CDCl3
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DEPT Spectrum of Norselic Acid B (3.5), 125 MHz, CDCl3 
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gCOSY Spectrum of Norselic Acid B (3.5), 500 MHz, CDCl3 
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gHSQC Spectrum of Norselic Acid B (3.5), 500 MHz, CDCl3 
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gHMBC Spectrum of Norselic Acid B (3.5), 500 MHz, CDCl3 
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ROESY Spectrum of Norselic Acid B (3.5), 500 MHz, CDCl3 
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1H NMR Spectrum of Norselic Acid C (3.6), 500 MHz, CDCl3
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13C NMR Spectrum of Norselic Acid C (3.6), 125 MHz, CDCl3 
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DEPT Spectrum of Norselic Acid C (3.6), 125 MHz, CDCl3 
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gCOSY Spectrum of Norselic Acid C (3.6), 500 MHz, CDCl3 
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gHSQC Spectrum of Norselic Acid C (3.6), 500 MHz, CDCl3 
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gHMBC Spectrum of Norselic Acid C (3.6), 500 MHz, CDCl3 
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ROESY Spectrum of Norselic Acid C (3.6), 500 MHz, CDCl3 
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1H NMR Spectrum of Norselic Acid D (3.6), 500 MHz, CDCl3 
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13C NMR Spectrum of Norselic Acid D (3.7), 125 MHz, CDCl3 
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DEPT Spectrum of Norselic Acid D (3.7), 125 MHz, CDCl3
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gCOSY Spectrum of Norselic Acid D (3.7), 500 MHz, CDCl3 
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gHSQC Spectrum of Norselic Acid D (3.7), 500 MHz, CDCl3 
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gHMBC Spectrum of Norselic Acid D (3.7), 500 MHz, CDCl3 
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ROESY Spectrum of Norselic Acid D (3.7), 500 MHz, CDCl3 
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1H NMR Spectrum of Norselic Acid E (3.8), 500 MHz, CDCl3 
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13C NMR Spectrum of Norselic Acid E (3.8), 125 MHz, CDCl3
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DEPT Spectrum of Norselic Acid E (3.8), 125 MHz, CDCl3 
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gCOSY Spectrum of Norselic Acid E (3.8), 500 MHz, CDCl3 
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gHSQC Spectrum of Norselic Acid E (3.8), 500 MHz, CDCl3 
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gHMBC Spectrum of Norselic Acid E (3.8), 500 MHz, CDCl3 
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ROESY Spectrum of Norselic Acid E (3.8), 500 MHz, CDCl3 
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Appendix B: NMR Data for Chapter 4
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ROESY Spectrum of Wai-1(4.25), 500MHz, CDCl3
 201 
CY5331-6-Fr2-fr1-HPLC2-4proton
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
N
o
rm
a
liz
e
d 
In
te
n
si
ty
 1H NMR Spectrum of Wai-2 (4.33), 500 MHz, CDCl3 
CY5331-6-Fr2-fr1-HPLC2-4carbon
180 160 140 120 100 80 60 40 20
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
N
o
rm
a
liz
e
d 
In
te
n
si
ty
17
2.
49
15
1.
96
14
7.
72
12
6.
50
11
8.
23
77
.
27
77
.
02
76
.
76
43
.
83
35
.
04
32
.
02
29
.
89
20
.
87
18
.
97
11
.
24
 
 
13C NMR Spectrum of Wai-2 (4.33), 125 MHz, CDCl3 
 
OH
O
 202 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical Shift (ppm)
1
2
3
4
5
6
7
8
F
1
 
C
h
e
m
i
c
a
l
 
S
h
i
f
t
 
(
p
p
m
)
 
COSY Spectrum of Wai-2(4.33), 500MHz, CDCl3 
OH
O
 203 
9 8 7 6 5 4 3 2 1
F2 Chemical Shift (ppm)
0
50
100
150
F
1
 
C
h
e
m
i
c
a
l
 
S
h
i
f
t
 
(
p
p
m
)
 
HSQC Spectrum of Wai-2(4.33), 500MHz, CDCl3 
OH
O
 204 
8 7 6 5 4 3 2 1
F2 Chemical Shift (ppm)
0
50
100
150
F
1
 
C
h
e
m
i
c
a
l
 
S
h
i
f
t
 
(
p
p
m
)
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Appendix C: NMR and CD Data for Chapter 5 
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ROESY Spectrum of Wai-16 (5.1), 500 MHz, CDCl3
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ROESY Spectrum of Wai-17 (5.2), 600 MHz, CDCl3
 249 
 
ROESY Spectrum of Wai-17 (5.2), 600 MHz, CDCl3 (expanded) 
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